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The effects of changes in urine flow rate and pH on the distrib¬
ution and elimination of salicylates was compared in 12 healthy volun¬
teers given therapeutic doses of aspirin and diflunisal and 50 patients
with aspirin overdosage. Specific, sensitive and reproducible high
performance liquid chromatographic methods were developed for the
estimation of acetyl salicylic, salicylic and salicyluric acids and
diflunisal in plasma and urine. Salicylate protein binding was
investigated in-vitro and in-vivo and compared with albumin binding
using an ultrafiltration technique.
Alkalinisation of the urine by oral administration of sodium
bicarbonate in the healthy volunteers given 20 mg/kg aspirin orally
resulted in a significant increase in the total body and renal clear¬
ances of salicylic acid but not salicyluric acid. Urinary recovery of
acetyl salicylic and salicylic acids were markedly increased with
alkaline diuresis whereas the salicyluric acid recovery was signifi¬
cantly decreased. There were significant positive correlations
between the renal clearance of salicylic acid and urine pH or flow
rate, but in a corresponding study with diflunisal, there were no such
relationships. Forced alkaline diuresis would therefore be ineffective
in diflunisal poisoning.
Adult patients with aspirin overdosage (plasma concentrations
400-800 ug/ml) were treated with one of four i.v. regimes of fluid and
alkali (over 3 hr) to establish the relative importance of urine flow
rate and pH on salicylate elimination. Sixteen patients received
forced alkaline diuresis (FAD - 18.9 g NAHCO^ in 6L isotonic fluid),
6 forced diuresis (FD - 6L isotonic fluid), 6 alkali (A - 18.9 g NaHCO^
in /
in 1|L) and 6 FAD with 80 mg i.v. frusemide (FAD + F). No specific
treatment was given to 16 control patients with mild salicylism
(300-450 yg/ml).
Acetyl salicylic acid was rapidly hydrolysed to salicylic acid
and was only detected when absorption was delayed (25 patients). All
treatments produced similar initial rapid falls in plasma salicylic
acid concentrations during the infusion period (0-4 hr), but urinary
salicylate excretion was only increased with the alkalinisation regimes.
Haemodi1ution and increased apparent volume of salicylate distribution
probably contributed to this initial fall particularly in the non-
alkalinisation regime. From 4-16 hours the mean plasma elimination
half-lives of salicylic acid were 30, 31, 12, 14 and 9 hours in the
control, FD, FAD, FAD + F and A groups respectively. Total body
clearance, renal clearance and urinary recovery of salicylic acid were
significantly higher with the alkalinisation regimes than with forced
diuresis alone. The renal clearance of salicylic acid was a function
of both urine flow and pH in all groups. There was a direct relation
with the former but the influence of pH increased dramatically above
7.0 where it completely dominated the elimination kinetics of sali¬
cylic acid. The mean renal clearances of salicylic acid during the
first 16 hours in the control, FD, FAD, FAD + F and A groups were
1.4, 4.4, 18, 13 and 24 ml/min respectively.
The binding of salicylic acid to plasma proteins was highly
concentration-dependent and the mean unbound fraction rose from 14%
at 50 pg/ml to 80% at 800 yg/ml, a finding of toxicological signifi¬
cance. Salicylic acid was bound, in-vitro, less to albumin than to
equivalent concentrations of total plasma proteins.
Plasma concentrations of salicyluric acid were uniformly very
low /
low (< 10 yg/ml) and constant in all groups which reflected satura¬
tion of glycine conjugation of salicylic acid. The very high renal
clearance of salicyluric acid was independent of urine flow rate or pH.
Fluid retention and weight gain were significantly greater and
haematological and biochemical abnormalities resulting from haemo-
dilution were more obvious in the forced diuresis and FAD groups.
Administration of alkali alone was more effective than the other
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Chapter 1. REVIEW OF PHARMACOLOGY AND TOXICOLOGY OF SALICYLATES
(a) Hi story
Drugs have beer used to treat diseases for thousands of years,
traditionally their effectiveness was established by trial and error.
Hippocrates some 2,400 years ago recommended leaves of willow tree
in childbirth, Pliny made a paste from the ash of willow bark for
removing corns and callosities in the first century (Gross and
Greenberg, 1948; Baywaters, 1962; Avicenna, in the eleventh century,
included willow bark as one of his medicinal drugs (Girdwood, 1976).
In the 18th century, the antipyretic properties of the bark of
willow "salix alba vulgaris" were discovered in England by the
Reverend Edward Stone, in an attempt to find a cheap substitute for
expensive imported cinchona, a bark which contains quinine, and was
used as antipyretic analgesic. He carried out a clinical trial of
50 patients with the "auge" each of whom received 20 grains of
powdered willow bark extracted in a dram of water every 4 hours.
According to Stone, the results were excellent (Bowman and Rand,
1980). The active ingredient in the willow bark was a bitter glyco¬
side called salicin, first discovered by Leroux in 1827. On hydro¬
lysis, salicin liberates glucose and salicylic alcohol (saligenin).
Piria, in 1838, made salicylic acid from salicin. Six years later,
salicylic acid was prepared from oil of gaultheria (oil of winter-
green) by Cahours (Martin, 1962; Flower, Moncada and Vane, 1980). In
fact, the word "salicylate" is derived from the botanical name for
the /
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the willow family "salicaceae" (Bowman and Rand, 1980). Kolbe and
Lautemann produced salicylic acid synthetically from phenol in 1860
and Kolbe devised a commercially practical process in 1874 (Sollman,
1936). Sodium salicylate was first used as an antipyretic by Buss
in 1875, and in the following year its value in rheumatic fever was
discovered by Strieker. Phenyl salicylate was introduced into medi¬
cine in 1866 by Nencki. Moore (1879) reviewed thousands of cases of
various diseases treated with salicylic acid and its compounds.
Acetyl salicylic acid was first synthesised in 1897 by Hoffman and
introduced into the clinical medicine under the trade name of aspirin
in 1899 by Dresser. The name aspirin comes from "Spirsciure" the
German word for salicylic acid (Goodman and Gillman, 1956).
Many salicylic acid derivatives have been synthesised and
introduced into medicine in this century. Diflunisal, one of the
new salicylates discovered in 1971 has been used as an analgesic
anti-inf1ammatory agent in clinical practice since 1977 (Hannah,
Ruyle, Jones, Matzuk, Kelly, Witzel, Holtz, Houser, Shen and Sarett,
1977).
In 1798, Longmore described methyl salicylate poisoning in 14
men of the Royal Artillery in Quebec who drank tea made of three
herbs (Ledum, Andromeda and Gaultheria). The symptoms were those of
poisoning by oil of wintergreen contained in the gaultheria. In
1884, May reported 28 cases of salicylism out of 192 rheumatic pat¬
ients who had taken either salicylic acid or sodium salicylate
(Gross and Greenberg, 1948).
Hanzlik in 1913 summarised the clinical record of nearly 400
patients in whom toxic symptoms appeared after administration of
various /
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various salicylate compounds. Several thousands of cases of sali¬
cylate overdosage, mainly acetyl salicylic acid with or without
fatalities have been reported in this century most of which have
been reviewed by Gross and Greenberg (1948); Smith (1966);
McCleave and Havill (1974); Mofenson and Greensher (1975); Bender
(1975) and McQueen (1977).
(b) Terminology
The word "salicylate" is generally employed as a generic term
for the class of compounds containing the salicyl radical C6H4 (OH).
C00-, in application to the free acid, its salts, esters and ethers.
The term "salicyl" is sometimes employed to designate the salicylic
acid radical. Occasionally the word "aspirin" is used instead of
acetyl salicylic acid (Smith, 1949). The term "salicylism" is
employed for chronic intoxication of salicylate and the word
"poisoning" for acute intoxication of salicylate.
(c) Chemistry
Of the three isomers of hydroxybenzoic acid, only the ortho
compound (salicylic acid) came into medical use, because of its
stronger action. Salicylic acid is so irritating that it can only
be used externally, therefore, many of its derivatives have been
synthesised for systemic use (Gross and Greenberg, 1948). Sali¬
cylic acid derivatives are divided into two large classes, namely
"esters of salicylic acid" obtained by substitutions in the carboxyl
group (e.g. methyl salicylate) and "salicylate esters of organic
acids" in which the carboxyl group of salicylic acid is retained
and substitution is made in the hydroxyl group (acetylsalicylic
acid). /
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acid). In addition, the effects of simple substitutions on the
aromatic ring have been extensively studied, and new salicylate
derivatives are still being synthesised (Flower et al., 1980).
Diflunisal (21,4'-difluoro-4-hydroxy-3-biphenyl-carboxylic acid) is
one of the new salicylic acid derivatives with a longer duration of
action (Steelman, Cirillo and Tempero, 1978). Structural formulae
of the salicylates are shown in Figure 1.
(d) Mode of action of salicylates
Although salicylates were known to inhibit a wide variety of
reactions in vitro, no convincing relationship could be established
with their known analgesic-antipyretic and anti-inf1ammatory effects
(Flower et al., 1980). In 1971, Vane, and at the same time, Smith
and Willis, reported that low concentrationsof aspirin inhibited the
enzymatic production of prostaglandins. The prostaglandins and
related compounds are derived from 20-carbon essential fatty acids
that contain three, four or five double-bounds. They fall into several
main classes, designated by letters and distinguished by substitution
on the cyclopentane ring. Those derived from arachidonic acid (the
most abundant precursor in man) carry the subscript 2. Prostaglan¬
dins of E and Foe series are sometimes referred to as the "primary
prostaglandins" which are the most common (especially E2 and F2«c ).
Arachidonic acid is rapidly metabolised to oxygenated products by
two distinct enzymatic mechanisms, a cyclooxygenase and a lypo-
oxygenase. The unesterified precursor acids are oxygenated and
cyclized by cyclooxygenase, to form the cyclic endoperoxide deriva¬
tives, prostaglandin G and prostaglandin H. These endoperoxides
which are chemically unstable (half lives of 5 minutes at 37°C and
pH 7.5) are then isomerised into different products, prostaglandins
E, /
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Fig 1 Metabolic pathways of acetylsalicylic acid and diflumsal (Modified from Milne 1962, and
Steelman et al, 1978)
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E, F or D. The endoperoxide prostaglandin is also metabolized
into unstable and highly biologically active thromboxane and
prostacyclin (prostaglandin I»). Thromboxane has a very short
half-life (t| = 30 seconds at 37°C and pH = 7.5) and breaks down
into the stable thromboxane B^ (Moncada, Flower and Vane, 1980).
All mammalian cell types studied (with the possible exception
of erythrocytes) have microsomal enzymes for the synthesis of prosta¬
glandins. Prostaglandins are always released when cells are damaged
(Flower et al., 1980). Macrophages are a substantial source of pros¬
taglandin E^ formation and aspirin is the only non-steroidal anti¬
inflammatory drug which appears capable of impairing lymphocyte
activation in therapeutic concentrations (Morley, 1977). Aspirin
and related compounds prevent production of the prostaglandin endo-
peroxides by the inhibition of the cyclooxygenase enzyme and as a
result, all the products below them in the metabolic pathway (Flower, 1974).
Following the isolation of cyclooxygenase, it was reported
that aspirin quantitatively and selectively acetylated the oxygenase
and interfered with its function. The in vitro inhibition by aspirin
is about four times more potent than salicylic acid. The methyl ester
of aspirin is also much less active, but gentisic acid is almost as
effective as aspirin (Shen, 1979). Aspirin exerts two separate
inhibitory effects on prostaglandin formation i_n vivo, a rapid
action of the intact molecule on easily accessible tissue and a later
action due to its metabolic conversion to salicylic acid. Salicylic
acid inhibits prostaglandin biosynthesis i_n vi vo as salicylate ion
itself and there is no formation of subsequent active metabolites
(Smith, Ford-Hutchinson, Walker and Slack, 1979).
The non-acetylating salicylate, diflunisal, exerts its anti¬
inflammatory /
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anti-inflanmatory and analgesic effects in man with a concomitant
decrease of the excretion of 7* -hydroxy-5,11, diketotetranoprostane -
1-16, dioic acid, the major urinary metabolite of prostaglandin El
and E2 (Steelman, Smith-Sibinga, Schulz, Vanden Heuvel and Tempero,
1976; Schulz, Perrier, Febert-Perret, Vanden Heuvel and Steelman,
1979)
(e) Pharmacological and toxicological effects of salicylates
1. Analgesia and antipyresis
The salicylates have lower maximal effects than do the opiate
analgesics and hence are used only for pain of slight to moderate
intensity. In a comparison of antipyretic and analgesic activity of
aspirin with paracetamol, aspirin had some advantage over paracetamol
for analgesia (Lovejoy, 1978). Whereas moderate doses of salicylate
reduce an elevated body temperature, they also increase oxygen con¬
sumption and metabolic rate. In toxic doses, salicylates have a
pyretic effect that results in sweating (Flower et al., 1980) and
even malignant hyperthermia (Havill, 1974; Skjoto and Reikvam, 1979).
2. Respiration, acid-base and electrolyte disturbances
Salicylates stimulate respiration directly and indirectly. Full
therapeutic doses of salicylates increase oxygen consumption and CO^
production as a result of uncoupling of oxidative phosphorylation.
The increased production of CO^ stimulates respiration, but elevated
alveolar ventilation balances the increased CO^ production, there¬
fore pCO^ does not change or is reduced. If the salicylate is taken
in overdosage it will gain access to the medulla and directly stimu¬
late the respiratory centre. This results in marked hyperventilation
with /
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with increased respiratory minute volume (as much as ten-fold), low
arterial pCO^ and respiratory alkalosis (Ryder, Shaver and Ferris,
1945). Not only does salicylate increase pulmonary ventilation, it
also results in enhanced sensitivity of the respiratory centre to
arterial pCO^ and concentration of hydrogen ions (Winters, White,
Hughes and Ordway, 1959).
Although therapeutic doses of salicylate produce definite changes
in the acid-base balance and electrolyte pattern (respiratory alka¬
losis), compensation promptly ensues by increased renal excretion of
bicarbonate, sodium and potassium (compensated respiratory alkalosis).
Ingestion of toxic doses of salicylate by children or occasionally
adults is followed by changes in acid-base status. With very large
doses, respiratory depression occurs and the enhanced production of
CO^ outstrips its alveolar excretion; consequently, arterial pCO^
increases and pH decreases. Since the concentration of bicarbonate
in plasma is already low due to its increased renal excretion, an
uncompensated respiratory acidosis occurs superimposed however, on a
true metabolic acidosis (Atkins, 1969). Respiratory alkalosis may
not be observed in children. In 33 salicylate overdose patients,
mostly infants and young children, significant reduction in the total
CO^ and plasma pCO^ on admission were reported (Winters et al., 1959),
whereas in 62 adults with severe salicylate poisoning, only 8 were
found to be acidaemic, although the mean plasma salicylate concen¬
trations of the acidaemic and non-acidaemic patients were similar
(Proudfoot and Brown, 1969). In another study of 67 adults with
salicylate intoxication, 25% had simple respiratory alkalosis




The association of pulmonary oedema and salicylate intoxication
in man was first reported by Granvi11e-Grossman and Sergeant (1960)
in a 32 year old man without heart disease who survived. Davis and
Burch (1974) reported fatal non-cardiogenic pulmonary oedema in two
adults and speculated that the cause might be salicylate-induced
centrally mediated pulmonary oedema. Another fatal case of salicyl¬
ate intoxication with pulmonary oedema was reported by Tweeddale
(1974) and similar patients who survived by Tashima and Rose (1974),
Hrnicek, Skelton and Miller (1974), Broderick, Reinke and Goldman
(1976), Heffner, Starkey and Anthony (1979).
Respiratory distress syndrome
Adult respiratory distress syndrome in salicylate intoxication
with extravasation of protein-rich fluid in the lungs, decreased
pulmonary compliance, hypoxaemia and "white lungs" on chest X-ray
was described by Sorensen (1979) in a 54 year old woman with a
plasma salicylic acid concentration of 3.8 mmol/1 (684 pg/ml). A
similar case was reported by Thomas (1979) and a fatal respiratory
distress syndrome in a two year old girl with a plasma salicylate
concentration of 2.7 mmol/1 (486 ug/ml) was described by Kahn and
Blum (1979). Gullner (1979a) suggested that inhibition of prosta¬
cyclin biosynthesis by salicylate may be a contributory factor in
the pathogenesis of respiratory distress syndrome and could explain





The effects of 7 to 200 mg/kg of acetyl salicylic acid given by
intravenous infusion on renal function in the dog were investigated
by Berg and Bergan (1976). They reported a significant dose-depend¬
ent decrease in sodium excretion (23%) and para-aminohippuric acid
clearance (108.7 ml/min after 7 mg/kg of acetylsalicylic acid falling
to 58.8 ml/min after 200 mg/kg)and also a 10% decrease in the renal
tubular reabsorption of free water. The creatinine clearance was
unchanged. Berg and Bergan offered the prostaglandin synthetase
inhibitory effects of acetylsalicylic acid as one explanation of the
effects on renal blood flow and sodium excretion. In fact the oppos¬
ite effects of prostaglandins l^. and on renal function in the
dog have been reported (Moncada et al., 1980). Berg (1977a) also
reported on the acute effects of acetylsalicylic acid on renal func¬
tion in normal man. There was a significant decrease in the 24 hour
sodium excretion and Na/K ratio, which was prominent during day time
and when sodium intake was low. He also confirmed the antidiuretic
effects of acetylsalicylic acid (which was most marked at night) and
that the creatinine clearance was unchanged by aspirin treatment.
Acute renal failure associated with therapeutic doses of aspirin and
ibuprofen with patchy nonspecific ultrastructural changes in the
tubular epithelium was reported by Kimberly, Sherman, Mouradian and
Lockshin (1979). Further studies of the effect of acetylsalicylic
acid on the creatinine clearance and inulin clearance in man revealed
no significant changes (Nielsen, Rasmussen and Hilden, 1980; Muther
and Benneth, 1980).
Renal "irritation" by salicylates was shown by an increase in
the urine-cel1-count (Scott, Denman and Dorling, 1963). The urine-
cell- /
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cell-count reached a maximum on the second and third day of aspirin
treatment and later returned to normal even though the drug was
continued. However, in a control study in which a new method was
employed for the enumeration of renal tubular cells, 10 healthy vol¬
unteers (5 males and 5 females) took 3.6 g acetyl salicylic acid for
5 days. There was a dramatic rise in renal tubular cell output
after a latent period of about 24 hours. This increase was not sus¬
tained, but by the fifth day the average renal-tubular-cel1 excretion
was still more than four times the control value and in no volunteer
had the count returned to normal (Prescott, 1965).
(2) Chronic effects
The obvious nephrotoxicity of salicylates and their probable
primary role in the aetiology of analgesic nephropathy was emphasised
by Prescott (1966a). A large number of patients with analgesic neph¬
ropathy have been described who took aspirin alone or with other
analgesics without phenacetin (e.g. Prescott, 1966b; 1969; Clark and
Linton, 1973; Wilson and Gault, 1977; Gokal and Matthews, 1977).
Aspirin produces renal papillary necrosis more readily in animals
than phenacetin (Molland, 1978; Nanra, Stuart-Taylor, De Leon and
White, 1978). Moll and (1978) suggested that the early papillary
changes might be due to ischaemia, medullary blood flow being red¬
uced as a result of aspirin's action as an inhibitor of prostaglandin
synthesis.
The urinary excretion of N-acetyl-6 glucosaminidase (NAG) has
been used as a marker for identifying nephrotoxic drugs. A signifi¬
cant increase in the excretion of this enzyme was found in 83% of
rheumatic patients receiving aspirin therapy. Single doses of
650, /
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650, 1300 or 1950 mg of aspirin in healthy volunteers resulted in a
significant increase in urinary NAG at 2 to 4 hours after the higher
doses (Proctor and Kunin, 1978). In a comparative nephrotoxicity
study of aspirin and diflunisal in osteoarthritic patients, NAG
excretion increased in a dose-related manner with a relatively
greater increase in the aspirin group (Dieppe, 1978).
Acute interstitial nephritis in a patient with aspirin hyper¬
sensitivity was reported by McLeish, Senitzer and Gohara (1979). The
nephrotoxicity and hepatotoxicity of antipyretic analgesics (includ¬
ing aspirin) was reviewed by Prescott (1979a).
4. Hepatic effects
Prolonged administration of salicylates, particularly in rheum¬
atic patients, may cause liver failure and encephalopathy which
simulate Reye's syndrome (Lyon and Nevins, 1974; Daum, Zunker and
Cohen, 1976). In animal experiments salicylates produced elevation
of transaminases and fatty changes, but the changes differed from
those seen in Reye's syndrome (Linnemann, Ueda, Hug, Schaeffer,
Clark and Schiff, 1979). However, there is no doubt that chronic
salicylate administration, even with plasma salicylate concentra¬
tions less than 25 mg/100 ml, may induce hepatotoxicity (Bernstein,
Singsen, King and Hanson, 1977; Schaller, 1978; Kanada, Kolling and
Hinddin, 1978). A case of aspirin hepatotoxicity and disseminated
intravascular coagulation was also reported (Sbarbaro and Bennett,
1977).
5. Gastrointestinal effects
The ingestion of salicylate may cause epigastric distress,
nausea, /
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nausea, vomiting, errosive gastritis and gastrointestinal haemorr¬
hage. The relationship between aspirin ingestion and massive gastro¬
intestinal haemorrhage was reviewed by Shirley (1977) who was uncon¬
vinced of a cause and effect relationship. There has even been a
suggestion that aspirin consumption may not necessarily be the
cause of bleeding but an associated phenomenon (Langman, 1977).
However, in an investigation of gastrointestinal blood loss (Vakil,
Kulkarni, Kulkarni, Mehta, Gharpure and Pispati, 1977) and an endo¬
scopic study of gastrointestinal injury (Vakil, Shah, Dala,
Wagholikar and Pispati, 1977) in 24 healthy volunteers treated with
non-steroidal anti-inf1ammatory agents it was demonstrated that
aspirin produced the greatest degree of blood loss and most severe
mucosal damage. This was also confirmed by histopathological find¬
ings. Similar studies were reported by Silvosa, Ivey, Butt, Lokard,
Holt, Sisk, Baskin, Mackercher and Hewett (1977), Mielants, Veys,
Verbruggen and Schelstraete (1979), Cohen (1979), and Faivre, Faivre,
Lery, Ducluzeau, Moulinier and Paliard (1979). However, intravenous
aspirin did not produce detectable histological mucosal damage in
healthy subjects and it was concluded that high blood salicylate
concentrations do not acutely damage gastric mucosa (Ivey, Paone
and Krause, 1980). Hunt and Fisher (1980) reported that despite a
rise in plasma salicylate concentrations from 55 to 74 mg/1 the
rate of blood loss into the gastric lumen declined.
In a comparative study of diflunisal versus aspirin on their
effects on faecal blood loss in the presence and absence of alcohol,
diflunisal did not significantly increase blood loss, while aspirin
had a significant effect, which was enhanced by the addition of
alcohol (De Schepper, Tjandramaga, Verhaest, Daurio and Steelman, 1978).
6. /
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6. Effects on the blood
Aspirin has multiple adverse effects on haemostasis (Prescott,
1977). It may cause anaemia through different mechanisms. The
commonest is simple iron deficiency anaemia caused by occult blood
loss from the gastrointestinal tract, but haemolytic, macrocytic and
aplastic anaemias have also been documented (Prescott, 1975; Eldar,
Aderka, Shoenfeld, Lirni and Pinkhas, 1979). Hypoprothrombinaemia
may occur if large doses of salicylates are taken for a long period,
but it is rarely responsible for serious bleeding and responds to
injection of vitamin K1 (Prescott, 1968).
There are many reports of the effects of acetyl salicylic acid
on platelet function (e.g. Evans, Packam, Nishizawa, Mustard and
Murphy, 1968; Weiss, Aledort and Kochwa, 1968; O'Brien, 1968;
Morse, 1977; Rajah, Penny, Crow, Pepper and Watson, 1979). Acetyl-
salicylic acid interferes primarily with the second phase of plate¬
let aggregation. The effects of aspirin on platelet aggregation as
a function of dosage and time were reported by Paccioretti and Elock
(1980). They concluded that platelet aggregation inhibition by a
single oral dose of 81 mg aspirin or more may be expected to persist
for the lifetime of the platelets affected. The differential inhibi¬
tion of prostacyclin production and platelet aggregation by aspirin
was studied by Masotti, Galanti, Poggesi, Abbate and Neri Serneri (1979)
and Pareti, D'Angelo, Mannucci and Smith, 1980; O'Brien (1980).
Masotti et al. pointed out that inhibition of platelet cyclo-oxygenase
occurs with smaller dose of aspirin (3.5 mg/kg) and lasts longer than
inhibition of vessel-wall cyclo-oxygenase. Hoogendijk and Ten Cate
(1980) reported different results in patients and concluded that
results obtained in healthy volunteers may not be applicable to
patients. /
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patients. Huijgens, Imandt and Van Den Berg (1980) also concluded
that 3 mg/kg of aspirin seems to give maximal platelet aggregation
inhibition. Following ingestion of 650 mg of aspirin, cyclo-oxygen-
ase activity was inhibited 95% within 45 minutes. Enzyme activity was
observed to increase within 8 hours and reached 10% of control level
by 24 hours. It has been suggested that only circulating platelets
are affected by acetyl salicylic acid (Ali, McDonald, Thiessen and
Coats, 1980).
Although the bleeding time was prolonged significantly by
aspirin relative to control values (Stuart, Miller, Davey and Wolk,
1979) it was still within the normal bleeding time range in the
general population.
A single oral dose of 100 mg aspirin reduced serum thromboxane
by 98% during the first hour and single doses of 100-400 mg
resulted in 94-98% inhibition after 24 and 48 hours which returned
to control levels within a time course consistent with platelet
turnover (Patrono, Cialiattoni, Pinca, Pugliese, Castrucci, De Salvo,
Satta and Peskar, 1980).
7. Central Nervous System Effects
The effects of salicylates on the central nervous system are not
only prominent in overdosage, but are also reported as common side
effects with therapeutic doses. Among 2,391 hospitalised patients
receiving plain aspirin tablets, 1.2% had central nervous system
side effects (second only to heartburn and nausea). Of these
tinnitus was reported most often (0.8%) and deafness occurred in
0.3% of cases and was associated with high doses (Miller and Jick,




Large doses of salicylates have been reported to increase
cardiac output, and the plasma volume may be increased as a result
of salt and water retention (Prescott, 1972). Allergic reactions
(e.g. asthma, urticaria, shock, collapse and angioneurotic oedema),
teratogenicity, endocrinal and many other side effects are also
documented (e.g. Seltzer, 1973; Prescott, 1978, 1979b and 1980;
Hunter, Dorward, Knill-Jones and Gunn, 1978).
Salicylate poisoning
Acute salicylate intoxication usually occurs following inten¬
tional ingestion of aspirin in overdosage in adults and accidental
or therapeutic poisoning in children (Pierce, 1974; Buchanan, 1975).
Methyl sal icy!ate (oil of wintergreen) is more toxic than aspirin.
As little as 5 ml of oil of wintergreen will kill a child and can
produce a plasma concentration over 700 pg/ml in an infant, which
is equal in toxic effect to 15 adult aspirin tablets (Locket, 1973).
Intoxication following percutaneous absorption of salicylic acid
has also been reported (Smith and Lyons, 1980; Davies, Briffa and
Greaves, 1979). Salicylate poisoning occurred in a 21-month-old
boy following the use of a teething ointment containing 8.7% choline
salicylate (Paynter and Alexander, 1979). Chronic salicylate
poisoning in children during therapy with aspirin is aggravated by
the dose-dependent kinetics of the drug (Done, 1978). Two cases of
therapeutic salicylate poisoning in children were reported by
Mitchell (1979). Self-medication for treating "knee jerk" in a
52 year old woman caused severe salicylate intoxication (Edward
and /
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and Taylor, 1980). Chi 1 dren are much more susceptible to the
toxicity of salicylate than adults (Done, 1978). Many children have
died following therapeutic doses or accidental overdosage of aspirin
(Krasnoff and Bernstein, 1947; Greenberg, 1950; Shannon, 1965; Craig,
Ferguson and Syme, 1965; Whitehall, 1973; Done, 1978). Between 10%
and 20% of adult self-poisoning in Edinburgh involves aspirin
(Proudfoot and Park, 1978).
Clinical manifestations in 49 children with salicylate poisoning
included hyperpyrexia, respiratory alkalosis, dehydration, metabolic
acidosis and hypernatraemia. The fatal cases were children under
two years of age (Segar and Holliday, 1958). Acid-base changes in
salicylate poisoning are complex and depend on the severity and
duration of the intoxication, individual sensitivity and age.
Metabolic acidosis is very common in children and may dominate the
respiratory alkalosis which is usually seen in severe salicylate
poisoning in adults (Winters et al., 1959; Temple, 1978). Experi¬
ments in mice and rats using radioactive and non-radioactive tech¬
niques showed that brain salicylate concentrations were almost
doubled in acidaemic compared with the alkalaemic animals (Hill,
1973). However, there are reports of disturbed cerebral function
with high plasma salicylate concentrations in poisoned adults who
were not acidaemic (Levy, 1968; James and Matrinak, 1975; Proudfoot
and Prescott, 1977).
Clinical features of salicylate poisoning include tinnitus,
deafness, sweating, vasodilation and hyperventilation. Contrary to
the belief of many doctors, loss of consciousness is very rare in
salicylate poisoning, and when it does occur, intoxication is severe
and likely to be fatal (Bender, 1975; Proudfoot and Prescott, 1977;
McQueen, /
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McQueen, 1977; Rumack, 1979). Although salicylates cause hypopro-
thrombinaemia and gastric erosions, severe bleeding is a rare
complication of the acute poisoning (Proudfoot and Prescott, 1977).
Hypoglycaemia and convulsions seem to occur almost exclusively in
young children (Prescott, 1975; Bray and Gardiner, 1977).
The diagnosis of salicylate poisoning is usually easy, but can
easily be overlooked. The diagnosis of salicylate intoxication was
suspected in a 37-year-old man because of the results of serum
electrolyte and arterial blood gas analysis (Greenbaun, Togba, Becker
and Grace, 1974). In a study of 73 consecutive adults hospitalised
with salicylate intoxication, 27% of the patients were undiagnosed as
long as 72 hours after admission, although the initial clinical find¬
ings and laboratory data in patients not diagnosed on admission did
not markedly differ from the findings in patients diagnosed on
admission. However, the patients with delayed diagnosis were older,
rarely had a previous history of drug overdose and more often became
accidentally intoxicated through therapeutic use of aspirin (Anderson,
Potts, Gabow, Rumack and Schrier, 1976). Unusual abdominal compli¬
cations (blind-loop syndrome) were reported in a suicidal 67-year-
old woman following ingestion of aspirin, amitriptyline and diazepam
(Mehta, Mehta and Matthew, 1978). Springer and Groll (1980) reported
a nearly fatal salicylate overdose occurring suddenly after gastric
retention of enteric-coated aspirin, ingested over a 14-week period.
Measurement of the plasma salicylate concentrations on admission
and its subsequent rate of decline provides a valuable indication of
the severity of poisoning and a useful guide to treatment (Brown,
Cameron and Matthew, 1967). There appears to be a direct relation¬
ship between dose absorbed and plasma concentrations two hours
after /
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after ingestion (McCleave and Havill, 1974), but salicylate concen¬
trations may not always correlate well with the clinical severity of
intoxication (Done, 1960; Prescott, Roscoe and Forrest, 1973).
However, Done (1960) found a better correlation between a theoretical
zero-time concentration and clinical severity of salicylate intoxi¬
cation in children. In 59 subjects experiencing tinnitus the serum
salicylate level was invariably greater than 196 ug/ml (Mongan,
Kelly, Nies, Porter and Paulus, 1973).
Treatment of salicylate poisoning
Therapy of salicylate poisoning should be aimed principally at
replacement of fluid and electrolytes, correction of acidaemia,
prevention of further salicylate absorption and enhancement of
salicylate elimination (Temple, 1978). As much as 20 g of salicyl¬
ate was recovered by gastric aspiration and lavage in one case, nine
hours after ingestion of 200 aspirin tablets (Matthew, Mackintosh,
Tompsett and Cameron, 1966). In another report, Matthew (1970)
recommended gastric aspiration and lavage for acute poisoning using
a simple rule of a 4-hour interval since ingestion with the excep¬
tion of salicylate in which the interval is extended to 12 hours.
Gastric lavage with sodium bicarbonate solution has been used for
removing enteric-coated aspirin (Sogge, Griffith, Sinar and Mayes,
1977). Despite gastric lavage, the plasma salicylate concentrations
may continue to rise for several hours. Facial petechiae may be
noted, particularly on the oyelids, probably as a result of the
effects of aspirin on platelet and capillary function and the added
mechanical effects of the lavage (Proudfoot and Prescott, 1977).
Emetics, /
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Emetics, such as ipecac, (but not sodium chloride) may be used
instead of gastric lavage and should be administered as soon as
possible. A 3 year-old-boy was given salt as an emetic and later
gastric lavage with a saline solution following accidental ingestion
of aspirin. He became comatose and died with severe persistent
hypernatraemia and hyperchloraemia although his plasma salicylate
concentrations declined from 509ug/ml to 90yg/ml (Barer, Hill, Hill
and Martinez, 1973). Activated charcoal may also be given (Levy and
Tsuchiya, 1969). Although it will reduce aspirin absorption if
given at the same time it is largely ineffective if given more
than 1 hour after ingestion (Levy and Tsuchiya, 1972). Charcoal-
sorbitol mixture and kaolin pectin are both less effective in
reducing aspirin absorption than charcoal slurry (Mayersohn,
Perrier and Picchioni, 1977; Juhl, 1979).
Different methods of treatment have been used to enhance
salicylate elimination. The effects of forced diuresis, alkaline
diuresis, forced alkaline diuresis and diuretics on salicylate
kinetics are reviewed in detail later. Osmotic diuresis by
mannitol was used in three patients with severe salicylate poisoning
giving a plasma elimination half-life of 12 hours (Ghose and Joekes,
1964). Mannitol was found to have a transient diuretic effect on
the acute symptoms associated with fluid retention in salicylate
poisoning, but only strict fluid restriction resulted in a prompt
and satisfactory diuresis (Temple, George, Done and Thompson, 1976).
The use of acetazolamide for salicylate poisoning, in the absence of
definitive clinical and chemical data, cannot be recommended
(Winters, 1959). Acetazolamide and intravenous fluids were admini¬
stered to 27 patients with salicylate poisoning (Feurestein,
Finberg /
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Finberg and Fleishman, 1960). However, Bonginovanni (1960) criti¬
cised the use of acetazolamide in this study in patients with plasma
salicylate concentrations less than 350 yg/ml (maximum therapeutic
concentration), which accounted for its apparent effectiveness.
Finberg (1960) replied that the time interval from ingestion of the
drug is more relevant. Although acetazolamide enhances salicylate
elimination, it might aggravate the profound acidosis present in
most children with severe salicylate poisoning (Reimold, Worthen and
Reilly, 1973; Jewett, 1973).
Haemodialysis for aspirin poisoning was first reported by Doolan,
Walsh and Wishinsky (1951) and they recommended early treatment.
Dukes, Blainey, Cumming and Windowson (1963) compared simultaneous
haemodialysis and forced diuresis with forced alkaline diuresis for
the treatment of salicylate poisoning and both were effective. The
effects of charcoal haemoperfusion and haemodialysis for severe
salicylate poisoning in laboratory animals have been compared (Hill,
1973).
f - Salicylate pharmacokinetics and the use of forced alkaline
diuresis for poisoning
1. Absorption
Salicylates are almost always taken orally (Levy, 1962) and the
most common form is acetyl salicylic acid, a weak organic acid with
a pKa value of 3.5. Its gastrointestinal absorption occurs predom¬
inately by passive diffusion of non-ionised molecules across the
biological membrane (Milne, Scribner and Crawford, 1958; Levy and
Leonard, 1966). In the acidic gastric contents (pH 1-2) acetyl-
salicylic acid is nonionised, thus it enters the mucosal cells
where /
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where it becomes ionised (pH 7.0). Ionised acetyl sal icy!ic acid
passes slowly into neighbouring compartments such as endothelial
cells and capillaries (Brune, Graf and Rainsford, 1977). Three
factors (gastric emptying, aspirin dissolution and intragastric pH)
which influence acetyl salicylic absorption were studied in human sub¬
jects and dogs. The major portion of the salicylate in the blood
during the first 20 minutes came from the stomach. The impedance of
gastric emptying did not affect, but low pH and rapid dissolution
accelerated acetyl salicylic acid absorption (Truitt and Morgan,
1964). Pottage, Nimmo and Prescott (1974) showed that the pH-
partition theory did not hold in clinical practice. They found that
achlorhydric patients absorbed the drug more rapidly than healthy
volunteers.
Levy (1961) showed that the in vivo absorption rates of different
commercial aspirin tablets were proportional to the ijn vitro dissol¬
ution rate. Leonard (1963) also studied the influence of solubility
on the rate of gastrointestinal absorption of aspirin in a total of
168 experiments in 55 normal subjects. He demonstrated that plain
aspirin was absorbed relatively slowly and maximum blood concentrations
of salicylate were not attained by 60 minutes. Buffered aspirin pre¬
parations were more rapidly absorbed with peak plasma concentrations
at 30 to 45 minutes and for effervescent tablets the peak was at 20 to
30 minutes. Similar results were obtained with aspirin dissolved
in hot water. In another study, it was found that buffered aspirin
in a test meal (pH 7.0) emptied more rapidly from the stomach than
a test meal containing unbuffered (pH 2.8) aspirin. After 10 min¬
utes at least ten times less was absorbed from the buffered solution
(Cooke /
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(Cooke and Hunt, 1970) demonstrating rapid gastric absorption of
unbuffered aspirin. Chiou and Onyemelukwe (1974) showed that there
were no statistically significant differences in cumulative salicyl¬
ate urinary excretion at 3, 6, 12 and 24 hours, between five differ¬
ent brands of buffered aspirin tablets. Food tends to reduce the
rate of absorption of acetyl salicylic acid (Koch, Schultz, Wills,
Hallquist and Welling, 1978). The absorption kinetics following oral
administration of an aqueous solution of 650 mg aspirin were studied
by Rowland, Riegelman, Harris and Sholkoff (1972). They concluded
that absorption was a first-order process, with a half-life ranging
from 4.5 to 16 minutes suggesting that absorption is predominately
from the stomach. Only 68% of the dose reached the peripheral cir¬
culation intact and the remainder was hydrolysed during absorption by
esterases in the gut wall.
Drug interactions may enhance absorption (Prescott, 1973).
Plasma salicylate concentrations were greater following oral admini¬
stration of the codeine-containing preparation, Safapryn-Co than from
the identical preparation without codeine, Safapryn (Nimmo, King and
Prescott, 1979; Bradbrook, Morrison, Rodgers and Spector, 1979).
In summary, unbuffered aspirin appears to be absorbed more
rapidly from the stomach. However, gastric emptying is more rapid
with buffered aspirin, which is then absorbed from the small intestine.
2 - Distribution and Metabolism
Over the dose range 0.3 to 1.2 g of acetyl salicylic acid, the
area under the acetyl salicylic acid concentration-time curve was
proportional to the dose administered. Salicylic acid was shown to
be /
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be the exclusive metabolite of acetyl salicylic acid. Following
absorption, the liver and perhaps the kidney were proposed as the
principal sites of hydrolysis of acetyl salicylic acid. After intra¬
venous administration of 650 mg acetyl salicylic acid or 500 mg
salicylic acid, the first exponent plasma elimination half-life was
2-5 minutes for both compounds, whereas the second exponent was
13 - 19 minutes and 3.5 - 4.5 hours for acetyl salicylic acid and
salicylic acid respectively (Rowland and Riegelman, 1968; Thompkins
and Lee, 1969). The plasma elimination half-life of salicylate is dose-
dependent. An average half-life of 20 hours (15 - 29 h) in 17 intoxi¬
cated children with salicylate was reported by Done (1960).
Levy and Leonards (1966) pointed out that relatively slow diff¬
usion across certain tissue barriers may result in lag effects, with
maximum salicylate concentrations occurring at different times in
different tissues. High concentrations of acetyl salicylic and
salicylic acids are found in the glandular region of the stomach and
the kidney tubules of the rat as well as in inflamed tissue (Brune,
1977). Even at high plasma salicylate concentrations very little is
present in the human erythrocytes (Smith, Gleason, Stoll and 0'Gorzalek,
1946).
The major metabolite of salicylic acid is the glycine conjugate,
salicyluric acid. Salicylic acid forms an ether or phenolic glucur-
onide and an ester or acyl glucuronide. In addition, a small fraction
is oxidised to gentisic or 2,5 dihydroxybenzoic acid and an even
smaller fraction to 2,3 dihydroxybenzoic and 2,3,5 trihydroxybenzoic
acids (Milne, 1962) (Fig.l). The formation of salicyluric acid from sali¬
cylic acid reaches a maximal rate when the total amount of salicylate
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in the body exceeds 300 mg (Levy, 1965 a). Administration of glycine
has no effect on the formation of salicyluric acid, but benzoic acid
has a pronounced inhibitory effect and surprisingly this is not pre¬
vented by the co-administration of glycine (Amsel and Levy, 1969).
Inter-individual differences in glycine conjugation in 58 male and
27 female healthy volunteers were largely normally distributed, but
with a 12-fold range (Caldwell, O'Gorman and Smith, 1980). Phenolic
glucuronide formation is also capacity-limited (Hollister and Levy,
1965; Levy, Tscuchiga and Amsel, 1972).
The apparent volume of distribution of salicylate is dose-
related. In children it ranged from 162 to 345 ml/kg and was larger
at the higher doses (Levy and Yaffe, 1974). Presumably the larger
distribution at higher doses is due to the highly concentration-
dependent nature of salicylate protein binding, vasodilation, higher
cardiac output and increasing uptake into tissues as a result of
acidosis.
The kinetics of salicylate metabolism were the same in patients
with rheumatoid arthritis and non-inflammatory backache. (Gibson,
Zaphiropoulos, Grove, Widdop and Berry, 1975). Neither the plasma
salicylate concentration-time curves nor the plasma elimination half-
lives differed in young and elderly subjects in one report (Melander,
Bodin, Danielson, Gustafsson, Hugland and Westerland, 1978), but in
another study the plasma elimination half-lives and the volume of
distribution of salicylate were significantly lower in the young
subjects (Cuny, Royer, Mur, Serot, Faure, Netter, Millard and Penin,
1979).
Time-dependent changes in the pharmacokinetics of acetylsali-
cylic acid were studied following a single 1500 mg oral dose.
The /
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The bioavailability of the drug was significantly greater when it was
administered at 06.00 than at 18.00 or 22.00 hours (Markiewicz and
Semenowicz, 1979).
The effects of chronic administration of aspirin (3.9 g/day)
were studied in eight subjects. Plasma and salivary salicylate con¬
centrations declined significantly after peak levels were achieved
between days 3 and 10, possibly due to an induction of salicylurate
formation. The mean salicylurate excretion increased with time dur¬
ing the study, although the change was not statistically significant
(Rumble, Brooks and Roberts, 1980).
The plasma protein binding of salicylate will be reviewed in
Chapter 3, Section II.
3 - Excretion
The renal excretion of unconjugated salicylate involves glomer¬
ular filtration, active tubular secretion and tubular reabsorption
(Schachter and Manis, 1958).
The rate of elimination of salicylate following oral single and
multiple doses of acetyl salicylic acid in healthy male volunteers
was studied (Bedford, Cummings and Martin, 1965) and the excretion
patterns were as follows :
(i) an initial period when drug absorption, distribution and
metabolism affect the rate of excretion
(ii) an intermediate period when the rate of excretion is by
simultaneous first-order and zero-order processes
(iii) a final period when all metabolites are formed with apparent
first-order kinetics
Practically all of a dose of acetyl salicylic acid can be
recovered /
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recovered in the urine as salicylic acid and its various metabolites
and elimination is slower at high than at low doses (Levy, 1965b;
Levy and Yaffe, 1968). The rate of excretion of acetyl salicylic
acid metabolites depends on factors such as urine pH and flow rate
(Davison, 1971).
Urinary excretion kinetics of salicyluric acid following oral
administration of 640 mg acetyl salicylic acid in healthy volunteers
and intravenous administration of salicyluric acid in man (196 mg)
and dog (9 mg/kg) were studied. The mean urinary excretion rate
constant was found to be 0.109 in man and 0.0139 in the dog
(Elliott, 1966). In another study, the kinetics of salicyluric
elimination in man after intravenous (97.5 mg) and oral (150 mg) sali¬
cyluric acid and salicylic acid (1 g orally 3 hr earlier) followed by
benzoic acid (3.2 g orally) as the blocker in healthy volunteers
resulted in a rate-limiting formation step in the excretion of
salicyluric acid following salicylic acid administration (Levy, Amsel
and Elliott, 1969).
The urinary excretion of gentisic acid in man accounted for 0.6%
of a 0.32 g and 1.1% of a 1.28 g dose of oral acetyl salicylic acid,
suggesting that the excretion of gentisic acid is dose-dependent
(Boreham and Martin, 1969).
4- Effects of urine pH and flow rate on salicylate excretion
following therapeutic doses
According to Hanzlik (1926), Fleisher in the last century
reported that the administration of sodium bicarbonate shor¬
tened the "period of elimination" of salicylate from 36 to
14 hours and Ehrmann made a similar claim, but this was not
confirmed by Hanzlik, Scott and Thoburn. However, the
administration of 3 g sodium bicarbonate every 3 hours together
with /
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with 2 - 3 g sodium salicylate every 6 hours in rheumatic patients
lowered plasma salicylate levels. The renal excretion and clearance
of free salicylate increased as the urine pH rose above 7.0 (Smith,
Gleason, Stoll and Ogorzalek, 1946). In another study, oral admini¬
stration of 7.8 g sodium bicarbonate within 3.5 hours of a single
oral dose of acetyl sal icy!ic acid in healthy volunteers increased
the mean urinary excretion of salicylate from 925 to 1501 mg (Lester,
Lolli and Greenberg, 1946). Hoffman and Nobe (1950) also studied
the influence of urinary pH on the renal excretion of salicyl deriv¬
atives during aspirin therapy and concluded that when sodium bicar¬
bonate was administered in quantities sufficient to alkalinise the
urine, the free salicylate clearance was increased by a factor of
3-13.
The effect of changes in urine flow rate and pH on salicylate
excretion was studied in two healthy adult male volunteers and three
patients (one with normal renal function and two with chronic glomero-
nephritis and uraemia). There was a good correlation between the
urine pH and free salicylate clearance, less effect with water
diuresis and a moderate effect with osmotic diuresis. Salicylate
excretion was lower in the patients with moderate uraemia (McPherson,
Mi 1ne and Evans, 1955).
The effects of infusion of 5 g sodium bicarbonate in 600 ml (3 g
in 100 ml in 10 minutes and 2 g in 500 ml as sustaining infusion) on
the simultaneously determined renal clearances of salicylate, inulin
and p-amino-hippurate were studied in 10 normal human subjects by
Gutman and Sirota (1955) with the following results :
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1. Inulin and p-aminohippurate clearances were not consistently
affected by infusion of sodium salicylate alone or in combin¬
ation with sodium bicarbonate.
2. The free salicylate/inulin clearance ratios ranged from 5% to
60% and as the urinary pH rose, the salicylate clearance
increased approximately three-fold while the net tubular
reabsorption of free salicylate decreased correspondingly.
When the urine pH exceeded 7.5 more salicylate was usually
excreted than filtered, implying active tubular secretion.
It was suggested that the renal elimination of salicylate is
a complex process involving glomerular filtration, tubular
conjugation, tubular secretion and tubular reabsorption.
The administration of 4 g of sodium bicarbonate in 13 subjects
taking 4 g of aspirin daily resulted in a statistically significant
decrease in plasma salicylate concentrations (Levy and Leonard, 1971).
Antacids may increase urine pH and can lower steady-state plasma
salicylate concentrations under clinical conditions (Levy, 1978).
5 - Effects of forced alkaline diuresis in aspirin poisoning
Intravenous administration of 3.5 to 5 mEq/kg of sodium
bicarbonate resulted in an alkaline urine in 15 of 18 children with
salicylate poisoning. There was a significantly more rapid fall in
serum salicylate concentrations than in control patients who received
fluid alone (Oliver and Dayer, 1960). The possible therapeutic use¬
fulness of forced diuresis for the treatment of salicylate poisoning




A forced alkaline diuresis regime consisting of infusion of
500 ml of 0.9% sodium chloride, 5% dextrose and 2% sodium bicarbonate
in rotation at 2 litres per hour for 8 hours gave results apparently
comparable to haemodialysis in producing clinical and biochemical
improvement in severe salicylate poisoning (Dukes et al., 1963).
Intravenous sodium chloride and sodium bicarbonate solution produced
an average urine-flow rate of 6.9 ml/min at a mean pH of 7.5 in
patients with aspirin poisoning and resulted in a diminution of
serum salicylate concentration to one-half of the original values in
a mean time of 7.5 hours. Serum potassium concentrations also fell
during treatment from a mean of 5.1 to 3.2 mEq/1 (Cumming, Dukes and
Widdowson, 1964). In 28 patients suffering from moderate to severe
salicylate poisoning, forced alkaline diuresis produced few complica¬
tions and there was no mortality (Mackintosh and Matthew, 1964). It
was suggested that with the use of 5% sodium bicarbonate in 3% glucose
additional chloride (as potassium chloride) might be given to offset
losses due to sweating and vomiting (Garber, 1964). Beveridge,
Forshall, Munro, Owen and Weston (1964) infused one litre of M/6
sodium bicarbonate and one litre of 5% dextrose during the first 2
hours, followed by smaller amounts to maintain an alkaline urine
with a urine flow rate of over 500 ml/hour. This regime was not
effective in some patients and was criticised by Lawson, Mackintosh
and Matthew (1964) for the use of such a modest infusion.
Lawson, Proudfoot, Brown, Macdonald, Fraser, Cameron and
Matthew (1969) compared different regimes of forced diuresis for
aspirin poisoning in adults, with clinical and biochemical monitoring.
They concluded that although forced alkaline diuresis (0.5 litre of
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0.9% saline, 5% laevulose and 1.26% sodium bicarbonate in rotation
at a rate of 2 litres per hour, with one gram of potassium chloride
added to each 0.5 litre bottle from the fifth onwards) produced the
quickest fall in plasma salicylate concentrations, its use was com¬
plicated by hypokalaemia despite the considerable potassium supple¬
ments and there was also a potentially dangerous rise in arterial pH.
They recommended forced "cocktail" diuresis (a mixture of 0.5 litre
of normal saline, one litre of 5% laevulose, 0.5 litre of 1.26%
sodium bicarbonate and 3 gram of potassium chloride, given a 2 litres
per hour for 3 hours) as the treatment of choice for acute salicylate
poisoning in adults, and it could be safely undertaken without bio¬
chemical control. Infusion of the "cocktail" failed to alkalinise
urine (pH > 7.0) which is possibly due to oxidation of laevulose in
the alkaline solution.(Conn and Stumpf, 1972). Hypokalaemia
induced by the forced alkaline diuresis may be due to the late
infusion of potassium (from the fifth bottle onwards).
A 36 year old man with severe salicylate poisoning (blood
salicylate concentration over 1300 pg/ml) was treated successfully
with a different regime of forced alkaline diuresis (immediate intra¬
venous administration of 150 mEq of sodium bicarbonate followed by
the rapid infusion in rotation of sodium bicarbonate, normal saline
and 5% dextrose). During the first 12 hours, 14 litres of fluid
were administered and the urine output was 10.3 litres ; 190 g of
mannitol was given in attempts to counter fluid retention (Savage,
Ward, Simpson and Cohen, 1969). They did not consider the great
insensible loss due to hyperventilation and sweating in severe
salicylate poisoning and if the patient had been weighed before
infusion and 24 hr. later, it could have been realised that there
was no indication for the mannitol.
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The effects of alkaline mannitol diuresis (10 litres containing
348 mEq of sodium bicarbonate and 475 g of mannitol) and forced
alkaline diuresis (10 litres containing 360 mEq of sodium bicarbonate
and 365.5 g of dextrose) were compared in two groups of patients with
moderate to severe salicylate poisoning. Mannitol did not increase
the excretion of salicylate, although there was a smaller fall in the
serum potassium and rapid removal of salicylate for a smaller rise
in serum pH than with the forced alkaline diuresis alone (Prowse,
Pain, Marston and Cumming, 1970).
Morgan, Bennett and Polak (1968) proposed the administration of
one litre of 10% mannitol in the first hour and one litre of M/6
lactate over the next two hours, and subsequently compared it with an
acetazolamide-bicarbonate regime in which 250 mg i.v. acetazolamide
followed by one litre of 1.4% sodium bicarbonate was given in the
first hour and one litre of 1.4% sodium bicarbonate plus 20 mEq potas¬
sium chloride in the second hour (Morgan and Polak, 1969). The two
groups of patients had serum salicylate concentrations ranging from
440 to 880 pg/ml and the relationship between urine pH and salicylate
clearance was the same in both groups although they were higher with
the acetazolamide-bicarbonate treatment. The influence of urine
flow rate on the relationship between salicylate clearance and urine
pH was also similar (Morgan and Polak, 1971). Since there was a
highly significant negative relationship between salicylate elimina¬
tion half-life and the renal clearance and it is known that acetazo-
lamide may depress tubular secretion of salicylate by competitive
inhibition (Weiner, Washington and Mudge, 1959) the superior effects




Water diuresis (0.225% saline solution with 2.5% glucose and
20 mEq/litre potassium chloride, given at a rate of 2 ml/minute),
forced alkaline diuresis (the same regime as the water diuresis, but
including sodium bicarbonate to increase the urine pH above 7.5) and
forced alkaline diuresis plus acetazolamide (10 mg/kg) were compared
in three groups of young dogs with salicylate intoxication (blood
salicylate concentration 1000 yg/ml). Blood salicylate concentra¬
tions fell at about the same rate in all three groups. Urinary sal¬
icylate excretion and pH increased rapidly following acetazolamide
while there was a three-hour delay in salicylate excretion after bicar¬
bonate and it did not increase at all with water diuresis. Although
the rapid action of acetazolamide favours its use in the treatment of
salicylate poisoning, the profound acidosis present in most children
precludes its administration (Reimold et al., 1973).
Prescott (1974) stressed the haemodilution and changes in the
volume of distribution of salicylate which occur during forced
alkaline diuresis and believed that the amounts of drug claimed
to have been removed by this method of treatment may be overestimated.
6 - Effects of forced alkaline diuresis with loop diuretics in
aspirin poisoning
Berg (1977b) compared the effects of frusemide and bumetanide
(20 mg and 0.5 mg 2 hourly) in two groups of patients (9 and 8 resp¬
ectively) with plasma salicylate concentrations of 300-600 yg/ml who
were receiving forced alkaline diuresis (0.9% saline, 5% dextrose and
1.4% sodium bicarbonate with potassium and calcium chloride supple¬
ments infused at a rate of 250-300 ml/h for 16-48 hours). The two
groups /
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groups had equivalent 24 hour urine outputs (about 6 1/24 hours),
but the patients on frusemide retained significantly less fluid
than the other group (means of 696 and 1152 ml respectively). The
urine flow rate was at least as much as could be achieved by osmotic
diuretics and since the latter have more side effects, they should
not be used for forced diuresis. Dehydration was a common problem in
patients who had ingested aspirin more than 12 hours before admission
and Berg concluded that diuresis may prevent rehydration. However,
in the average adult patient who is admitted early after aspirin
ingestion, sodium and water retention is more likely and forced
alkaline diuresis with loop diuretic should be used with careful
supervision of fluid balance.
Infusion of 75 ml of 20% mannitol and 40 mg frusemide followed
by 500 ml of 5% dextrose plus 50 mEq sodium bicarbonate, 500 ml of
5% dextrose plus 25 mEq potassium chloride and 500 ml of normal sal¬
ine in rotation at a rate of 30 ml/kg/hr. was recommended (McQueen,
1977) as the urgent treatment for salicylate poisoning, but there is
no evidence to support the efficacy of this regime.
Interaction between salicylate and two loop diuretics
(frusemide and piretanide) was studied in four healthy subjects
(3 M and 1 F) by Valette and Apoil (1979). When lysine acetyl-
salicylic acid was given before frusemide (but not piretanide),
there was a significant decrease in the diuresis and sodium excretion
and an increase in potassium excretion. They suggested different
mechanisms of interaction such as prostaglandin synthetase inhibition




In unpaired and paired studies in man, the effects of 1000 and
1500 mg of intravenous acetyl salicylic acid on the glomerular fil¬
tration rate, urinary sodium and potassium excretion and osmolality
were studied with and without 40 and 10 mg of intravenous frusemide
(Bartoli, Arras, Faedda, Soggia, Satta and Olmeo, 1980). Aspirin
alone caused no significant change in any of the variables measured.
In the unpaired study, frusemide greatly increased urine flow
rate and sodium and osmolar clearances and these effects were antag¬
onised by aspirin. However, these findings were not confirmed by the
paired studies and surprisingly the higher dose of aspirin had less
inhibitory effects. Overall there was no significant difference in
the effect of frusemide in the presence or absence of aspirin in
the same subjects. The blunting of the diuretic effect of frusemide
by acetyl salicylic acid was thought to be due to inhibition of proxi¬
mal tubular secretion rather than inhibition of prostaglandin
synthesis.
SUMMARY
Acetyl salicylic acid is a weak organic acid with pKa 3.5 and
its gastrointestinal absorption occurs predominately by passive
infusion of nonionised molecules across the mucosal membrane.
Aspirin and other salicylates can inhibit the enzymatic produc¬
tion of prostaglandins.
Acetyl salicylic acid is rapidly hydrolysed to salicylic acid and
the latter is conjugated with glycine and glucuronide with a limited
capacity to form salicyluric acid, salicyl phenyl and salicyl acyl
glucuronides respectively. A small amount of salicylic acid is
hydroxy!ated /
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hydroxy!ated to give gentisic acid and two other hydroxy metabolites.
Diflunisal is a new salicylic acid derivative with longer duration of
action which is conjugated with glucuronic acid.
Salicylates in therapeutic doses have pharmacological and some¬
times toxic effects on most organs of the body. In overdosage they
cause tinnitus, deafness, sweating, hyperventilation, respiratory
alkalosis and metabolic acidosis. Salicylate metabolism and elimin¬
ation are dose-dependent. The renal excretion of salicylate involves
glomerular filtration, tubular conjugation, active tubular secretion
and passive tubular reabsorption.
The renal excretion and clearance of salicylic acid is pH
dependent, and thus administration of sodium bicarbonate may enhance
elimination. The urine flow rate also affects salicylate elimination,





PURPOSE AND OUTLINE OF THE STUDY
(a) Objectives
The author has been concerned with the management of poisoning
for many years, first as physician in charge of the Poisoning Treat¬
ment Unit, Mashhad University, Iran, and subsequently as Research
Fellow in the University Department of Therapeutics and Clinical
Pharmacology and the Regional Poisoning Treatment Centre at the Royal
Infirmary, Edinburgh. In spite of the different pattern of poisoning
in Mashhad, analgesic overdosage is one of the commonest causes of
admission to the Unit (second to hypnotics), and salicylate poisoning
is the commonest analgesic overdosage (Balali-Mood and Salehi-Mi 1 ani,
1979).
Acetylsalicylic acid is one of the cheapest, most easily avail¬
able and most widely used drugs in the world. In the United Kingdom
more than two million kg of aspirin is consumed every year; an aver¬
age of about 2 tablets per week for every member of the population.
In the United States of America, the average intake per head is about
twice that of the United Kingdom (Bowman et al., 1980). In the
United Kingdom, the number of aspirin tablets sold to the public
increased from 3156 million in 1973 to 3450 million in 1976, whereas
the corresponding sale of paracetamol was 2526 and 2872 million
tablets respectively (Fryers, 1977).
Aspirin was for many years the most frequently taken poison
and killer of children in the United States (Kaye, 1972). Although
there has been a substantial reduction in the number of fatal
poisonings /
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poisonings in children under 5 years (61 deaths in 1968 compared with
26 in 1973) due to the use of safety packing and reduction in the unit
dose of flavoured aspirin in the United States (Mofenson and Greensher,
1975; McQueen, 1977; Done, 1978), adult aspirin preparations pose the
greater hazard (Done, 1978). Locket (1973) reported that the number
of admissions for aspirin poisoning in the United Kingdom had increa¬
sed steadily from 3800 in 1960 to more than 13,000 in 1973. Of the
16,000 children admitted to hospital for accidental poisoning in
Great Britain each year, about 5,000 were due to the especially flav¬
oured "Junior" aspirins (Sweetnam, 1974; Legg, 1974).
The number of patients admitted to hospital for salicylate
poisoning between 1972 and 1974 in New Zealand had remained about the
same (around 300 cases per year), but the number of deaths was higher
in 1974 (3) than in 1972 (1) (McQueen, 1977). Since 1967 between 10
and 20 per cent of all admissions to the Regional Poisoning Treat¬
ment Centre, Royal Infirmary, Edinburgh, have been due to salicylate
poisoning (Proudfoot and Park, 1978).
Poisoning with diflunisal is still not common and to date only
one brief report of overdosage has been published (Upadhyay and
Gupta, 1978). Forced alkaline diuresis has been employed routinely
for the treatment of moderate to severe salicylate poisoning whereas
haemodialysis and column haemoperfusion are reserved for very severe
cases (Ferguson and Boutros, 1970).
Forced alkaline diuresis has been recommended for the treatment
of diflunisal overdosage (ABPI Data Sheet Compendium 1979-1980) but
the effects on its removal were unknown. In one report, it appeared
to have little beneficial effect, although no measurements were made
(Upadhyay and Gupta, 1978).
Different /
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Different regimes of forced alkaline diuresis in salicylate
poisoning have been used by many workers, but the effects of this
treatment on salicylate distribution, metabolism and elimination
have not been investigated in detail. The assays used to estimate
the drug in overdose patients responded only to salicylic acid and
did not measure metabolites and unchanged acetyl salicylic acid. A
simple, sensitive and specific high performance liquid chromato¬
graphic assay was therefore developed to estimate acetyl salicylic
acid and its metabolites in plasma and urine.
The present study was undertaken to investigate the causes of
the following problems encountered with salicylate poisoning.
1. The increase in plasma salicylate concentrations observed
despite gastric lavage in some patients with aspirin poisoning.
This could be due to delayed absorption or slow hydrolysis of
acetyl salicylic acid to salicylic acid after absorption.
2. Although plasma salicylate concentrations usually decline with
clinical improvement after forced alkaline diuresis, the amount
of salicylate recovered in the urine is not nearly enough to
account for the fall observed. This spurious reduction in plasma
salicylate could be due to fluid retention and increased volume
of distribution of salicylate.
3. Effects of frusemide combined with forced alkaline diuresis on
salicylate distribution and elimination following overdosage.
4. The role of protein binding of salicylic acid and its metabolites
in salicylate poisoning.
5. Failure to adequately raise the urine pH in some patients.
6. /
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6. Induction of hypokalaemia, hypocalcaemia, hypophosphataemia,
hypomagnesaemia and other biochemical abnormalities.
7. Effects of prostaglandin-mediated effects of salicylate on the
kidney (e.g. antidiuretic effect).
8. Haematological changes in aspirin poisoning.
9. Frequency of clinical features of salicylate poisoning and
the effects of forced alkaline diuresis on clinical manifest¬
ations.
10. Effects of forced alkaline diuresis on diflunisal elimination.
(b) Outline of the study
1. Laboratory investigations
Sensitive, specific and reproducible high performance liquid
chromatographic methods were developed for the estimation of
acetyl sal icy!ic, salicylic and salicyluric acids and diflunisal
in plasma and urine. Salicylate protein binding was investigated
in-vitro and in-vivo and compared with in-vitro albumin binding
using an ultrafiltration technique. Solutions used for forced
alkaline diuresis and forced diuresis were titrated against
acid and base.
2. Healthy volunteers
The effects of changes in urine pH and flow rate on the
elimination of acetylsalicylic acid and its metabolites and
diflunisal were studied in healthy volunteers as the basis




The relative importance of urine flow rate and pH on salicylate
elimination following overdosage was investigated in four groups of
patients who received either forced diuresis, alkali alone, forced
alkaline diuresis or forced alkaline diuresis with frusemide.
Another group of patients with mild to moderate salicylate poison¬
ing received no specific treatment as the controls. Clinical feat¬
ures, biochemical and haematological abnormalities were also studied.
SECTION II
ANALYTICAL METHODS FOR THE ESTIMATION OF ACETYLSALICYLIC ACID
AND ITS METABOLITES AND DIFLUNISAL IN PLASMA AND URINE.




ESTIMATION OF ACETYLSALICYLIC ACID AND ITS METABOLITES IN PLASMA
AND URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
(a) - Review of analytical methods
Several methods have been reported for the estimation of sali¬
cylate including colorimetry, fluorimetry, ultra-violet spectro¬
photometry, gas liquid chromatography, liquid chromatography and high
performance liquid chromatography.
A simple colorimetric method for routine estimation of plasma
salicylic acid concentrations with the usual therapeutic doses was
reported by Brodie, Udenfriend and Coburn (1944). This involved a
separation of salicylic acid from plasma by extraction into ethylene
chloride and its return to an aqueous phase as the coloured iron
complex. Smith (1951) described another colorimetric method for the
quantitation of acetyl salicylic and salicylic acids (with and without
hydrolysis) using an aqueous solution of the Folin-Ciocalteu phenol
reagent following two phases of acid and alkaline extractions. This
assay was simplified by employing only one plasma sample for both
salicylates, but two calibration curves at the end which resulted in
more accurate estimation of acetyl salicylic acid and better recovery
than the Smith method (Muni, Leeling, Helms, Johnson, Bare and
Phillips, 1978) Trinder (1954) developed a rapid colorimetric
assay /
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assay for the determination of salicylate in biological fluids based
on a reagent containing ferric nitrate, mercuric chloride and hydro¬
chloric acid, which precipitates the proteins and simultaneously
reacts with salicylic acid to give a purple colour.
Sensitive fluorimetric methods for the specific estimation of
salicylic acid and each of its principal metabolites in plasma and
urine using spectrophotof1uorometry were described by
Schachter and Manis (1958). With these methods, the salicyl conjug¬
ates were detected and estimated in the plasma of normal subjects
given a single oral dose of salicylate.
A simple ultraviolet spectrophotometric method was developed
for the simultaneous determination of salicylic acid, acetyl salicylic
acid, salicylamide, caffeine and phenacetin in tablets and powders at
three different wavelengths and under three different conditions of
acid and base content (Clayton and Thiers, 1966).
Rowland and Riegelman (1967) described a specific and sensitive
method for estimation of acetyl salicylic and salicylic acids in
plasma. These compounds were extracted from acidified plasma with
ether. Acetyl salicylic acid was measured by gas liquid chromatography
following derivatisation and salicylic acid was measured spectrophoto-
fluorometrically. A rapid, sensitive gas liquid chromatographic
method for the simultaneous analysis of acetyl salicylic and salicylic
acids in admixtures and in single component aspirin tablets was repor¬
ted by Watson, Crescuolo and Matsui (1971). This method was modified
to quantitate acetyl salicylic and salicylic acids in human plasma as
well (Tarn, Au and Abbott, 1979). Other gas liquid chromatographic
methods for the estimation of acetyl salicylic and salicylic acids
were /
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were also reported (Thomas, Solomonraj and Col dwell, 1973; Walter,
Biggs and Coutts, 1974).
Conditions for the routine separation and quantitation of aspirin,
caffeine, 4-hydroxyacetani1ide, 4-ethoxyacetani1ide and salicylamide
by liquid chromatography were described by Stevenson and Burtis (1971).
An automated high-pressure liquid chromatographic method for the
separation and determination of aspirin, phenacetin and caffeine in
pharmaceutical dosage forms was reported (Ascione and Chrekian, 1975).
Other high-pressure liquid chromatographic assays for the estimation
of aspirin and salicylic acid in different dosage forms were also
reported (Das Gupta, 1980a; Das Gupta, 1980b; Kirchhoefer and Juhl,
1980; Kirchhoefer, 1980).
A simple and rapid high-pressure liquid chromatographic method
was developed to estimate acetyl salicylic, salicylic and salicyluric
acids simultaneously in plasma. The procedure involved the solvent
extraction of these compounds from acidified plasma with a benzene
ethyl acetate mixture using phthalic acid used as internal standard.
The mobile phase was 30% (V/V) acetonitrile in diluted phosphoric acid
with a flow rate of 1 ml/min and ultraviolet detection at 237 nm (Peng,
Gadalla, Smith, Peng and Chiou, 1978). Two other similar high-pressure
liquid chromatographic methods for the estimation of acetyl salicylic
and salicylic acids in plasma were also reported (A1i, McDonald,
Thiessen and Coates, 1980; Lo and Bye, 1980). Another high-pressure
liquid chromatographic assay was developed to determine salicylic,
salicyluric and gentisic acids in mouse and rat blood, urine and
faeces and rat embryos. The procedure involved aqueous dilution of
the biological sample, addition of methanol - 1% acetic acid in water
(40 : 60), centrifugation and injection of the supernatant onto the
column /
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column (Maulding and Young, 1980). A simultaneous liquid chromatogra¬
phic quantitation of salicylic, salicyluric and gentisic acid in
plasma using ultra-violet detection at 313 nm and two solvents (5%
acetic acid in water and pure methanol) at 2.6 ml/min flow rate, was
described (Cham, Johns, Bochner, Imhoff and Rowland, 1979). They used
o-methoxybenzoic acid as internal standard and acetonitrile as
protein precipitant with no solvent extraction. Sensitivity was 20 pg/L
with linear response and complete recovery. Another simultaneous det¬
ermination of salicylic acid, indomethacin and its major metabolites
in serum and urine by reversed-phase liquid chromatography was repor¬
ted (Terweij-Groen, Heemstra and Kraak, 1980).
In conclusion, the colorimetric and fluorometric determinations
of acetyl salicylic and salicylic acids are not specific and measure
acetyl salicylic acid only by difference after hydrolysis to sali¬
cylic acid. The differential ultra-violet spectrophotometry of the
two salicylates based on the pH-dependent shift in their absorbance
may require correction because of overlap of their absorption spectra.
Furthermore, these methods may yield high and variable blank values.
Gas liquid chromatographic assays are specific and sensitive and
permit the measurement of both compounds simultaneously, but extraction
and chemical derivatisation are needed, which are time-consuming and
can be complicated by hydrolysis of acetyl salicylic acid to salicylic
acid and multiple product formation. High performance liquid chrom¬
atographic methods which involved solvent extraction are again time-
consuming and complicated by the acetyl salicylic acid hydrolysis,
but those without solvent extraction that measure acetylsalicylic,
salicylic, salicyluric and gentisic acids simultaneously are
appropriate.
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Acetyl sal 1cy1ic acid hydrolysis
It is well known that acetyl salicy1ic acid is rapidly hydrolysed
in aqueous solution and its hydrolysis accelerated by esterases
found in the blood or plasma (Lester et al., 1946). The in vitro
hydrolysis was found to obey pseudo-first-order kinetics with a mean
half-life of 32 minutes for blood and 66 minutes for plasma at a concen¬
tration of 13 pg/ml. Excessive concentrations of acetyl salicylic
acid might saturate the enzymes and cause the reaction to follow zero-
order kinetics (Harris and Riegelman, 1967). It has been shown that
the hydrolysis rate of aspirin is constant with minimum hydrolysis
at pH 4 and maximum at pH 8 (Landecker, Wellington, Thomas and Piper,
1977; Dearden and George, 1979).
(b) Development of high performance liquid chromatographic methods
for the simultaneous determination of acetyl salicylic acid and
its metabolites in plasma and urine
(i) Materials
Acetyl salicylic acid and ethyl acetate were obtained from May
and Baker Ltd., salicyluric acid, gentisic acid and benzoic acid
from Sigma Chemical Company, salicylic acid, acet-p-toluidide,
isopropanol, sodium acetate, monopotassium phosphate, disodium phos¬
phate, sodium chloride, potassium fluoride and potassium nitrate
from BDH, methanol from James Burroughs Ltd., glacial acetic acid
from Koch-Light Laboratories Ltd., perchloric acid from Fisons
Scientific Apparatus and B-glucuronidase from Sigma Chemical Co.
(ii) Instrumentation
The high performance liquid chromatographic system consisted
of /
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of a Pye Unicam LC3 UV detector, set up at 243 nm (although the maximum
UV-absorbance for acetyl salicylic, salicylic and salicyluric acids was
220, 230 and 239 nm respectively, because of ethyl acetate in the
mobile phase 243 nm was chosen as the wavelength), an Orlita DMP AE
10.4 pump, a Bryans Model 28000 recorder and a Shandon type column
and septum injector. The column was 150 x 4.5 mm i.d. internally
polished, stainless steel, slurry packed with Hypersil 0DS, C18 -
TMS (Shandon), 5 y particle size.
(iii) Plasma assay
Chromatographic conditions
The mobile phase consisted of 0.02 M potassium nitrate in 2% acetic
acid, isopropanol and ethyl acetate (100:12:4) and was degassed under
reduced pressure before use. The flow rate was 1.2 ml/min with a
working pump pressure of 1200 psi. Detector sensitivity was set at
0.08 absorbance units full scale and changed to 0.32 after the acet-
p-toluidide peak had eluted.
Preparation of standard solutions for plasma assay
Aqueous solutions of salicylic acid (2 mg/ml), salicyluric acid
(1 mg/ml) and acet-p-toluidide (500 yg/ml) as internal standard for
acetyl salicylic and salicyluric acids were prepared and kept under
refrigeration (4°C). The pH of the solutions were 3.0, 3.3 and 4.9
respectively and did not change during the study. These standard
solutions were stable and used for up to six months. Benzoic acid
was used as the second internal standard, for salicylic acid.
Acetyl salicylic and benzoic acid standard solutions (500 yg/ml)
were
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were always made up freshly before use. The internal standard solu¬
tion contained 100 pg/ml benzoic acid and 5 pg/ml acet-p-toluidide
in 6% perchloric acid and was used as the plasma protein precipitant.
Plasma standards were prepared by spiking blank plasma from five
healthy volunteers with acetyl salicylic acid (10-200 pg/ml), salicylic
acid (50-1000 pg/ml) and salicyluric acid (0.5-10 pg/ml).
Collection and storage of plasma samples
The blood samples were collected into lithium heparin tubes
(Searle Diagnostic, High Wycombe) containing 50 pi of 20% (W/V)
potassium fluoride solution. Plasma was separated immediately and
placed in glass tubes containing 50 pi of potassium fluoride solution
and 50 pi of glacial acetic acid and stored at -20°C until analysis.
Over 600 plasma samples from the healthy volunteers and patients
with aspirin overdosage were collected, stored and assayed.
Procedure for plasma assay
To 100 pi of unknown plasma sample or the spiked plasma standard
in a Dreyer tube was added 100 pi of the internal standard solution
(5 pg/ml acet-p-toluidide and 100 pg/ml benzoic acid in 6% perchloric
acid). After mixing, the sample was centrifuged at 2000 r.p.m. for
5 minutes and a 5-25 pi aliquot of the clear supernatant directly
injected into the chromatograph.
Two plasma standards of acetylsalicylic, salicylic and salicyluric
acids (100, 400, 5 pg/ml and 50, 200, 2.5 pg/ml respectively) were
assayed with each set of unknown samples.








M = concentration of the compound in the plasma (iig/ml)
M'= concentration of the compound in the standard (pg/ml)
R = peak height response ratio of the compound to internal standard
R'= peak height response ratio of the standard to internal standard
The glucuronide conjugates were measured by the difference
after hydrolysis as follows :
To 1 ml plasma was added 0.5 ml of 0.1M acetate buffer pH 5.0 and
0.1 ml 3-glucuronidase 120,000 activity, and after mixing, incubated
overnight at 37°C. The total salicylic and salicyluric acids were
measured as above
Results of plasma assay
A typical chromatogram of plasma obtained from a patient with
mild salicylism is shown in Figure 2.1. The retention times of sali¬
cyluric acid, acetylsalicylic acid, acet-p-toluidide, benzoic acid
and salicylic acid were 3, 3.5, 5, 7 and 10 minutes respectively. No
other interfering peaks were observed.
Validation of plasma assay
The calibration graphs of acetylsalicylic, salicylic and sali¬
cyluric acids were linear and passed through the origins (Figs. 2.2,
2.3 and 2.4 respectively). The precision and reproducibi1ity for
each compound are shown in Tables 2.1, 2.2 and 2.3 as the results of
5 replicate analyses of the spiked plasma. The overall recoveries
(drug /
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Figure 2.1. Chromatogram of blank plasma (left) and plasma from
a patient with aspirin overdosage (right).
SUA = salicyluric acid, ASA = acetyl salicylic acid,
APT = acet-p-toluidide and BA = benzoic acid as
internal standards, SA = salicylic acid.
0 to 80 120 160
PLASMA ACETYLSAIICYLIC ACID CONCENTRATION (>jg/ml)
200
Figure 2.2. Calibration graph for the estimation of acetyl-
salicylic acid in plasma, using high performance
liquid chromatography with acet-p-toluidide as
internal standard.
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PLASMA SALICYLIC ACID CONCENTRATION (>jg/ml)
Figure 2.3. Calibration graph for the estimation of salicylic
acid in plasma, using high-pressure liquid




PLASMA SALICYLURIC ACID CONCENTRATION (jjg/mt ]
Figure 2.4. Calibration graph for the estimation of salicyluric
acid in plasma using high-pressure liquid chromato¬
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45.5 94.2 191.6 383.3 600.0 788.5 1018
51.3 98.1
191.5 389.7 600.0 796.2 958.9
56.7 105.2 194.7 389.0 588.0 828.7 987.2
50.6 102.6 208.2 394.5 578.0 817.6 988.5
49.8 99.6 202.1 401.4 579.9 794.4 1005
50.8 99.9 197.6 391.6 589.2 805.1 991.5
4.00 4.22 7.32 6.78 10.6 17.20 22.22














































































drug found) of acetylsalicylic, salicylic and salicyluric acids for the
spiked plasma at the concentrations used were 100.9 ± 6.5, 99.6 ± 3.8 and
100.4 ± 5.5 (mean ± SD) % respectively. The accuracy of the assay
was determined by assaying two national quality control plasma samples
of salicylic acid on two occasions. Results of 400 pg/ml and 437
pg/ml for the controls of 400 pg/ml and 433 pg/ml respectively were
obtained on one occasion and 415 pg/ml and 410 pg/ml for the con¬
trols of 410 pg/ml and 410 pg/ml on another. The limits of detection
were 0.2 pg/ml, 0.5 pg/ml and 2 pg/ml for salicyluric, acetylsali¬
cylic and salicylic acids respectively.
Stabi1ity
A total of 198 plasma samples of acetylsalicylic, salicylic and
salicyluric acids were prepared (100 pi of each in a Dreyer tube)
and stored under different conditions (Table 2.4). The samples
were assayed on the day of preparation, weekly up to 8 weeks and
then at the 11th and 23rd weeks.
Salicyluric acid (5 pg/ml) was stable at -20°C and 4°C, with or
without the other compounds for 23 weeks. The loss of salicylic acid
(200 pg/ml) with potassium fluoride and acetic acid was 8.5% at 4°C
by the 11th week and 19% by the 23rd week, whereas without the
preservatives the losses were 20% and 30% respectively at -20°C.
The concentrations of salicylic acid stored with acetylsalicylic
and salicyluric acids without preservatives at -20°C increased up to
22%, but with the preservatives at -20°C did not change up to the 11th
week and increased only 8% by the 23rd week. These increases were
due to acetylsalicylic acid hydrolysis.
Acetylsalicylic /
TABLE2.4.





















































































































*with2ug/mlpotassiumflu rideindistilledwat rnm1/mlg aciaceticac dd tilledwa er.**withoutpreservative
Acetyl salicylic acid (50 pg/ml) with the preservatives at 4°C
or without at -20°C was not stable and hydrolysis was complete after
7 days. However, with salicylic and salicyluric acids and the
preservatives it was stable up to 4 weeks at -20°C.
(iv) Urine assay
Chromatographic conditions
The mobile phase consisted of 0.02 M potassium nitrate in 2%
acetic acid and isopropanol (100:18), and was degassed under
reduced pressure prior to use. The flow rate was 1 ml/min with the
working pump pressure of 1000 p.s.i.
Detector sensitivity was usually set at 0.16 absorbance units
full scale, but appropriate changes were made for higher or lower
concentrations. A 2 to 10 fold dilution of the sample prior to injec
tion was necessary with samples containing more than 400 pg/ml.
Preparation of standard solutions
The aqueous standard solutions of acetyl salicylic, salicylic
and salicyluric acids and acet-p-toluidide were prepared as described
for the plasma assay. Acet-p-toluidide (50 pg/ml) was the only inter
nal standard used.
Urine standard solutions were prepared by spiking blank urine
from five different healthy volunteers with salicylic acid (50 - 400
pg/ml) and salicyluric acid (25-200 pg/ml).
Collection and storage of urine samples /
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Collection and storage of urine samples
For the measurement of pH and for biochemical investigations,
20 ml aliquots of each urine sample were placed into Universal
containers and the remainder collected in 1 or 2 litre plastic
bottles containing 250 pi or 500 pi of 20% potassium fluoride solution
and 250 pi or 500 pi of glacial acetic acid.
The pH (using a pH meter, Radiometer Model pH M62) and volume of
each sample were measured immediately and 10-15 ml aliquots were
stored at -20°C.
Procedure for urine assay
To 0.5 ml of urine or standard in a disposable polypropylene
tube (Lukhams LP3), was added 0.5 ml of a solution containing 50 pg/ml
acet-p-toluidide as the internal standard and 100 pi of 6% perchloric
acid. After mixing and centrifugation 5-25 pi of the clear super¬
natant was directly injected into the chromatograph.
Perchloric acid was added to reduce the pH and to precipitate
proteins.
At least three urine standards containing salicylic acid (50-400 pg/
ml), salicyluric acid (25-200 pg/ml) and acetyl salicylic acid (10-
200 pg/ml) were assayed with each set of unknown samples. The con¬
centrations of each compound were determined using the standard
calibration graphs.
Gentisic acid was also measured, but because of interfering peaks
in some overdose patients and because of its unknown toxicological
significance (urinary recovery of about 1% of the total dose) it was
excluded in routine analyses.
Salicylic /
Salicylic and salicyluric acid glucuronide conjugates in urine
were measured by the difference after hydrolysis as follows :
To 0.5 ml of urine was added 0.5 ml of 0.1M acetate buffer pH5 and
0.1 ml $-glucuronidase and the mixture was incubated at 37°C overnight
Total salicylic and salicyluric acid concentrations in urine were
measured as described above.
Results of urine assay
A typical chromatogram of urine obtained from a healthy volun¬
teer 3 hours after oral administration of 20 mg/kg aspirin is shown
in Figure 2.5. The retention times of gentisic, salicyluric and
acetyl salicylic acids, acet-p-toluidide (internal standard) and
salicylic acid were 3.3, 3.7, 5, 8 and 12 minutes respectively. No
other interfering peaks were observed except with gentisic acid in
some overdose patients.
The effects of pH on the precision and reproducibility of the
assay were studied in urine and water standard solutions containing
200 ug/ml of salicylic acid. The mean peak height ratios of
salicylic acid to internal standard did not change in the water
standard with increasing pH, but the peak height ratios in the urine
standards decreased from 0.73 at pH 1.9 to 0.22 at pH 7.9. The
explanation for this finding is unknown.
Validation of urine assay
The standard calibration graphs were linear and passed through
the origin (Figs. 2.6 and 2.7).The precision and reproducibility of










Figure 2.5. A typical chromatogram of urine obtained from a
healthy volunteer at time 0 (left) and 3 hours after
oral administration of 20 mg/kg aspirin (right).
GA = gentisic acid, SUA = salicyluric acid,
ASA = acetyl salicylic acid, APT = acet-p-toluidide as
internal standard, SA = salicylic acid.
0 100 200 300
URINE SALICYLIC ACID CONCENTRATION (yg/ml)
400
Figure 2.6. Calibration graph for the estimation of salicylic
acid in urine, using high performance liquid
chromatography with acet-p-toluidide as internal
standard.
URINE SALICYLURIC ACID CONCENTRATION (pg/ml)
Figure 2.7. Calibration graph for the estimation of salicyluric
acid in urine, using high performance liquid
























































































































results of 5 replicate analyses. The overall mean recoveries (drug
found) of salicylic and salicyluric acids for the concentration ranges
of spiked urine were 99.9 ± 0.4 and 100.8 ± 2.4% (S.D.) respectively.
The limits of detection were 1 and 5 pg/ml for salicyluric and salicy¬
lic acids respectively.
A preliminary report of this method with the high performance
liquid chromatographic assays of other analgesic drugs has already
been published (Prescott, King, Brown, Balali and Adriaenssens, 1979).
(c) Comparison of colorimetric and high performance liquid chromato¬
graphic methods
A modification of the method of Trinder (1954) was used as a
ward side room assay for the rapid estimation of plasma salicylate in
patients with aspirin overdosage.
Materials : Ferric nitrate, 0.038 M nitric acid and a colorimeter
(Corning Model 252).
Method : Two solutions were prepared as the blank (0.038 M
nitric acid) and reagent (11 g ferric nitrate diluted to 2 litres
with the blank solution). The colorimeter was set up at zero using
the blank and the absorbance after formation of the coloured iron-
salicylate complex was read at 540 nm.
Results : In 39 samples from 19 patients with aspirin overdosage
salicylate concentrations were measured by both methods (Fig. 2.8).
The results with colorimetric assay were 11.4 ± 7.3% higher than with
the high performance liquid chromatographic method.
(d) Summary and conclusions /
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD
Figure 2.8. Comparison of the high performance liquid chromato¬
graphic method and ward side-room assay (modified
Trinder's method) for the estimation of plasma
salicylic acid concentrations.
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(d) Summary and conclusions
Simple, specific, sensitive and reproducible high performance
liquid chromatographic assays were developed for the simultaneous
estimation of acetyl sal icy!ic, salicylic and salicyluric acids in
plasma and acetyl salicylic, salicylic, salicyluric and gentisic
acids in urine. Acet-p-toluidide and benzoic acid were used as the
internal standards for the plasma assay and acet-p-toluidide for the
urine assay. Perchloric acid (6%) was used for the precipitation of
proteins and following centrifugation the clear supernatant was
injected directly into the chromatograph.
The standard calibration graphs for each compound were linear
and passed through the origin. Good separation and reproducibility
were obtained. The limits of sensitivity were 0.5 ug/ml, 1 yg/ml
and 5 pg/ml for salicyluric, acetyl salicylic and salicylic acids
respectively.
Rapid colorimetry (modified Trinder's method) was used as a
ward side room assay for the rapid estimation of plasma salicylate
from patients with aspirin overdosage. The results of this assay
were an average of 11.4% higher than the concentrations measured by
high performance liquid chromatography.
SECTION II
Chapter 2.
ESTIMATION OF DIFLUNI SAL IN PLASMA AND URINE BY HIGH
PERFORMANCE LIQUID CHROMATOGRAPHIC AND FLUOROMETRIC
METHODS
(a) Introduction
Gas chromatographic, radio-isotopic and f1uorometric methods
have been used for quantitation of diflunisal (Tocco, Breault, Zacchei
Steelman and Perrier, 1975), but all have disadvantages. The gas chro
matographic assay includes extraction and evaporation stages and
derivatisation, while the radio-isotopic and fluorometric methods are
non-specific.
Since the present work was started, a high-performance liquid
chromatographic method for the determination of diflunisal in plasma
has been reported (Van Loenhout, Ketelaars, Gribnau, Van Ginneken and
Tan, 1980). The diflunisal and naproxen (internal standard) are
extracted from plasma with ether and n-hexane followed by evaporation
to dryness. The diflunisal peak was broad and tailed, relative
errors were 8.85% at low concentrations and the limit of detection
was only 5 pg/ml. The present method does not require extraction.
It can be completed in a fraction of the time, chromatography is
more efficient and the results superior.
(b) Development of high performance liquid chromatographic methods




Diflunisal was obtained from Thomas Morson Pharmaceuticals,
Division of Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, and
flufenamic acid (the internal standard) from Parke Davis & Co. (Usk
Road, Pontypool, Gwent). All solvents and reagents were obtained
commercially.
Preparation of standard solutions
5 mg of diflunisal was dissolved in 1.0 ml of methanol in a
100 ml volumetric flask and brought to volume with l/15-molar( m)
phosphate buffer (pH 7.2). Further dilutions were made with water or
plasma to produce final concentrations of 1-10 and 10-100 yg/ml.
Flufenamic acid (5 mg) was dissolved in 1.0 ml methanol in a 100 ml
volumetric flask and made up to volume with 0.001 M sodium bicarbonate.
The stock solutions were stored for 8 weeks at 4°C.
Standards were prepared by spiking blank urine or plasma from
five healthy volunteers.
Chromatographic conditions
The high performance liquid chromatographic system consisted of
a Pye LC3 UV detector set at 251 nm, an Orlita DMP AE 10.4 pump, a
loop injector (Rheodyne Model 7120) and a recorder (Bryans Model 28000).
The column was 150 X 4.5 mm i.d. internally polished stainless steel
slurry packed with 5 um Hypersil O.D.S. (Shandon).
The mobile phase was a mixture of 0.08 M potassium nitrate in
2% acetic acid, isopropanol and ethylacetate (55:25:20) which was
degassed under reduced pressure prior to use.
Procedure for plasma assay /
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Procedure for plasma assay
To 0.5 ml of plasma containing 10-100 pg/ml of diflunisal in a
disposable polypropylene tube was added 0.5 ml of flufenamic acid
solution (500 pg/ml) followed by 0.5 ml of acetone to precipitate the
proteins. After mixing, the sample was centrifuged for 5 minutes and
25 pi aliquots of the clear supernatant directly injected into the
chromatograph. For lower concentrations 50 pi of the flufenamic acid
solution was used.
Plasma diflunisal concentrations of more than 100 pg/ml are
diluted appropriately with normal saline.
The flow rate was 1.1 ml/min with the working pump pressure of
1600 p.s.i. Detector sensitivity was 0.08 absorbance units full
scale.
Procedure for urine assay
To 1.0 ml of urine containing 1-10 pg/ml of diflunisal in a dis¬
posable polypropylene tube was added 100 yl flufenamic acid solution
(500 pg/ml). After mixing, 25 pi was injected directly into the
chromatograph.
Urine containing more than 10 pg/ml of diflunisal was diluted
appropriately with distilled water.
The flow rate was 1.3 ml/min with the working pump pressure of
1800 p.s.i. Detector sensitivity was set at 0.02 absorbance units
full scale.
Two standards of diflunisal (5 and 50 pg/ml in plasma) and
(1 and 10 pg/ml in urine) were assayed with each set of unknown
samples. Diflunisal concentrations were calculated from peak height
ratios /
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ratios as described for the assay of acetyl sal icy!ic acid and
metabolites (Chapter 1, Section II).
Results
Two typical chromatograms of plasma and urine obtained from a
volunteer 3 hours after ingestion of 750 mg of diflunisal are
illustrated in Figures 2.9. and 2.10.The retention time of diflunisal
was about 6 minutes in both assays and samples could be injected
every 9 minutes. No other interfering peaks were observed.
The standard calibration graphs for the plasma and urine assays
were linear and passed through the origin (Figures 2.11 and 2.12).
The precision and reproducibility of the plasma and urine assays are
shown in Tables 2.7 and 2.8 respectively as the results of 5 replicate
analyses of spiked samples. The overall recovery (drug found) of
diflunisal was 100.4 ± 3.6 for plasma and 100.2 ± 5.3% for urine. The
accuracy was determined by assaying two control plasma and urine
samples containing 99.94, 10.95, 9.55 and 1.86 pg/ml of diflunisal
respectively. The results of the assays were 98.93, 10.42, 9.95
and 1.75 ug/ml. The limits of detection were 1.0 ug/ml and 0.5 pg/ml
for plasma and urine respectively.
The results of analyses in 17 plasma and 13 urine samples from
5 patients with diflunisal overdosage are given in Table 2.9.
Other considerations
Naproxen was initially chosen as the internal standard because
it eluted before diflunisal with good separation. However, an inter¬










Figure 2.9. A typical chromatogram of plasma from a healthy
volunteer at time 0 (left) and 3 hours after ingestion
of 750 mg of diflunisal (right). DF = diflunisal,
FA = flufenamic acid (internal standard).
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Figure 2.10. A typical chromatogram of urine from a healthy
volunteer at time 0 (left) and 3 hours after ingestion
of diflunisal (right). DF = diflunisal, FA = flufen-
amic acid (internal standard).
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.11. Calibration graph for the estimation of diflunisal
in plasma, using high performance liquid chromato¬
graphy with flufenamic acid as internal standard.
Figure 2.12. Calibration graph for the estimation of diflunisal
in urine using high performance liquid chromatography
with flufenamic acid as internal standard.
TABLE2.7.








































































































































































































































ingestion of diflunisal. The peak did not change after hydrolysis
of the urine with glusulase, whereas thin layer chromatography showed
that the glucuronide conjugates of diflunisal disappeared. The
interfering peak appeared to be an unknown metabolite of diflunisal.
(c) Comparison of fluorometric and high performance liquid
chromatographic methods
The high-performance liquid chromatographic method was compared
with the following fluorometric assay which is a modification of
the method described by Tocco et al. (1975).
Procedure
To 100 pi of plasma containing 1-30 pg/ml diflunisal in a
15 ml round bottomed glass tube was added 900 pi blank pooled plasma.
Appropriate dilutions were made for plasma containing high concentra¬
tions. After mixing, 1 ml of 5h hydrochloric acid was added
followed by extraction into 5 ml of chloroform. After centrifugation,
2 ml of the chloroform phase was extracted with 3 ml of 0.1 M phos¬
phate buffer pH 8.0. The fluorescence of the aqueous phase was
measured in an Aminco-Bowman Spectrophotof1uorometer set at 260 nm
(activation) and 425 nm (emission).
Concentrations were determined by reference to a previously
constructed calibration graph of transmission plotted against plasma
diflunisal concentrations obtained from 5 different sets of plasma
standards run through the procedure.
The method could not be used for the assay of unchanged difluni¬
sal in the urine, because of interference by glucuronide conjugates.
However, /
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However, both unchanged and conjugated diflunisal can be measured after
hydrolysis with perchloric acid (Tocco et al., 1975).
Results
The plot of per cent transmission minus the blank value versus
the plasma concentrations of diflunisal passed through the origin
and was linear up to 30 ug/ml. The limit of sensitivity was 0.5 pg/ml.
Plasma concentrations in 3 healthy volunteers after oral admini¬
stration of 750 mg diflunisal and 3 patients with diflunisal over¬
dosage were measured by both methods. (Figure 2.13). There was
excel 1ent agreement.
Conclusion
Both the high performance liquid chromatographic and fluoro-
metric methods are suitable for the estimation of diflunisal in
plasma. However, the high performance liquid chromatographic assay
has the advantages of simplicity, specificity and may also be used to
measure diflunisal in urine.
(d) Summary
Simple, rapid, specific and sensitive high performance chromato¬
graphic methods were developed for the estimation of diflunisal in
plasma and urine. The mobile phase consisted of 0.08 M potassium
nitrate in 2% acetic acid, isopropanol and ethyl acetate (55:25:20).
Flufenamic acid was used as the internal standard and acetone used
for the precipitation of plasma proteins. After centrifugation, the
clear supernatant was injected directly into the chromatograph.
Urine /
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD
500
Figure 2.13. Comparison of high performance liquid chromatographic
and fluorometric methods for the estimation of
diflunisal in 59 plasma samples. The individual
measurements (yg/m1) were plotted on logarithmic
graph paper with the line of identity (45°).
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The urine assay simply involved adding the internal standard,
mixing and injecting directly into the chromatograph.
The standard calibration graphs for plasma and urine were
linear and passed through the origin. Good separation and repro¬
ducibility were obtained. The limits of sensitivity for the plasma
and urine assays were 1.0 and 0.5 pg/ml respectively.
A modified fluorometric assay was also used for the estimation
of plasma diflunisal and compared with the high performance liquid
chromatographic method. The results were in excellent agreement.
The high performance liquid chromatographic method has the advantages





PLASMA PROTEIN BINDING OF SALICYLIC ACID
(a) Review of the literature
A thorough understanding of the nature and magnitude of drug-
protein binding is clearly fundamental to an accurate prediction of
therapeutic and toxic effects (Bridges and Wilson, 1976). Several
methods have been employed to measure plasma protein binding includ¬
ing equilibrium dialysis, ultracentrifugation, ultrafiltration and
gel filtration. None of these methods has a clear superiority
over the others (Rowland, 1980), although equilibrium dialysis
gave the best measure of binding capacity in one study (McArthur
and Smith, 1969).
Smith et al. (1946) studied salicylate protein binding by ultra¬
filtration and concluded that most of the salicylate in human plasma
is bound to the non-diffusible component, presumably plasma proteins.
In one study it was concluded that salicylate binds only to plasma
albumin and variation in the binding capacity of different sera for
salicylate is entirely dependent on changes in the albumin concen¬
tration (Reynolds and Cluff, 1960). In another investigation it was
concluded that salicylate is predominately bound to albumin in normal
subjects but in patients with abnormal plasma protein there i s1 ess binding of
salicylate to albumin and more binding to pre-albumin (Batterman,
Mouratoff, Karler and Tauber, 1962).
The binding of salicylic acid and related compounds to purified
proteins was studied by Davison and Smith (1961). They concluded
that /
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that the carboxylic acid function was the primary site of binding.
With most of the compounds there were two types of binding sites, one
of relatively high affinity but smaller in number, the second of low
affinity but in greater number. Wosilait (1976) showed by theoretical
analyses that at low salicylic acid concentrations (up to 14.5 ug/ml)
the high affinity sites (site 1) would bind most of the drug, but
as the concentration increased these sites approached saturation and
the low affinity (site 2) would bind increasing amounts of salicylate.
He also concluded that if the protein concentration was reduced, the
total amount of drug bound would decrease. Yacobi and Levy (1977)
also found a statistically significant negative correlation between the
concentration of albumin and unbound salicylic acid. Similar results
were obtained by Boobis and Chignell (1979). Decreased salicylate
binding in cutaneous hepatic porphyria is also due to reduced albumin
concentration (Steele, Boobis, Moore, Goldberg, Brodie and Sumner, 1978).
The binding of salicylate to plasma proteins was studied in
different species (Sturman and Smith, 1967). Binding was low in the
baboon, dog, rat, mouse, turkey and toad, but much higher (45-95%)
in the rhesus monkey, rabbit and guinea-pig. Salicylic and acetyl-
salicylic acids bind more strongly to bovine serum albumin than to
human serum albumin (Aarons, Clifton, Fleming and Rowland, 1980).
The binding of acetyl salicylic and salicylic acids was measured
using equilibrium dialysis and gel filtration (Amir Ali and Routh,
1969). In each case binding equilibrium was reached in 4-8 hours for
salicylic acid, but a progressive increase in binding of acetylsali-
cylic acid was found up to 53 hours. In a similar study it was
shown that salicylic acid and acetyl salicylic acid binding equilibria




The unbound fraction of salicylic acid increases with increas¬
ing total drug concentration both in vitro and in vivo (Smith et
al., 1946; Spector, Torkin and Lorenzo, 1972; Esktrand, Alvan and
Borga, 1979; Rowland, 1980), but the concentration ranges were
limited and no data are available at total plasma salicylate concen¬
trations above 512 pg/ml.
Indomethacin, ibuprofen, phenylbutazone and warfarin in concen¬
trations of 100 yg/ml displace a significant amount of salicylic
acid (10-500 pg/ml) bound to human serum albumin and thus may enhance
its therapeutic and toxic effects (Muirden, Deutschman and Phillips,
1974). In vitro addition of heparin to plasma had no quantitively
significant effect on the protein binding of salicylate and an in
vivo effect was reversible by treating the plasma with activated
charcoal, a procedure known to remove fatty acids from albumin
(Wiegand and Levy, 1979).
A study in dogs indicated that serum unbound salicylate concen¬
trations closely reflect those in cerebro-spinal fluid. As serum pH
declines, cerebro-spinal fluid salicylate concentrations increase
and free plasma salicylate decreases as a result of decreasing ionis-
ation of salicylate (Reed and Palmisano, 1975).
In normal subjects, the total body clearance of salicylic acid
changed relatively little over the therapeutic range because the
increasing fraction unbound compensated for the decreasing clearance
of unbound drug (Furst, Tozer and Melmon, 1979).
Salicylate binding to synovial fluid proteins was lower than
to plasma proteins over the therapeutic range, particularly at lower
drug concentrations which could mainly be due to decreasing affinity
of binding to site 1 (Trnavska and Trnavsky, 1980). The protein
binding /
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binding of salicylic acid is the same in heparinized plasma and
serum from the same healthy adult subjects. (Wiegand, Hintze,
Slattery and Levy, 1980).
In conclusion, albumin is not the only plasma protein to which
salicylate binds, but there are no data available to show its con¬
tribution. Salicylate binding to albumin and other plasma proteins
is concentration dependent and again the data are limited especially
at high concentrations (Smith et al., 1946).
(b) Estimation of salicylic acid binding to plasma proteins
(i) Preparation of fresh plasma
Since the amount of heparin in the lithium heparin tube is
very small (12.5 U/ml) and there is no in vitro interaction between
heparin and salicylate (Wiegand and Levy, 1979), 120 ml of blood
was taken into these tubes from 3 healthy male volunteers aged 28-
46 years who had not taken any drugs for at least 2 weeks. The
plasma was separated and immediately used for the in vitro protein
binding studies.
(ii) In vitro binding
Solutions containing 250, 500, 1000, 2000, 3000 and 4000 pg/ml
of salicylic acid in 0.01 M saline phosphate buffer pH 7.4 were made.
To each 2 ml of fresh plasma in a conical glass tube was added 0.5 ml
of salicylic acid solution to give final concentrations of 50, 100,
200, 400, 600 and 800 pg/ml. After mixing, the samples were incub¬
ated at room temperature for at least \ hour, then 100 pi from each
was removed for the estimation of total drug concentration by high
performance /
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performance liquid chromatography (Chapter 1, Section II). The
non-protein bound drug was separated by ultrafiltration using
Am icon Centriflo membrane cones (Type CF-25) as follows:
1. The cones were soaked in distilled water before use for at
least one hour.
2. Each membrane cone was locked into place in the support.
3. The support was pushed into a short boiling tube, seating
the flange on the tube. The tube was then centrifuged at
420 X g for 10 minutes to remove excess water.
4. The boiling tubes were replaced by clean dry tubes and
2.4 ml of plasma was placed in the cones. The cones were then
spun at 700 X g for 30 minutes. The volume of ultrafiUrate
was 0.5 to 1.5 ml.
5. Each filtrate was tested with Albustix and if protein was
present (> 0.3 g/L), the cone and sample were discarded.
6. The ultrafiItrate was then assayed by high performance liquid
chromatography in the usual manner to determine the plasma
free (unbound) salicylic acid concentration (D^).
7. The fraction bound (B) was then calculated from the unbound
and total (D^) salicylic acid concentrations :
8. After use the filter cones were rinsed with distilled water
and soaked in 5% (W/V) sodium chloride solution for an hour
followed by several rinses with distilled water. The cones
were stored in 0.1% (W/V) sodium azide.
(iii) /
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(iii) In vivo binding
Ten ml blood samples were taken from patients with aspirin
overdosage (Section IV) into lithium heparin tubes. The plasma was
separated immediately, 100 pi was removed for the estimation of total
salicylic acid by high performance liquid chromatography and 2.4 ml
was subjected to ultrafiltration as described above before analysis.
(c) Salicylic acid binding to albumin
Human albumin (20 g/dl) prepared by the Scottish National
Blood Transfusion Service was diluted with 0.01 M saline phosphate
buffer pH 7.4 to give concentrations of 4 and 5 g/100 ml.
The procedure for the determination of the binding of salicylic
acid to human albumin was the same as described above (ii).
(d) Salicylic acid binding to the membrane cone
Procedure
1. Stock solutions of salicylic acid in 0.01 M phosphate buffer
pH 7.4 were prepared (50, 100, 200, 400, 600 and 800 ug/ml).
2. The membrane cones (6 for each run) were prepared as described
above.
3. 2.4 ml of each of the above stock solutions was added to the
cones.
4. The cones were spun at 700 X g for 30 minutes.
5. The ultrafi1trates and the stock solutions were assayed for
salicylic acid by the high performance liquid chromatographic




6. The fraction bound to the membrane cone (3) was calculate as :
7. The procedure was repeated twice with new and used cones.
8. The mean values for the fraction bound to the membrane cones (3)
was subtracted to give a corrected value for salicylic acid
binding to plasma proteins and albumin.
Results
The binding of salicylic acid to new membrane cones was lower
than to the used cones (Table 2.10). The mean binding of salicylic
acid to new and used cones not more than 3 times increased from
6.5% at 50 pg/ml to 16% at 800 pg/ml. The membrane cones used more
than 3 times for salicylic acid binding to plasma proteins or albumin
had 25-30% binding at 800 yg/ml.
The greater salicylic acid binding to used membrane cones could
be due to the presence of protein residues, which were not removed
by washing.
Effects of salicylic acid concentration on protein binding
The effects of salicylic acid concentration on the binding in
vitro and in patients with aspirin overdosage are shown in Table
2.11 and 2.12. The results of in vitro study showed that as the
total salicylic acid concentrations increased from 50 pg/ml to 800
pg/ml, the bound fraction decreased from 86% to 20%. The protein
binding of salicylic acid in plasma obtained from 7 patients with
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Two new and 2 used cones are used at each concentration
and results expressed as means
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TABLE 2.11.
COMPARISON OF SALICYLIC ACID BINDING TO HUMAN ALBUMIN
AND TOTAL PLASMA PROTEIN IN VITRO









50 52.2 ± 2.7 13.9 ± 1.3 3.7
100 59.1 ± 3.3 17.2 ± 1.3 3.4
200 65.3 + 4.5 27.2 ± 1.1 2.4
400 74.8 ± 4.3 46.8 ± 3.6 1.6
600 81.5 ± 5.2 61.9 ± 5.7 1.3
800 90.2 ± 5.1 79.6 ± 3.4 1.1
Values are given as mean ± standard deviations
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TABLE 2.12.
THE BINDING OF SALICYLIC ACID TO PLASMA PROTEINS IN








52-9 106 22 21
52-8 112 23 21
50-8 122 24 19
53-6 192 42 22
58-10 194 77 40
55-8 223 61 27
58-9 225 100 45
55-7 237 64 27
53-5 244 55 23
59-5 313 125 40
59-4 328 140 43
59-6 336 129 39
59-3 359 171 48
58-5 369 211 57
58-4 373 223 60
54-4 400 249 62
58-3 423 286 68
58-2 457 329 72
54-3 473 330 70
54-1 571 441 77
54-2 587 439 75
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as the total plasma salicylic acid concentrations increased from
120 to 571 pg/ml respectively.
The unbound fraction of salicylic acid in plasma increased
linearly with the plasma concentration both in vitro and in vivo
(Figs. 2.14 and 2.15). The binding in vitro and in vivo was similar
and the regression lines (Figs. 2.14 and 2.15) were compared by
covariance analysis (Snedecor and Cochran, 1976). There was no
significant difference (F variance ratio = 0.0271, p > 0.05).
(e) Differences in binding of salicylic acid to total plasma protein
and human albumin
The mean percentages of salicylic acid unbound to human albumin
and to total plasma proteins at different drug concentrations are
given in Table 2.11. As shown by the ratios of drug unbound to
albumin:unbound to total plasma proteins, binding to the latter increased
disproportionately at lower salicylate concentrations. Thus there was
less binding to albumin than to other proteins at low concentrations.
The fraction bound to albumin decreased from 48% at a salicylic
acid concentration of 50 pg/ml to 10% at 800 pg/ml, whereas the
binding to total plasma protein at these concentrations was 86% and
20% respectively. The relationship between the fraction bound to
albumin and the salicylic acid concentration was not linear (Fig. 2.16).
The binding to other proteins was calculated from the difference
between the binding to albumin and total plasma protein.
Albumin /
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Figure 2.14. Concentration-dependent binding of salicylic acid to
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Figure 2.15. Concentration-dependent binding of salicylic acid to
plasma proteins. The samples were obtained from the
patients with aspirin poisoning.
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Figure 2.16. Binding of salicylic acid to human albumin and total
plasma proteins at different salicylic acid concen¬
trations. The binding to other proteins was calculated
from the differences between binding to total plasma
protein and human albumin.
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Albumin binding accounted for 50% and 55% of the total binding to
plasma proteins at concentrations of 800 pg/ml and 50 ug/ml of
salicylic acid respectively.
(f) Summary and conclusions
The binding of salicylic acid to plasma proteins in 3 healthy
volunteers and 7 patients with aspirin overdosage (in vivo) was
studied and compared with in vitro binding to human albumin. The
fraction unbound to total plasma proteins increased as the plasma
salicylic acid concentrations increased and was similar both in
vitro and in vivo. The binding of salicylic acid to albumin
accounted for about half of the binding to plasma proteins.
SECTION III
THE EFFECTS OF CHANGES IN URINE pH AND FLOW RATE ON THE
PHARMACOKINETICS AND ELIMINATION OF A THERAPEUTIC DOSE OF




DISPOSITION OF ACETYLSALICYLIC ACID IN HEALTHY VOLUNTEERS
AND THE EFFECTS OF CHANGES IN URINE pH AND FLOW RATE
(a) Introduction
Until recently there have been no simple specific and sensi¬
tive methods for monitoring acetyl salicylic acid and its metabolites
in plasma and urine. Since high performance liquid chromatographic
methods have been developed to measure the acetyl salicylic acid and
its metabolites, no comprehensive work on the pharmacokinetics of
the drug in healthy volunteers has been reported.
Studies on the effects of changes in urine pH and flow rate
on salicylate elimination started last century, but different
methods were used for alkalinisation and the results were contro¬
versial. Smith et al. (1946) in a comprehensive study, confirmed
that alkalinisation of urine increases salicylic acid elimination.
Since then, this aspect was studied by other workers (see pages 26-
28), but again the methods they employed to estimate the drug and
its metabolites were not specific and the word "salicylate" was
used in very general terms, thus causing confusion.
This study was undertaken to investigate the disposition
and elimination of acetyl salicylic acid in healthy volunteers after
a single oral dose of aspirin under different conditions of urine




Six healthy ambulant male volunteers aged 24-37 years
weighing 63-80 kg were studied with informed consent. They had
not taken any drugs for at least two weeks before the study. Each
took 20 mg/kg aspirin dissolved in 200 ml of water following an
overnight fast. Food, fluids and tobacco were withheld for 2 hours
after. Venous blood (5 ml) was taken at 0, I, 1, 2, 3, 5, 8
and 24 hours in lithium heparin tubes containing 50 pi of a 20%
(w/v) solution of potassium fluoride. The plasma was separated
immediately and placed in glass tubes containing 50 pi of 20%
potassium fluoride with 50 pi of glacial acetic acid and stored at
-20°C until analysis. Urine was collected at time 0 (blank) then
2 hourly for 12 hours and from 12 to 24 hours. Approximately 20 ml
was kept for immediate measurement of pH and the remainder placed
in one or two litre plastic bottles containing 250 pi or 500 pi of
20% potassium fluoride and 250 pi or 500 pi of glacial acetic acid
respectively. The pH was measured with a pH meter (Radiometer
Model pH M62). The total volume of each sample, including the
urine kept for pH measurement was measured and 10-15 ml of the
sample with preservative was stored at -20°C until analysis.
Normal fluid intake, diet and activity were allowed, but alcohol
and other drugs were not taken during the study.
The experiment was repeated in the same volunteers not less
than 2 weeks later with oral administration of sodium bicarbonate
capsules (3 g 4 times daily) the day before and during the
study. The fifth dose of sodium bicarbonate (the first dose on the
second day) was given one hour before the aspirin. Fluid intake
was /
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was increased to give a urine output of about 4 litres daily.
Acetyl sal icy!ic acid and its metabolites in plasma and
urine were estimated by the high performance liquid chromatographic
method (Chapter 1, Section II). The plasma elimination half-life,
total body clearance, volume of distribution, renal clearance and
urinary recovery of salicylic acid and other metabolites (where
indicated) were calculated for the control study and for the
alkaline diuresis study. The plasma half-life was calculated
from the slope of the linear elimination phase by the method
of least squares and the area under the plasma-concentration-
time curve (AUC) by the trapezoidal rule. The total body clearance
was calculated by dividing the dose by AUC. The latter was calcul¬
ated by adding the AUCQ_tand the AUC from the time (t) of last
plasma concentration (Cp) to infinity (°°) using the following
equation :
C X tA
AUC. = -E *
0.693
where t2 is the plasma elimination half-life of the drug. The
2
apparent volume of distribution (Vd) was estimated from the follow¬
ing equation :
...
_ TBC X tjV Q — 2
0.693
where TBC is the total body clearance.
The renal clearance was calculated by dividing the amount of
drug or metabolite excreted in the urine during a collection period
by the corresponding AUC. The renal clearance of salicylic and
salicyluric acids were calculated for each period of urine
collection /
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collection and for the whole period of study as well.
Comparisons were performed using the paired two tailed
Student t-test, taking p < 0.05 as the minimum level of statistical
significance.
N.B. Since pH is the reciprocal of the logarithm of the hydrogen
ion concentration, means and standard deviations could not be
calculated directly from each pH value (a common mistake in the
medical literature). The pH values were converted to hydrogen
ion concentrations, the means and standard deviations were calculated
and then converted back to pH values. The values are given as mean
and standard deviations unless otherwise stated.
(c) Results
Acetyl salicylic acid absorption
Acetyl salicylic acid was absorbed rapidly with a mean peak
plasma concentration of 15 pg/ml at 30 minutes in the control study.
With sodium bicarbonate absorption was faster and the mean maximum
plasma acetyl salicylic acid concentration was 17 pg/ml at 15 minutes.
Both salicylic and salicyluric acids plasma concentrations at 15
minutes were significantly higher (p < 0.05) with sodium bicarbonate
than with the controls (Fig. 3.1). The mean peak plasma salicylic
acid concentrations were reached within 1 and 3 hours with and
without sodium bicarbonate respectively. These findings demonstrate





Mean plasma concentrations of acetyl salicylic,
salicylic and salicyluric acids following a single
oral dose of 20 mg/kg of aspirin with and without
sodium bicarbonate in 6 healthy subjects.
A O □ = without. = with sodium bicarbonate.
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Plasma concentrations of acetyl salicylic acid and its metabolites
Plasma acetyl salicylic acid concentrations declined very rapidly
both with and without sodium bicarbonate and the overall mean half-
life was 34 ± 17 minutes (Fig. 3.1.). Acetyl salicylic acid was not
detected in plasma (< 0.5 pg/ml) in any subject after 5 hours.
The mean plasma salicylic acid concentrations were higher with
sodium bicarbonate than in the control study up to 2 hours after
ingestion (p < 0.001), but decreased more rapidly subsequently as shown
in Figure 3.1. However, the mean areas under the plasma salicylic acid
concentration-time curves (0-8 hr) were only slightly lower with
alkaline diuresis than in the control study (414 ± 88 and 434 ± 51
pg. ml ^ hr respectively). Salicylic acid was not detected (< 2 pg/ml)
at 24 hours in 3 subjects without and in all with sodium bicarbonate.
The mean plasma salicyluric acid concentrations at 15 minutes
were 0.66 pg/ml and 0.41 pg/ml with and without sodium bicarbonate
respectively (p > 0.10), but thereafter were always lower (p < 0.001)
with sodium bicarbonate (Fig. 3.1.).
Plasma salicylic and salicyluric acid glucuronide conjugates were
measured in 3 subjects without administration of sodium bicarbonate.
Salicylic acid glucuronide conjugate concentrations varied from 0.68
pg/ml to 53 pg/ml in different samples and accounted for 0 - 2.5 times of
the unconjugated salicylic acid. Salicyluric acid glucuronide
conjugate concentrations varied from 0.03 to 2.08 pg/ml and accounted
for 0 - 1.2 times of the unconjugated salicyluric acid.




The plasma half-life, total body clearance and volume of distri¬
bution of salicylic acid are given in Table 3.1.
The plasma salicylic acid half-life was shorter with the
administration of sodium bicarbonate than without in all subjects.
The shortest half-life with alkaline diuresis was 2.61 hours whereas
the corresponding value in the control study was 4.24 hours. The
mean values were 3.56 and 5.66 hours, with and without sodium
bicarbonate respectively and this difference was clinically and
statistically significant (p < 0.05).
The mean total body clearance was significantly increased from
23.2 ml/min in the control to 33.4 ml/min with the administration of
sodium bicarbonate (p < 0.005). This change in the total body clear¬
ance was due entirely to the increased renal clearance of salicylic
acid with alkaline diuresis (Table 3.1.).
The apparent volume of distribution of salicylic acid did not
change significantly with sodium bicarbonate. The mean values were
147 and 164 ml/kg with and without alkaline diuresis respectively.
Effects of changes in urine pH and flow rate on renal clearance
and metabolite excretion
Urine pH and flow rate were significantly higher (p < 0.001
and p < 0.005 respectively) with the alkaline diuresis than in the
control study (7.5 ± 0.1 and 6.3 ± 0.2; 4.20 ± 0.94 and 0.89 ± 0.21
ml/min respectively). The mean urine pH and flow rate for each
period /
TABLE3.1.
























































































































period of urine collection with and without sodium bicarbonate are
given in Table 3.2.
The renal clearance of acetyl salicylic acid was only measur¬
able in the first 2 hour samples of 5 subjects as shown in Table 3.3.
However, the mean values were 7-51 ± 3-96 ml/min and 27.8 ± 12.4
ml/ min before and after sodium bicarbonate respectively and there
were significant overall positive correlations between the renal clear¬
ance of acetyl salicylic acid and urine pH or flow rate (r = 0.863
p < 0.01 and r = 0.917, p < 0.01 respectively).
The renal clearance of salicylic acid was significantly
higher (p < 0.001) with sodium bicarbonate than without (Table 3.1.)
The mean values were 12.5 ± 3.9 and 2.2 ± 1.9 ml/min respectively.
As expected, there was an overall highly significant positive
correlation between the renal clearance of salicylic acid and urine
pH (r = 0.70, p < 0.001). The correlation was even greater when
the renal clearance of salicylic acid was corrected for flow rate
(r = 0.79) as shown in Figure 3.2. The renal clearance corrected
for flow rate is the ratio of concentrations in urine and plasma, which
is mathematically independent of urine pH or flow rate. However, there
was no significant correlation between the ratio of urine to
plasma salicylic acid concentration and urine flow rate (r = -0.19).
The renal clearance of salicyluric acid (Table 3.4) was
also significantly greater with alkaline diuresis than in the con¬
trol study (567 ± 84 and 443 ± 117 ml/min respectively, p < 0.05).
There was a significant positive correlation between the renal
clearance of salicyluric acid and urine pH (r = 0.41, p < 0.01),
but not with urine flow rate (r = 0.23).
The /

















































RENAL CLEARANCE OF ACETYLSALICYLIC ACID 0-2 HOURS
Renal clearance (ml/min)
Subject Control With NaHCOg
M.B. 4.21 13.7
M.L. 6.41 N.M.*







RENAL CLEARANCE OF SALICYLURIC ACID 0-8 HOURS
Renal clearance (ml/min)









p - value < 0.05
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URINE pH
Figure 3.2. Correlation between renal clearance of salicylic acid
and urine pH, following a single oral dose of 20 mg/kg
of aspirin with (•) and without (o) sodium bicarbonate
in 6 healthy subjects.
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The urinary recovery of acetylsalicylic acid and its metabo¬
lites is shown in Table 3.5. The mean urinary recoveries of acetyl¬
salicylic and salicylic acids were significantly increased from 15
to 26 and 82 to 390 mg respectively with alkaline diuresis (p < 0.005
and p < 0.001 respectively) but the recovery of salicyluric acid
was significantly decreased from 901 to 607 mg (p < 0.01). The
mean percentage recoveries of acetylsalicylic, salicylic and
salicyluric acids (as acetylsalicylic acid) were 1.2, 8.3 and 62
in the control study and 2, 38 and 42 with sodium bicarbonate res¬
pectively. However, the total recoveries excluding glucuronide
conjugates as the percent of the dose were 82 and 71 with and
without sodium bicarbonate respectively (p < 0.025).
The ratio of urinary recovery of salicylic to salicyluric
acids (as percentage of the dose) increased seven-fold with
alkaline diuresis compared with the control study (0.90 and 0.13
respectively). The urinary recovery of gentisic acid was only 1%
of the total while glucuronide conjugates accounted for 10%, 21%
and 33% of the total in the 3 subjects studied without administration
of bicarbonate.
(d) Discussion
Acetylsalicylic acid was absorbed more rapidly when given
after sodium bicarbonate and this could be due to better dissolution
and more rapid gastric emptying. This is consistent with previous
reports (Leonard, 1963; Cooke and Hunt, 1970). Acetylsalicylic
acid was hydrolysed very rapidly to salicylic acid and only 1-2% of
the




























































































































the dose was recovered unchanged in the urine. Although the mean
plasma elimination half-life and area under the plasma concentration-
time curve of acetyl salicylic acid did not change with sodium
bicarbonate, the renal clearance was significantly increased and
the renal clearance of acetyl salicylic acid was related to the
urine pH and flow rate.
Although the plasma salicylic acid concentrations were greater
up to 2.5 hours with sodium bicarbonate, the glycine conjugation of
salicylic acid apparently saturated at the same time (2 hr) with
and without alkaline diuresis (Fig. 3.1.). The significantly lower
area under the plasma salicyluric acid concentration-time curve
with sodium bicarbonate could be due to increased renal clearance
of salicyluric acid which correlated significantly with urine pH.
However, the elimination of salicyluric acid followed zero-order
kinetics until the amount of salicylate in the body declined to
approximately 360 mg (Levy, 1965b) and the plasma salicylic acid
concentration dropped below 50 pg/ml. Since there were highly
significant positive correlations between the renal clearance of
salicylic acid and urine pH, particularly when corrected for flow
rate, the significantly lower plasma half-life and higher total body
and renal clearances, and urinary recovery are all dependent on
urine pH. The influence of urine pH increased remarkably above
7.0, where it completely dominated the elimination kinetics of
salicylic acid. Since the renal clearance is derived from the flow
CU
rate (RC = — flow rate), it is not aporopriate to calculate the
CP
correlation between the renal clearance and flow rate. The ratio
of urine to plasma concentration (CU/CP) is the renal clearance
corrected for flow rate which is mathematically (but not biologi¬
cally) independent of urine flow rate. As expected, there was
no /
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no correlation between the ratio of urine to plasma concentrations
and flow rate.
The ratio of ionized/unionized salicylic acid in the renal
tubular fluid increases with increasing pH, thus salicylic acid
reabsorption decreases and its urinary excretion is enhanced
(Schacter and Manis, 1958; Bedford et al., 1965). Since acetyl-
salicylic acid has similar pKa to salicylic acid (3.5 and 3.0
respectively) and its renal clearance also correlated well with
urine pH, the same mechanism probably applies to acetylsalicylic
acid; pH-dependent renal excretion of acetylsalicylic acid has not
been described previously.
Although the renal clearance of salicyluric acid was signifi¬
cantly higher with sodium bicarbonate, the ratio of the urinary
recovery of salicylic to salicyluric acid increased seven-fold with
alkaline diuresis. The significantly lower urinary recovery of
salicyluric acid with alkaline diuresis is due to increased total
body and renal clearances of salicylic acid. The renal excretion
of salicyluric acid involves active renal tubular secretion and
conjugation (Levy, Amsel and Elliot, 1969).
(e) Summary
The disposition of acetylsalicylic acid following a single
dose of 20 mg/kg aspirin was studied in 6 healthy volunteers with
and without alkaline diuresis.
Acetylsalicylic acid was absorbed more rapidly when it was
taken one hour after sodium bicarbonate.
The mean plasma half-life of salicylic acid decreased signifi¬
cantly from 5.66 hours in the control to 3.56 hours with alkaline
diuresis /
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diuresis (p < 0.05). The total body clearance of salicylic acid was
significantly higher (p< 0.005) with sodium bicarbonate than in the
control (33.4 and 23.2 ml/min, respectively). This increase was due
entirely to an increased renal clearance of salicylic acid following
sodium bicarbonate. The volume of salicylic acid distribution was
slightly, but not significantly lower with alkaline diuresis than
in the control (147 and 164 ml/kg respectively).
The mean renal clearances of acetyl salicylic and salicylic
acids increased from 3.75 and 2.2 ml/min in the control study to
18.5 and 12.5 ml/min with sodium bicarbonate, respectively. The
mean urinary recoveries of acetyl salicylic and salicylic acids were
also increased significantly from 15 and 82 mg in the control to 26
and 390 mg with alkaline diuresis respectively. There were signifi¬
cant positive correlations between the renal clearances of acetyl-
salicylic and salicylic acids and urine pH and flow rate.
The renal clearance of salicyluric acid was increased from
443 to 567 ml/min with alkaline diuresis, but its urinary recovery
decreased from 901 to 607 mg, due to increased salicylic acid
elimination. The ratio of the urinary recovery of salicylic to
salicyluric acids increased seven-fold with alkaline diuresis.
Alkaline diuresis enhanced the elimination of acetyl salicylic
and salicylic acids and the proportion of the dose recovered in the




THE EFFECTS OF CHANGES IN URINE pH AND FLOW RATE
ON DIFLUNISAL ELIMINATION IN HEALTHY VOLUNTEERS
(a) Introduction
Diflunisal (2',4',difluoro-4-hydroxy-3-biphenylcarboxylic acid)
is a derivative of salicylic acid (Fig. 1) with similar pharmacology
and toxicology (Stone et al., 1977). However, it is longer acting
(Tempero, Cirillo and Steelman, 1977) and is claimed to cause less
gastrointestinal bleeding (De Schepper and Tjanramaga, 1978) and to
have less marked effects on platelet function (Smith Sibinga, 1977)
although bleeding from duodenal and gastric ulcers has been reported
(Talbot and Rees, 1978; Scott, 1979; Admani and Khaleque, 1979).
Diflunisal is a 1ipid-soluble, organic acid (pKa 3.3) and as
such its renal clearance should be pH-dependent (Milne, 1965). On
the other hand, it is very highly bound to plasma proteins, an average
of 99.8% at 50 pg/ml (Verbeeck, Boel, Buntinx and De Shepper,
1980). Diflunisal elimination is dose-dependent. The area
under the plasma concentration-time curve was 18 times higher follow¬
ing a dose of 500 mg than with 50 mg (Tocco et al., 1975)
The effects of urine pH and flow rate on the renal clearance of
diflunisal were studied by conventional clearance techniques in
anaesthetised dogs (Baer, Breault and Russo, 1978). The net renal
clearance of diflunisal was very low (about 1% of the glomerular
filtration rate) and changes in the urine flow or pH had very little
effect. About half of a single intravenous dose of diflunisal is
excreted in the urine in dogs (50% unchanged and 50% as glucuronide
conjugates) /
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conjugates), whereas in man, 95% of an oral dose appears in the
urine, principally as glucuronide conjugates (Tocco et al., 1975).
Verbeeck, Tjandramaga, Mullie, Verbesselt, Verberckmoes and De
Schepper (1979) studied the biotransformation of diflunisal and the
renal excretion of its glucuronides in renal insufficiency and
found that the plasma half-life was increased by a factor of up
to ten in patients with renal failure. Levy (1979) pointed out that
renal dysfunction would cause a larger fraction of conjugated
diflunisal to be excreted in the bile. Only a small fraction of
diflunisal (< 5%) is excreted unchanged in the urine in man and it
is difficult to see how diflunisal elimination could be enhanced by
increasing urine pH and flow rate. Nevertheless, forced alkaline
diuresis has been recommended for the treatment of diflunisal over¬
dosage (ABPI Data Sheet Compendium, 1979-1980), although its efficacy
is unknown.
The present study was carried out to measure the plasma half-
life concentrations, volume of distribution, total body clearance,
renal clearance and excretion of diflunisal in healthy volunteers
under different conditions of urine pH and flow rate.
(b) Methods
Six healthy ambulant male volunteers aged 20-37 years, weighing
60-83 kg were studied with informed consent. The subjects had not
taken any drugs for at least 2 weeks before the study. Each took
750 mg of diflunisal (3 "Dolobid" tablets) with 200 ml of water
following an overnight fast after which food, fluids and tobacco
were withheld for 2 hours. Venous blood (5 ml) was taken
at 0, 1, 2, 3, 4, 8, 12, 24, 36, 48 and 72 hours and urine
was /
122
was collected at time 0 (blank urine), 2 hourly for 12 hours and
then 12 hourly for another 60 hours. Blood samples were placed in
lithium heparin tubes and the plasma separated. The volume and
pH of each urine sample were measured. The urine and plasma
samples were stored at -20°C. Normal fluid intake, diet and
activity were allowed, but alcohol and other drugs were not taken
during the study.
The experiment was repeated in the same volunteers not less
than 2 weeks later with administration of sodium bicarbonate
capsules (3 gm 4 times daily) the day before and for 48 hours after
the diflunisal. The fifth dose of sodium bicarbonate (the first
dose on the second day) was given one hour before the diflunisal.
Fluid intake was increased to give a urine output of about 4 litres
daily.
Unchanged diflunisal was estimated in plasma and urine by
the high performance liquid chromatographic method (Chapter 2,
Section II). The plasma elimination half-life, area under the
plasma concentration-time curve, total body clearance, volume of
distribution and renal clearance of diflunisal were calculated
before and during alkaline diuresis as described in Chapter 1 of
this Section. Statistical tests were also performed in the same
way.
(c) Results
The plasma concentrations of diflunisal were almost identical
in both studies (Fig. 3.3.). Peak plasma concentrations were
reached within 3-4 hours and the mean values were 112 ± 15 and 118 ±
11 (S.D.) jjg/ml with and without sodium bicarbonate respectively.
The /
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Figure 3.3. Mean plasma concentrations of diflunisal following a
single oral dose of 750 mg with and without sodium
bicarbonate in 6 healthy subjects.
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The effects of alkaline diuresis on the disposition of diflunisal
are summarised in Table 3.6. The mean plasma elimination half-life
values were virtually identical in both studies (12.9 + 1.8 and 12.5
± 1.8 hours). If anything, plasma diflunisal concentrations were
higher rather than lower during alkaline diuresis. The mean area
under the plasma diflunisal concentration-time curve (0-72 hours)
was also greater with sodium bicarbonate than in the control study
(1954 ± 343 and 1807 ± 207 yg.ml ^ hr. respectively), but
the difference was not statistically significant (0.20 < p < 0.30).
The total body clearance of diflunisal was lower rather than higher
with alkaline diuresis and, surprisingly, its apparent volume of
distribution significantly decreased with sodium bicarbonate
(Table 3.6.).
Urine pH and flow rate were significantly higher (p < 0.001
and p < 0.005 respectively) with sodium bicarbonate than the
control (pH 7.5 ± 0.4 and 6.3 ± 0.3, flow rate 2.7 ± 0.2 and 0.9 ±
0.2 ml/min respectively).
The mean urine pH and flow rate for each period of urine coll¬
ection with and without alkaline diuresis are given in Table 3.7.
The 72 hour urinary recovery of diflunisal was more than
doubled by alkaline diuresis (Table 3.6), but even so, only 5-7%
of the administered dose was excreted unchanged. There was a
significant increase in the renal clearance of diflunisal from 0.21
to 0.43 ml/min with alkaline diuresis (Table 3.6), but there was
no statistically significant correlation overall between the renal
clearance /
TABLE3.5.


























































































































































































clearance of diflunisal and urine pH or flow rate (r = 0.08 and r =
-0.04 respectively). Unexpectedly, there was a progressive and
highly significant increase in the renal clearance of diflunisal with
time (Fig. 3.4) irrespective of urine pH or flow rate (r = 0.75,
p < 0.001 with diflunisal alone and r = 0.49, p < 0.001 with
alkaline diuresis). The overall mean renal clearance of diflunisal
increased from 0.22 ml/min over the period of 0-24 hours to 0.73 ml/
min from 48-72 hours. There was a correspondingly significant nega¬
tive correlation between plasma concentrations and renal clearance of
diflunisal with and without sodium bicarbonate (r = -0.50, p < 0.001
and r = -0.65, p < 0.001 respectively).
(d) Discussion
Although the mean renal clearance and the 72-hour urinary
recovery of diflunisal were significantly increased by alkaline
diuresis, the total body clearance decreased and only 5-7% of the
administered dose was excreted unchanged. There was no reduction in
the mean plasma concentrations or half-life. Plasma concentrations
were actually higher with alkaline diuresis, possibly due to the
increased absorption or decreased volume of distribution. The
mean plasma half-life of 12-13 hours is consistent with the
previous reports of dose-dependent elimination of diflunisal (Tocco
et al., 1975; Tempero, Cirillo and Steelman, 1978). The total
body clearance and volume of distribution of diflunisal in the
control were also compatible with values cited in the literature
(Verbeeck et al., 1979).
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Figure 3.4. The increase in mean renal clearance of dif1unisal
with time following a single oral dose of 750 mg
with and without sodium bicarbonate in 6 healthy
subjects.
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volume of distribution of diflunisal with alkaline diuresis and no
significant overall correlation between the renal clearance of
diflunisal and urine pH or flow rate. On the other hand, there was
a highly significant relationship between time after administration
(and plasma concentration) and renal clearance of diflunisal
irrespective of urine pH or flow rate. The explanation for these
findings is unknown. Possibilities include induction of renal
tubular transport of diflunisal with time, or that the maximum
tubular secretory capacity was exceeded at higher plasma concen¬
trations. Similar findings were reported for the renal clearance
of salicyl acyl glucuronide (but not salicylic acid) by Schachter
and Manis (1958). We have confirmed that there is no correlation
between the renal clearance of salicylic acid and its plasma concen¬
trations or time after administration of therapeutic doses of
aspirin in healthy volunteers. Interestingly, an opposite relation¬
ship has been described between the plasma concentration and renal
clearance of disopyramide which was attributed to concentration-
dependent plasma protein binding (Cunningham, Shen, Shudo and
Azarnoff, 1977). Enhancement of diflunisal elimination by alkaline
diuresis would be most unlikely since being very highly bound to plasma
proteins, so little is excreted unchanged (Verbeeck and De
Schepper, 1980; Tocco et al., 1975).
Forced alkaline diuresis has been recommended for the treat¬
ment of diflunisal overdosage. In one report it appeared to have
little beneficial effect, although no measurements were made
(Upadhyay and Gupta, 1978). According to the results of the present




(e) Summary and conclusions
The effect of alkaline diuresis on the elimination of a single
oral dose of 750 mg diflunisal was studied in 6 healthy male volunteers.
The plasma concentrations and half-life of diflunisal were
not reduced by alkaline diuresis. The total body clearance and
the volume of distribution of the unchanged drug were reduced.
The 72-hour urinary recovery of diflunisal was more than doubled,
but even so, only 5-7% of the administered dose was excreted
unchanged. With alkaline diuresis there was a significant increase
in the mean renal clearance of diflunisal from 0.27 to 0.46 ml/min
but there was no significant correlation between the renal clear¬
ance of diflunisal and urine flow or pH. However, there was a
significant increase in the overall mean renal clearance of
diflunisal from 0.22 ml/min over the period of 0-24 hours to
0.73 ml/min from 48-72 hours.
Forced alkaline diuresis is of no value in diflunisal
poisoning.
SECTION IV
EFFECTS OF CHANGES IN URINE pH AND FLOW RATE ON





PHARMACOKINETICS OF ACETYLSALICYLIC ACID IN OVERDOSAGE
WITHOUT TREATMENT BY FORCED ALKALINE DIURESIS
(a) Introduction
Although acetyl salicylic acid has been one of the most
frequently taken poisons in most countries of the world and hundreds
of cases of aspirin overdosage have been reported (e.g. Gross and
Greenberg, 1948; Smith, 1966; Kaye, 1972; Locket, 1973;
McCleave and Havil, 1974; Mofenson and Greensher, 1975; Bender, 1975;
McQueen, 1977; Done, 1978; Proudfoot and Park, 1978),its pharmacokin¬
etics in overdosage have not been investigated in detail. Until
recently it was not easy to measure acetyl salicylic acid and its
metabolites in plasma and urine (Chapter 1, Section II) and methods
employed to monitor salicylate concentrations in patients with
aspirin overdosage were not specific.
The present study was undertaken to investigate the disposition
and pharmacokinetics of acetyl salicylic acid in 16 control patients
with mild aspirin overdosage who received no specific treatment.
(b) Patients and methods
The patients aged 16-65 years and weighing 41-96 kg (5 males
and 11 females) were studied on admission to the Regional Poisoning
Treatment Centre, The Royal Infirmary, Edinburgh, with peak plasma
salicylate concentrations in the range of 300-450 pg/ml. The protocol
was /
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was approved by the Physicians' Advisory Ethical Committee. Patients
with significant overdosage of other drugs or alcohol and respiratory,
cardiac, renal, gastrointestinal and hepatic disease or pregnancy
were excluded.
On admission the plasma salicylate concentration was
measured by the modified Trinder's method in the ward side room
(Chapter 1, Section II) and repeated hourly to determine the peak
concentration. The following procedures were performed :
1. The patient was asked to empty his or her bladder. A 20 ml
aliquot of urine was placed in a plain tube and the remainder in a
one-litre bottle containing 250 pi of 20% (W/V) potassium fluoride
and 250 pi of glacial acetic acid. Each urine sample was collected
in the same way until the patient was discharged.
2. A No. 19 butterfly cannula with a 2-way tap was inserted in a
mid-forearm vein for blood sampling and kept open with a slow-
running saline infusion.
3. Blood samples (5 ml) were taken at 0, 1, 2, 3, 4, 5, 6, 8, 12,
16, 24, 36 and 48 hours and placed in lithium heparin tubes con¬
taining 50 pi of 20% potassium fluoride.
4. The blood samples were centrifuged immediately. The plasma
was placed in a glass tube containing 50 pi of 20% potassium
fluoride and 50pl glacial acetic acid and stored at -20°C until
analysis.
5. The pH of the 20 ml urine samples was measured using a pH
meter and the total volume of each sample measured, 10-15 ml of the




6. Acetyl salicylic acid and metabolite concentrations in plasma
and urine were measured by high performance liquid chromatography
(Chapter 1, Section II).
The binding of salicylic acid to plasma protein was
measured (Chapter 3, Section II) in fresh plasma samples from 2
patients (Nos. 50 and 52). Glucuronide conjugates of salicylic and
salicyluric acids were measured in the pooled urine samples of 6
patients.
7. Pharmacokinetic variables were calculated as for the healthy
volunteers (Chapter 1, Section III) except for the following :
1. The total body clearance of salicylic acid could not be
derived from the dose absorbed and instead was calculated
from the following equation :
TBC = ^
fe
TBC is the total body clearance of salicylic acid, RC the
renal clearance and fe the fraction excreted in the urine
as salicylic acid. The urine collection periods were
very short (average 3 hours) and it was assumed that the
change in the excretion rate in each period was linear.
2. The independent two-tailed student t-test, with p< 0.05
as the minimum level of statistical significance was used
for comparisons.
N.B. Since the periods of urine collection were not the
same, the urine flow rate and renal clearance were also
calculated 0 to 16 hours after admission in each
patient. The mean urine pH in each patient was calculated





Plasma concentrations and elimination of acetyl sal icy!1c acid
and its metabolites
Acetyl salicylic acid was detected in the plasma of only 4
patients (Fig. 4.1). The plasma concentrations on admission varied
from 3.3 yg/ml at 10 hours to 28 yg/ml at 3 hours after ingestion.
Plasma salicylic acid concentrations in these 4 cases increased during
the first few hours (up to 16 hours) after admission and then declined
(Fig. 4.1). The plasma salicylic acid concentrations on admission and
up to the time of peak concentration were measured by the ward side
room assay and were in the range of 300 to 450 yg/ml. However, the
values obtained were generally higher than those measured subsequently
by high performance liquid chromatography (Fig. 2.8). The plasma
salicylic acid half-lives were generally higher in these patients
than in those in whom acetyl salicylic acid was not detected, ranging
from 21 to 48 hours.
In another 7 patients in whom plasma acetyl salicylic acid was
not detected after admission, absorption was apparently delayed
(Fig. 4.1) and salicylic acid concentrations increased in one patient
(No. 50) up to 16 hours. Two patients (Nos. 7 and 9) had also
taken paracetamol plus d-propoxyphene with thyroxine and 2 had taken
alcohol (Nos. 35 and 52). The plasma half-lives in this group
ranged from 22 to 36 hours. Plasma salicylic acid concentrations in
the other 5 patients are shown in Figure 4.2. The maximum plasma
salicylic acid concentrations were observed on admission. The mean




































Figure 4.1. Plasma concentrations of salicylic acid in two groups
of patients with mild aspirin poisoning who received
oral fluids only showing delayed absorption. In the
4 cases (left) acetyl salicylic acid (inset, scale
on right) was detected in the initial plasma samples.
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HOURS AFTER INGESTION
Figure 4.2. Plasma concentrations of salicylic acid in
































































































































Plasma salicyluric acid concentrations were very low (mean 2.5-
3.3 ug/ml) and remained relatively constant throughout the study
(zero-order kinetics). The mean plasma salicyluric acid concentra¬
tion in the control patients compared with the patients receiving
intravenous treatment are shown in Figure 4.8.
Total body clearance and apparent volume of distribution of sali¬
cylic acid
The total body clearance and apparent volume of distribution
of salicylic acid are shown in Table 4.1. Since the total body clear¬
ance was calculated from the renal clearance and urine collection
was incomplete in patient No. 8, the total body clearance and thus
volume of distribution of salicylic acid in this patient was not
available. The total body clearance ranged from 2.7 to 9 ml/min
and the apparent volume of distribution varied from 102 to 594 ml/kg.
The patient who had the lowest volume distribution (102 ml/kg) was a
19 year old fat woman weighing 95.5 kg and the patient with the
highest, had the longest plasma half-life due to possibly delayed
and slow absorption.
The total body clearance of salicylic acid increased with time
after 16 hours (> 10 ml/min).
Renal clearance and excretion of acetyl sal icy!ic acid and its
metabolites
The renal clearance of acetyl salicylic acid was only measurable
in two patients (Nos. 1 and 13) and varied from 7 to 85 ml/min in
different urine samples. Acetyl salicylic acid was only found in the




The renal clearance and the urinary recovery of salicylic acid
over the period 0-16 hours are shown in Table 4.1. The renal
clearances ranged from 0.15 to 4.71 ml/min and the urinary recovery
from 51 to 1061 mg. The mean renal clearance and urinary recovery
of salicylic acid were 1.37 ml/min and 376 mg.
The renal clearance of salicyluric acid was much higher than
the clearances of acetylsalicylic or salicylic acids. The mean was
493 ± 317 ml/min during the first 16 hours after admission (Fig. 4.9).
The urinary recovery of salicyluric acid was much greater than that
of salicylic acid in all patients (1116 ± 549 mg) except for one
(No. 13). The urinary recoveries of salicyluric acid during the first
4 and 16 hours are given in Tables 4.19 and 4.20.
The urine pH did not change significantly during the study and
the differences between patients were small with an overall mean
of 6.1 ± 0.4. The urine flow rate varied from 0.58 to 3.03 ml/min
with a mean of 1.40 ± 0.79 ml/min. The mean urine pH and flow rate
over the first 4 and 16 hours are given in Table 4.9.
There was a highly significant correlation between the renal
clearance of salicylic acid and urine pH (r = 0.57, p < 0.001) but no
such correlation with salicyluric acid (r = 0.185, p > 0.1). There
was also a highly significant correlation between the renal clearance
of salicylic acid corrected for flow rate (the ratio of urine con¬
centration to plasma concentration of salicylic acid) and urine pH.
There was a negative correlation between the ratio of urine to plasma
concentration of salicylic acid and urine flow rate (r = -0.24,
p < 0.05).
Salicylic acid glucuronide conjugates accounted for 24% to 83%
(59.6 ± 21.7) of the total urinary recovery of salicylic acid (Table 4.22).
wh i 1 e /
while salicyluric acid glucuronide conjugates contributed 6% to 30%
(14.3 ± 8.2) of the total urinary recovery of salicyluric acid
(Table 4.23).
(d) Piscussion
The absorption of acetyl salicylic acid was delayed in some
patients after overdosage and in one it was detected as long as 24
hours after ingestion of 100 aspirin (Disprin) tablets. Since
aspirin is not absorbed appreciably from the stomach, these findings
indicate either slow dissolution or slow gastric emptying. This
confirms the previous concept that gastric aspiration and lavage is
never too late in aspirin poisoning (Matthew and Lawson, 1979).
Acetyl salicylic acid is rapidly hydrolysed to salicylic acid
and only a small portion of the absorbed drug was excreted unchanged
in the urine.
Salicylic acid is the major toxic metabolite of acetyl salicylic
acid and since its binding to plasma proteins decreases significantly
with increasing concentration (Chapter 3, Section II), disproportion¬
ately more unbound drug is available at higher concentrations to
enter the tissues and induce toxicity.
Glycine and phenolic glucuronide conjugation of salicylic acid
is saturated at low therapeutic concentrations (Levy, 1965a; Levy,
Tsuchiya and Amsel, 1972), therefore its elimination through conjuga¬
tion should have followed zero-order kinetics, although 32% of the sal
cylic acid was excreted unchanged. As a result the plasma half-life
of salicylic acid was prolonged after overdosage to about 30 hours
and was as long as 48 hours in one patient, whereas the mean in the
healthy /
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healthy subjects was 5.7 hours after an oral dose of 20 mg/kg
(Chapter 1, Section III). This is consistent with the previous
reports (Done, I960; Levy and Yaffe, 1968).
The total body and renal clearances of salicylic acid were
significantly lower in the overdose patients than the healthy volun¬
teers given a therapeutic dose (Table 3.1). In the case of total
body clearance this difference was due to saturation of glycine
conjugation, the major route of elimination of a therapeutic dose.
The increasing total body clearance of salicylic acid with time
and decreasing plasma concentration is consistent with a change from
zero-order to first-order elimination, although this could not be
demonstrated in most patients. The higher apparent volume of dis¬
tribution of salicylic acid following overdosage compared with the
results in the healthy volunteers is in agreement with the dose-
dependent volume of distribution found by Levy and Yaffe (1974).
However, the apparent volume of distribution of non-protein bound
salicylic acid declined over the concentration ranges found in
patients with moderate to severe salicylate poisoning (Chapter 2,
Section IV).
Renal clearance and excretion of salicylic acid is sensitive
to urine pH and the correlation becomes greater when the renal
clearance is corrected for flow rate. This is consistent with the
results in healthy volunteers and the same explanation could be applied.
The very high renal clearance of salicyluric acid was similar to that
of the healthy volunteers and consistent with the findings of Levy et al.
(1969). The mean urinary recovery of salicyluric acid was also
greater than the recovery of salicylic acid, but more salicylic acid
than /
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than salicyluric acid glucuronide conjugates were excreted in the
urine. This again is in agreement with the results in the healthy
volunteers (Chapter 1, Section III) and previous reports (Rowland et
al., 1967; Levy, 1978).
(e) Summary and conclusions
The pharmacokinetics of acetyl salicylic acid in overdosage
were studied in 16 poisoned patients with plasma salicylate concen¬
trations of 300-450 pg/ml.
Acetyl salicylic acid was slowly absorbed with delay in some
patients. It was rapidly hydrolysed to salicylic acid and only a
small fraction was excreted unchanged. The mean plasma half-life of
salicylic acid was very prolonged with a mean value of 30 hours.
The plasma concentration of salicyluric acid was very low and constant
throughout reflecting saturation of glycine conjugation of salicylic
acid.
There were direct relationships between the renal clearance of
salicylic acid (but not salicyluric acid) and urine pH. The renal
clearance of salicyluric acid exceeded the glomerular filtration rate
and was much higher than that of salicylic acid due to active renal
tubular secretion and conjugation.
The urinary recovery of salicyluric acid was greater than that
of salicylic acid. On average, 65% was recovered as salicyluric




EFFECTS OF CHANGES IN URINE pH AND FLOW RATE ON THE
PHARMACOKINETICS OF ACETYLSALICYLIC ACID FOLLOWING OVERDOSAGE
(a) Introduction
The effect of urine pH on the elimination of salicylate was
studied many years ago (Hanzlik, 1926) and it was later confirmed that
alkalinisation of the urine enhances salicylate elimination (Smith
et al., 1946). The effects of intravenous sodium bicarbonate in
children with salicylate poisoning (Oliver and Dayer, 1960) and the
possible therapeutic usefulness of forced diuresis for the treat¬
ment of aspirin overdosage (Cumming, 1961) were reported.
Different methods of forced alkaline diuresis (Dukes et al.,
1963; Cumming et al., 1964; Beveridge et al., 1964; Lawson et al.,
1969; Savage et al., 1969),alkaline-mannitol diuresis (Prowse et al.,
1970), mannitol-1actate and acetazolamide-bicarbonate (Morgan and
Polak, 1969, 1971) and forced alkaline diuresis with loop diuretics
(Berg, 1977) were reported. However, the separate effects of
changes in urine pH and flow rate on the pharmacokinetics of acetyl-
salicylic acid have not been investigated in detail. In addition,
problems such as delayed absorption, slow hydrolysis of acetyl-
salicylic acid, changes in salicylic acid distribution and the




This study was designed to investigate the pharmacokinetics
of acetyl salicylic acid and the elimination of salicylate in
patients with moderate to severe aspirin poisoning who were treated
with one of four intravenous regimes of fluid and alkali. The
study was approved by the Physicians' Advisory Ethical Committee
of the Royal Infirmary, Edinburgh.
(b) Patients
Seventeen males and 17 females admitted to the Regional
Poisoning Treatment Centre, Royal Infirmary, Edinburgh, with aspirin
overdosage were studied. The patients were aged 16-65 years and
their weights ranged from 43 - 86 kg. Patients with significant
overdosage of other drugs or alcohol, respiratory, cardiac, renal,
gastrointestinal and hepatic diseases or pregnancy were excluded.
The patients were divided into four groups, according to the
admission or peak plasma salicylate concentrations (Chapter 1 of
this Section) which were measured by the ward side room assay as
follows :
1. Six patients (3 males and 3 females) with plasma salicylate
concentrations of 400-550 ug/ml were treated by forced diuresis.
2. Six patients (3 males and 3 females) with plasma salicylate
concentrations of 400-600 ug/ml were treated by alkaline diuresis.
3. Sixteen patients (8 males and 8 females) with plasma salicyl¬
ate concentrations of 450-800 ug/ml were treated by forced alkaline
di uresis.
4. Six patients (3 males and 3 females) with plasma salicylate
concentrations of 400-700 pg/ml were treated by forced alkaline




The four intravenous regimes used were as follows :
1. Forced diuresis : One litre of 5% dextrose, 0.5 litre of nor¬
mal saline and 0.5 litre of 0.6% (W/V) potassium chloride was made
up in a glass bottle under sterile conditions. It was the standard
"cocktail" for forced alkaline diuresis without the sodium bicar¬
bonate and was infused at a rate of 2 litres per hour for 3 hours.
2. Alkali alone : 1.26% ( /^) sodium bicarbonate solution con¬
taining 1.5 g potassium chloride in each 0.5 litre was given intra¬
venously at a rate of 0.5 litre per hour for 3 hours.
3. Forced alkaline diuresis : One litre of 5% dextrose, 0.5 litre
of normal saline and 0.5 litre of 1.26% sodium bicarbonate plus 3 g
potassium chloride was infused at a rate of 2 litres per hour for 3
hours. This was the standard "cocktail" forced alkaline diuresis
and thus the same as regime 1 with the addition of 6.3 g sodium
bicarbonate to each 2-litre bottle. The sodium bicarbonate was
added just before use as 75 ml of 8.4% sodium bicarbonate to 1925
ml solution already in the bottle.
4. Forced alkaline diuresis with frusemide : The same regime
as the forced alkaline diuresis was used with the intravenous injec¬
tion of 40 mg frusemide at the end of the first 2 litres and a
further 2 doses of 20 mg each at the end of the 4th and 6th litres.
(d) Titration of solutions used for the forced diuresis and forced
alkaline diuresis
Twenty ml of the solution (cocktail) used for forced diuresis
was titrated against 0.001 N sodium bicarbonate using a pH M 62
standard pH meter (Radiometer, Copenhagen). The solution (cocktail)
used /
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used for forced alkaline diuresis (20 ml) was titrated against
0.01.N hydrochloric acid. These titrations were performed on five
randomly selected samples of the two types of cocktail solution.
The results are summarised in Table 4.2. and a titration curve
of each is shown in Figure 4.3. There were no significant differ¬
ences between the samples. The buffer capacity of the solution
used for forced alkaline diuresis was much greater than the solution
used for forced diuresis.
(e) Methods
Blood and urine sample collections and analyses were as des¬
cribed for the control patients (Chapter 1, Section IV) except for:
1. Blood sampling times : On admission, at the commencement of the
infusion, hourly for 5 hours and then at 7, 11, 15, 23, 35 and
47 hours after the start of intravenous therapy.
2. In 7 patients including 2 controls,the binding of salicylic
acid to plasma proteins was measured in freshly taken samples.
3. The total urinary output of salicylic acid including glucuronide
conjugates of salicylic and salicyluric acids was measured in 6 patients
from each group (except for forced alkaline diuresis with frusemide).
4. The volumes of distribution of the total and unbound salicylic
acid were measured by the method of Levy and Yaffe (1974) (i.e.
total body salicylate divided by the plasma concentration of
total/unbound salicylate) in five patients who were kept in the
ward until salicylate was no longer detectable in the urine.
5. In all the patients, including the controls, the apparent plasma
half-life of salicylic acid was calculated from the time of the peak
plasma /

































































TITRATION OF SOLUTIONS USED FOR FORCED DIURESIS AND
FORCED ALKALINE DIURESIS
NaHC03 0.001 N or HCI 0.01 N (ml)
Figure 4.3. Titration of 20 ml of the solution used for forced
diuresis against 0.001 N sodium bicarbonate, and
20 ml of the solution used for forced alkaline
diuresis against 0.01 N hydrochloric acid.
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plasma concentration up to 4 hours and from 4 to 16 hours. The
total body clearance and apparent volume of distribution of salicylic
acid were also calculated over these two time periods.
6. The renal clearances and urinary recoveries of salicylic and
salicyluric acids were calculated over the periods 0-4 and 0-16 hrs.
7. Comparisons within and between the groups were performed using
the one way analysis of variance. If the differences were signifi¬
cant (p < 0.05), individual groups were compared using the indepen¬
dent, two-tailed Student t-test.
8. Multiple regression analysis (Woolf, 1951) was used to evaluate
the separate effect of urine pH and flow rate on the ratio of urine
to plasma salicylic acid concentrations.
(f) Results
Plasma concentrations and elimination of acetylsalicylic acid
and its metabolites
Acetyl salicylic acid
Acetyl salicylic acid was detected in the plasma on admission
in 4, 5, 7 and 4 patients with forced diuresis, alkali alone, forced
alkaline diuresis and forced alkaline diuresis with frusemide res¬
pectively. The concentrations varied from 3.1 tag/ml to 37.4 yg/ml
and the means for each group were 10.2 ± 7.0, 15.4 ± 14.0, 11.4 ±
7.2 and 5.7 ± 1.8 pg/ml respectively. Plasma acetyl salicylic acid
concentrations rose following admission in one patient (No. 29)
with forced diuresis, one (No. 17) with forced alkaline diuresis
and two (Nos. 54 and 59) with forced alkaline diuresis plus fruse¬
mide. Serial plasma acetyl salicylic acid concentrations in each
group /
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group including the controls are shown in Figure 4.4. The plasma
acetyl salicylic acid concentration in patient No. 17 increased up
to 39.7 yg/ml at 6| hours in spite of infusion of 2 litres of fluid
and this accounts for the higher mean concentration at 2 hours
after admission in the forced alkaline diuresis group.
It was not possible to measure the plasma acetyl salicylic acid
half-life in most patients because absorption was apparently delayed
and variable.
Salicylic acid
The mean and standard deviations of serial plasma concentrations
of salicylic acid are given in Table 4.3. The interval between the
reported time of ingestion and the admission plasma sample varied from
1 - 24 hours with a mean of 9.5, 6.9, 6.8, 3.6 and 3.5 hours in the
forced alkaline diuresis, forced alkaline diuresis plus frusemide,
control, alkali alone and forced diuresis groups, respectively.
The mean plasma salicylic acid concentrations on admission were 497
± 87, 472 ± 63, 471 ± 84, 439 ± 86 and 328 ± 57 ug/ml for the forced
alkaline diuresis, forced alkaline diuresis with frusemide, forced
diuresis, alkali alone and control groups, respectively. The plasma
concentrations on admission were significantly higher in the treated
groups than in the control patients (p < 0.005). A late rise in
plasma salicylic acid concentrations was only observed in two cases,
presumably because of the lowering effects of treatment. The mean
plasma salicylic acid concentrations for all groups from the time
of admission up to 16 hours are shown in Figure 4.5.
During infusion (0-4 hours) /
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1-1 i , .
0 12 3
HOURS AFTER ADMISSION
CONTROL ( N = 4)
FORCED DIURESIS ( N = 4 )
FORCED ALKALINE OIURESIS (N = 6 )
FORCED ALKALINE DIURESIS
♦ FRUSEMIDE (N = 4 )
ALKALI ALONE (N = 5)
Figure 4.4. Mean plasma concentrations of acetylsalicylic acid
in patients with mild to severe aspirin poisoning










































































































































Figure 4.5. Mean plasma concentrations of salicylic acid in
patients with mild to severe aspirin poisoning
receiving different treatments of fluid and alkali.
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During infusion (0-4 hours)
The mean plasma salicylic acid concentrations increased after
admission in the control group, possibly due to delayed absorp¬
tion and or slow hydrolysis of acetyl salicylic acid. The mean plasma
salicylic acid concentrations declined during the infusion in all
treated groups. The apparent plasma half-life values of salicylic
acid from 0 to 4 hours in each patient including the controls are
given in Table 4.4. The mean plasma half-lives were 5.05, 6.37, 6.58,
8.54 and 19.4 hours with alkali alone, forced alkaline diuresis plus
frusemide, forced alkaline diuresis, forced diuresis and control
groups, respectively. The plasma half-life of salicylic acid was
significantly longer with the control than in the treated groups
(p < 0.001). There were no statistically significant differences
between the plasma salicylic acid half-lives of the alkalinisation
groups. However, it was significantly longer with the forced diure¬
sis than in the alkali alone group (p < 0.02), but not the other
alkalinisation groups.
After infusion (4-16 hours)
The rate of disappearance of salicylic acid from the plasma
during the 4-16 hour period was the same in the forced diuresis and
control groups (30.6 ± 5.7 and 30.1 ± 8.8 respectively). The
plasma half-life values of salicylic acid from 4 to 16 hours in
each patient are given in Table 4.5. The mean plasma half-lives
in the alkalinisation groups were 9.14, 11.6 and 14.1 with alkali
alone, forced alkaline diuresis and forced alkaline diuresis plus




PLASMA HALF-LIFE OF SALICYLIC ACID 0-4 HOURS (hr)
Control Forced alkaline FAD + Forced A1kali
diuresis (FAD) frusenide diuresis alone
No. hr No. hr No. hr No. hr No. hr
1 25.6 2 3.15 53 5.85 27 11.8 37 5.27
4 12.5 3 7.64 54 6.32 29 7.43 38 5.63
6 10.7 5 6.32 55 4.20 30 N.M. 44 4.50
7 13.7 10 7.59 57 5.01 31 9.92 47 6.94
8 16.3 14 3.32 58 6.74 32 5.56 49 3.32
9 7.4 15 5.91 59 10.1 33 7.97 51 4.62
13 47.7 17 18.5
16 6.9 19 N.M.*
34 7.5 20 4.24
35 16.3 21 5.59
36 25.6 22 5.21
43 15.6 23 3.27
45 45.7 24 11.8
48 21.6 25 3.74
50 14.2 26 3.47
52 23.8 41 8.92
Mean: 19.4 6.58 6.37 8.54 5.05
S.D.: 12.2 4.11 2.04 2.40 1 .22
Analysis














No. hr No. hr No. hr No. hr No. hr
1 21.2 2 4.48 53 5.93 27 39.2 37 9.11
4 20.3 3 11.3 54 13.0 29 32.2 38 18.9
6 32.6 5 9.74 55 27.2 30 N.M. 44 6.24
7 20.6 10 18.7 57 6.15 31 26.0 47 11.6
8 26.3 14 7.50 58 15.5 32 24.8 49 2.62
9 32.7 15 5.11 59 16.9 33 30.6 51 4.86
13 47.7 17 7.86
16 24.7 19 N.M.*
34 23.2 20 9.77
35 23.3 21 N.M.
36 34.1 22 4.97
43 29.5 23 N.M.
45 45.7 24 35.8
48 40.7 25 7.10
50 22.9 26 5.82
52 35.7 41 22.10
Mean : 30.1 11.6 14.1 30.6 9.14
S.D. : 8.8 9.01 6.7 5.73 5.88
Analysi s




differences between the plasma salicylic acid half-lives of the
alkalinisation groups. However, the plasma half-life values were
significantly shorter with the alkalinisation groups than in the for¬
ced diuresis and control groups (p < 0.001).
Plasma half-life of salicylic acid could not be measured in
patients Nos. 19 and 30 because of delayed absorption and infusion
of 8 litres of fluid in the former and incomplete plasma collection
in the latter.
Since the plasma concentrations of salicylic acid on admission
were not the same in all groups, subsequent values were expressed as
the percentages of the initial plasma concentrations and are shown
in Figure 4.6.
There was a significant negative correlation between the
plasma half-life of salicylic acid from 4-16 hours and the highest
urine pH measured in that period (r = -0.80, p < 0.001) as shown in
Figure 4.7. The patients treated with alkali alone (•) had higher
urine pH and shorter plasma half-life of salicylic acid, whereas the
control patients (o) and those treated with forced diuresis (©) had
lower urine pH and longer plasma half-life than the other groups.
Salicyluric acid
Plasma concentrations of salicyluric acid were very low in all
patients throughout the study, ranging from 0.5 to 10 pg/ml. The
mean plasma concentration curves of salicyluric acid are shown in
Figure 4.8. Although the mean plasma concentrations of salicyluric
acid were higher (not statistically significant) in the forced














Figure 4.6. Plasma concentrations of salicylic acid expressed as
percentage of initial concentrations in patients with
mild to severe aspirin poisoning receiving different
treatments of fluid and alkali.
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Figure 4.7. Correlation between the plasma half-life of
salicylic acid after infusion and the maximum urine
pH over that period. O control, © forced diuresis,
A forced alkaline diuresis, A forced alkaline
diuresis with frusemide, • alkali alone.
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. FORCED ALKALINE DRJRESIS
WITH FRUSEMIDE




1 1 1 1
0 4 8 12 16
HOURS AFTER ADMISSION
Figure 4.8. Mean plasma concentrations of salicyluric acid in
patients with mild to severe aspirin poisoning
receiving different treatments of fluid and alkali.
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significant differences between the areas under the plasma salicyl¬
uric acid concentration-time curves of any of the groups.
The plasma salicyluric acid concentrations in the treated
groups fell during the infusion (0-4 hr). The percentage fall
was 30, 29, 20 and 14 with forced alkaline diuresis, forced alkaline
diuresis with frusemide, forced diuresis and alkali alone,
respectively. These were all significantly higher than the 2% fall
in the control group (p < 0.001). The fall was significantly higher
in the forced alkaline diuresis than in the alkali alone group
(p < 0.01).
Total body clearance and apparent volume of distribution of
salicylic acid
The total body clearances and apparent volumes of distribution
of salicylic acid during the 0-4 and 4-16 hour periods are shown in
Table 4.6. In the control group the mean total body clearance was
slightly higher during the second period (4.90 ± 2.90 and 5.41 ±
1.94 respectively) and it appeared to increase with time. As the
plasma concentration of salicylic acid declined below 100 pg/ml
it increased more than 3 fold (above 18 ml/min). In the other
groups, however, the total body clearances of salicylic acid declined
after the infusion. The mean percentage decreases were 63, 60, 45
and 36 with forced diuresis, forced alkaline diuresis with frusemide,
forced alkaline diuresis and alkali alone groups, respectively. The
mean total body clearances of salicylic acid were 18.8, 36.8, 36.9
and 37.5 during, and 6.9, 14.7, 20.3 and 24 ml/min after infusion
respectively. These values were significantly higher than in the control
group, particularly during the infusion period (p < 0.001 and p < 0.01
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infusion respectively). There were no statistically significant
differences in the total body clearance of salicylic acid in the
alkalinisation groups, but the clearance values were significantly
higher in the alkalinisation than in forced diuresis groups (p <
0.05 during and p < 0.01 after infusion).
The mean apparent volumes of distribution of salicylic acid
during the infusion (0-4 hours) were 355, 330, 276, 217 and 131 ml/
kg in the forced alkaline diuresis, forced alkaline diuresis plus
frusemide, alkali alone, forced diuresis and control groups res¬
pectively. The values increased after 4 hours in the control,
forced diuresis and alkali alone groups, and decreased in the other 2
groups, but the changes were not statistically significant. The
mean apparent volume of distribution of salicylic acid at 4-16 hrs
was 348, 319, 292, 285 and 236 ml/kg in the forced alkaline diuresis,
alkali alone, forced alkaline diuresis plus frusemide, forced
diuresis and control groups, respectively. There were no statisti¬
cally significant differences in the apparent volume of distribu¬
tion of salicylic acid between the groups.
The apparent volumes of distribution of salicylic acid increa¬
sed significantly with concentration in all patients except No. 57
in whom acute on chronic salicylate intoxication occurred.
The volumes of distribution did not change significantly with
plasma salicylic acid concentrations in this patient (Table 4.7.).
Total body clearance and apparent volume of distribution of unbound
salicylic acid /









































































































Total body clearance and apparent volume of distribution of
unbound salicylic acid
The total body clearance and apparent volume of distribution
of unbound salicylic acid in the 5 patients are given in Table 4.8.
The mean values from 0-4 hours were 78 ml/min and 469 ml/kg which were
significantly greater than the corresponding total body clearance
and apparent volume of distribution of total salicylic acid (p <
0.01). Both the total body clearance and apparent volume of dis¬
tribution of unbound salicylic acid significantly increased after
infusion (p < 0.01) and the mean values (4-16 hours) were 151 ml/min
and 1148 ml/kg. These were much higher than the corresponding total
body clearance and apparent volume of distribution of total sali¬
cylic acid (p < 0.001).
The apparent volume of distribution of unbound salicylic acid
decreased with increasing plasma concentration of the total drug in
all patients except in patient No. 54 in which it did not change
significantly (Table 4.7.). However, there was a significant overall
negative correlation between the apparent volumes of distribution of
unbound salicylic acid and the plasma concentrations of the total
drug (r = -0.77, p < 0.001).
Urinary pH and flow rate
The mean and standard deviations of urine pH and flow rate
over the first 4 and 16 hours after admission for each group of
patients are given in Table 4.9. The range of urine pH in each
patient was usually small, except for the alkalinisation groups in
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0-4 hr 4-16 hr
Forced alkaline
diuresis






















P - value < 0.01 < 0.01
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TABLE 4.9.
URINE pH AND FLOW RATE IN PATIENTS WITH ASPIRIN OVERDOSAGE
Group
Urine pH Urine flow rate (ml/min)
0-4 hr 0- 16 hr 0-4 hr 0-16 hr









7.6 ± 0.5 7.5 + 0.4 24.8 ± 4.3 6.46 ± 1.15
Forced
diuresis 7.1 ± 0.6 6.5 + 0.3 8.18 ± 4.49 5.80 ± 1.88
A1kali
alone 8.2 ± 0.5 8.1 + 0.5 7.00 ± 4.50 2.60 ± 0.70
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infusion. The mean urine pH from 0-4 hrs was 8.2, 7.6, 7.6,7.1 and 6.4,
and from 0-16 hrs 8.1, 7.5. 7.4, 6.5 and 6.1 in the alkalie alone, forced
alkaline diuresis plus frusemide, forced alkaline diuresis, forced
diuresis and control groups respectively. There were no significant
differences between the period of infusion and the 12 hours after in
the treated groups, but there were differences between the alkal-
inisation regimes and the forced diuresis or control groups
(p < 0.001). Alkali alone gave the highest urine pH (0-16 hours)
which was significantly higher than with the forced alkaline diuresis
(p < 0.01), but not forced alkaline diuresis with frusemide.
There were no significant differences between the urine pH of the
forced diuresis and control groups.
The urine flow rates were significantly increased with forced
diuresis (with and without alkali), although the onset of diuresis
was often delayed. There was no delay in the patients who received
frusemide. The mean urine flow rates from 0-4 hours were 25,15, 8.2,
7.0 and 2.25; and from 0-16 hours 6.46, 5.05, 5.80, 2.60 and 1.40 ml/min
with forced alkaline diuresis plus frusemide, forced diuresis,
forced alkaline diuresis, alkali alone and the controls respectively.
There were highly significant differences between the urine flow
rates (0-16 hours) of the diuresis regimes and the control or alkali
alone groups (p < 0.001). The urine flow rates of the alkali alone
group were also greater than those of the controls (p < 0.005).
Renal clearance of acetyl salicylic acid
The renal clearances of acetyl salicylic acid could only be
measured in the first few urine samples from 10 patients (6 with
forced /
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forced alkaline diuresis, 2 controls, one with alkali alone and
one with forced alkaline diuresis plus frusemide). The renal
clearances ranged from 11.7 ml/min in a control patient (No. 1)
to 343 ml/min in a patient who received forced alkaline diuresis
with frusemide. Another patient (No. 23) given forced alkaline
diuresis also had a very high renal clearance of acetyl salicylic
acid of 333 ml/min. The overall mean renal clearance of acetyl -
salicylic acid was 110 ± 123 ml/min. The correlations between the
renal clearance of acetyl salicylic acid and urine pH or flow rate
(using individual urine samples) either corrected or uncorrected
for flow rate were not statistically significant.
Renal clearance of salicylic acid
The renal clearances of salicylic acid of all patients for the
first 4 and 16 hours after admission are shown in Tables 4.10 and
4.11. The mean renal clearances from 0-4 hours were 31, 22, 20, 4.4
and 2.2 ml/min in the alkali alone, forced alkaline diuresis plus
frusemide, forced alkaline diuresis, forced diuresis and control
groups, respectively. The renal clearances of salicylic acid
decreased significantly after the infusion only in the forced alkaline
diuresis with frusemide group (p < 0.01). The mean renal clearances
from 0-16 hours were 23.5, 17.5, 12.7, 4.40 and 1.37 in the alkali
alone, forced alkaline diuresis, forced alkaline diuresis plus
frusemide, forced diuresis and control groups respectively.
The renal clearances of salicylic acid over both periods were

















No. ml/min No. ml/min No. ml/min No. ml/min No. ml/min
1 3.69 2 50.0 53 19.2 27 3.12 37 13.6
4 3.60 3 14.5 54 26.7 29 2.30 38 18.4
6 2.10 5 16.5 55 20.8 30 0.65 44 19.0
7 4.52 10 17.2 57 6.31 31 12.5 47 24.0
8 N.A.* 14 9.60 58 32.8 32 4.62 49 26.3
9 1 .85 15 10.0 59 23.6 33 3.00 51 85.7
13 8.00 17 13.7
16 0.23 19 37.1
34 1.17 20 17.4
35 0.72 21 44.7
36 1 .33 22 8.22
43 0.20 23 18.1
45 1.30 24 2.75
48 1.40 25 19.3
50 0.65 26 37.6
52 2.03 41 3.08
Mean 2.20 20.0 21.6 4.37 31.2
S.D. 2.05 14.5 8.9 4.20 27.1
Analysis





RENAL CLEARANCE OF SALICYLIC ACID 0-16 HOURS (ml/min)
Forced
Control
alkaline FAD + Forced A1kali
diuresis(FAD) frusemide diuresis alone
No. ml/min No. ml/min No. ml/min No. ml/min No. ml/min
1 3.29 2 42.4 53 12.8 27 2.43 37 18.0
4 1 .90 3 6.7 54 14.8 29 3.56 38 10.2
6 3.22 5 22.0 55 13.2 30 4.04 44 28.4
7 2.44 10 15.3 57 7.5 31 6.79 47 16.4
8 N.A.* 14 27.7 58 14.8 32 7.18 49 48.7
9 1.07 15 N.A. 59 13.3 33 2.41 51 19.5
13 4.71 17 13.3
16 0.58 19 20.4
00CO 20 17.8
35 0.24 21 N.A.
36 0.21 22 19.2
43 0.15 23 N.A.
45 0.40 24 9.2
48 0.42 25 23.4
50 0.38 26 17.9
52 0.41 41 4.9
Mean: 1.37 17.5 12.7 4.40 23.5
S.D.: 1.42 10.1 2.3 1.78 13.7
Analysis




forced diuresis or control groups (p < 0.001). There were no
statistically significant differences between the three
alkalinisation groups, but there was a significant difference in the
renal clearance of salicylic acid 0-16 hours between the forced
diuresis and control groups (p < 0.005).
Renal clearance of unbound salicylic acid
The renal clearances of unbound salicylic acid of the 7 patients
in which measurements were made ranged from 0.65 ml/min in a control
patient (No. 52) to 172 ml/min in a patient (No. 49) treated with
alkali alone (Table 4.12). Two other patients (Nos. 54 and 58) who
received forced alkaline diuresis with frusemide also had renal
clearances of free salicylic acid above 100 ml/min in the individual
urine samples (118 and 125 ml/min respectively). Although the renal
clearances of unbound salicylic acid were much less in the control
patients (Nos. 50 and 52) than the other 5 treated patients, they
were greater than the corresponding total salicylic acid renal
clearances.
Renal clearance of salicyluric acid
The renal clearances of salicyluric acid from 0-4 and from 0-16 hrs
after admission are shown in Tables 4.13 and 4.14. The renal clear¬
ances of salicyluric acid were much greater than those of salicylic
acid /
TABLE 4.12.
RENAL CLEARANCE OF UNBOUND SALICYLIC ACID
Group No.
Renal clearance (ml/min)








Forced alkaline diuresis 25 54 34
Forced alkaline diuresis 54 69 11

























No. ml/min No . ml/min No. ml/min No . ml/min No. ml/min
1 270 2 625 53 773 27 855 37 459
4 422 3 317 54 460 29 191 38 654
6 261 5 398 55 343 30 778 44 342
7 420 10 413 57 285 31 602 47 474
8 N.A.* 14 484 58 1126 32 881 49 798
9 256 15 463 59 273 33 208 51 1037
13 518 17 539
16 457 19 568
34 241 20 305
35 450 21 908
36 308 22 351
43 387 23 218
45 189 24 461
48 598 25 695
50 902 26 987
52 1110 41 375
Mean 453 507 543 586 627
S.D. 255 212 340 315 257
Analysis
















No. ml/min No. ml/min No. ml/min No. ml/min No ml/min
1 318 2 411 53 583 27 740 37 309
4 329 3 410 54 207 29 265 38 415
6 955 5 508 55 463 30 589 44 255
7 246 10 352 57 492 31 264 47 292
8 N.A.* 14 476 58 375 32 323 49 1067
9 183 15 523 59 217 33 258 51 992
13 376 17 485
16 265 19 298
34 294 20 360
35 426 21 N.A.
36 403 22 383
43 422 23 N.A.
45 300 24 367
48 986 25 648
50 1231 26 482
52 663 41 263
Mean: 493 426 390 407 555
S.D.: 317 101 153 207 37.2
Analysis




acid, ranging from 183 ml/min in patient No. 9 to 1231 ml/min in
patient No. 50 - both were in the control group (0-16 hours). The
mean values from 0-16 hours were 555, 493, 426, 407 and 390 ml/min
with alkali alone, control group, forced alkaline diuresis, forced
diuresis and forced alkaline diuresis plus frusemide respectively.
There were no significant differences between the groups
(p > 0.05). Although the renal clearances of salicyluric acid
were higher during the infusions than after, the differences were
not statistically significant. There was no statistically signifi¬
cant correlation between the renal clearance of salicyluric acid
(corrected for flow rate or uncorrected) and urine pH or flow rate.
Urinary recovery of acetyl sal icy!ic acid
Acetyl salicylic acid was measurable in the first few urine
samples from 10, 6, 4, 4 and 4 patients with forced alkaline diuresis,
control group, forced diuresis, alkali alone and forced alkaline
diuresis plus frusemide groups respectively. The urinary recovery
varied from 2.77mg in patient No. 5 to 613 mg in patient No. 17
both in the forced alkaline diuresis group (Table 4.15).
The mean urinary recoveries of the above patients were 250, 125,
112, 77 and 42 mg with forced alkaline diuresis plus frusemide,
alkali alone, forced alkaline diuresis, forced diuresis and control
groups, respectively. There were no statistically significant





recovery of salicylic acid during the first 4
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TABLE 4.15.


















1 89.0 2 7.03 53 21.2 27 10.2 37 71.5
4 8.61 5 2.77 54 535 29 97.4 44 54.8
6 40.7 10 40.0 55 373 31 76.0 47 133
7 5.72 14 37.4 58 71.7 33 124 49 241
13 65.8 17 613
















of F - Ratio = 1.185 p > 0.05
variance :
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and 16 hours after admission are shown in Tables 4.16 and 4.17.
The mean urinary recoveries over the initial 4 hours (infusion
period) were 2435, 2172, 1551, 437 and 162 mg with alkali alone,
forced alkaline diuresis plus frusemide, forced alkaline diuresis,
forced diuresis and control groups, respectively. There were no
statistically significant differences between the alkalinisation
groups, but there were significant differences between these and
forced diuresis or control groups (p < 0.02 and p < 0.001 respec¬
tively). The difference between the salicylic acid urinary
recovery of forced diuresis and control group was not statistically
significant.
The mean urinary recovery during the first 16 hours was
3871, 3423, 3599, 1529 and 376 mg respectively. There were signifi¬
cant differences in the urinary recoveries of salicylic acid between
the alkalinisation regimes (particularly alkali alone) and the
forced diuresis or control groups (p < 0.02 and p < 0.001 respec¬
tively), but there were no statistically significant differences
between the alkalinisation groups. However, the urinary recovery
of salicylic acid (0-16 hours) was significantly higher in the
forced diuresis than the control group (p < 0.01)
The mean urinary recoveries of salicylic acid in each group were
normalised to an admission plasma concentration of 475 yg/ml and are
given in Table 4.18. The values from 0-4 hours were 2634, 2186, 1482,
441 and 235 mg and from 0-16 hours 4188, 3454, 3439, 1541 and 544 mg
with alkali alone, forced alkaline diuresis plus frusemide, forced
















No. mg No mg No. mg No mg No. mg
1 332 2 2374 53 1639.5 27 296 37 1229.5
4 148 3 1052 54 3108 29 185 38 1406
6 174 5 1660 55 2344 30 52 44 2120
7 335. 5 10 1934 57 621 31 1413 5 47 2230.5
8 N.A. * 14 977 58 3336 32 367 49 2044
9 171 15 820 59 1985 33 311 51 5581
13 533 17 1894
16 16. 5 19 2696
34 88 20 1802
35 44 21 3271
36 139. 5 22 818
43 19 23 721
45 105 24 308
48 124 25 1426.5
50 36 26 2543
52 162 41 517
Mean: 162
+
1551 2172.3 437. 4 2435
S.D.: 141. 2 866 998.5 491 1594
Analysis

















No. mg No mg No. mg No mg No. mg
1 1035 2 3078 53 2487 27 778 37 3480
4 169 3 1982 54 4925 29 816 38 2322
6 638 5 3586 55 3762 30 581 44 5359
7 558 10 5344 57 1664 31 3890 47 4532
8 N.A.* 14 N.A. 58 3855 32 2042 49 4980
9 297 15 N.A. 59 3901 33 1064 51 2552
13 1061 17 5031
16 84 19 4807
34 315 20 3583
35 115.5 21 3471 5
36 371 22 2759
43 51 23 3646
45 383.5 24 3420
48 242 25 3914
50 88 26 3212
52 234 41 2546
Mean: 376
_i_
3598. 5 3432.3 1528.5 3871
S.D.: 320.5 943. 0 1162.4 1267.0 1278.5
Analysis





URINARY RECOVERY OF SALICYLIC ACID NORMALISED TO







0 - 4 hr 0 - 16 hr
Control 328 235 544
Forced alkaline
diuresis (FAD) 497 1482 3439
FAD plus frusemide 472 2186 3454
Forced diuresis 471 441 1541
Alkali alone 439 2634 4188
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Urinary recovery of salicyluric acid
The urinary recoveries of salicyluric acid over the first 4
and 16 hours are shown in Tables 4.19 and 4.20. Except in the
control, less salicyluric acid was excreted than salicylic acid.
The mean recoveries during the first 4 hours were 444, 427, 329,
244, 231 mg and from 0-16 hours after admission were 1499, 1119,
1243, 1116, 1117 mg with forced alkaline diuresis plus frusemide,
forced alkaline diuresis, alkali alone, control group and forced
diuresis respectively. There were no statistically significant
differences between the salicyluric acid urinary recoveries in
any of the groups.
The mean urinary recovery of acetyl salicylic, salicylic and
salicyluric acids in each group for the first 4 and 16 hours is
shown in Figure 4.9. The mean ratios of recovery of salicylic to
salicyluric acid (expressed as salicylic acid equivalent) from
0-16 hours were 4.54, 4.40, 3.23, 1.93 and 0.48 with forced
alkaline diuresis, alkali alone, forced alkaline diuresis plus
frusemide, forced diuresis and control groups respectively. These
ratios were much higher during the infusion period (0-4 hours)
particularly with alkali alone (5.66, 10.5, 6.91, 2.68 and 0.94
respectively). The ratios of the recovery of salicylic to salicyl¬
uric acid for each patient during the whole hospitalisation period
are given in Table 4.21. The mean ratio for the forced alkaline
diuresis group was higher (but not significantly so) than
the other alkalinisation groups. This was due to the short period
of urine collections in 2 patients (Nos. 14 and 19). There was a
signficant correlation between the ratio of urinary salicylic to
















No. mg No mg No. mg No mg No. mg
1 255 2 312 53 343 27 516 37 389
4 262 3 156 54 482 29 66 38 298
6 140 5 402 55 434.5 30 172 44 315
7 390 10 515 57 576 31 298 47 372
8 N. A. ★ 14 171 58 642 32 117.5 49 348
9 158 15 366 59 185.5 33 214 51 249
13 350 17 438
16 378 19 208.5
34 133 20 62
35 322 21 715
36 185 22 261.5
43 343 23 61
45 101 . 5 24 456
48 173 25 607
50 249 26 722
52 422 41 1372
Mean: 243. 5 427 444 230.6 328.5
S.D.: 100. 2 327 164.4 161 51 .7
Analysis

















No. mg No mg No. mg No mg No. mg
1 1126 2 789.5 53 1272 27 1698 37 1321
4 544 3 686 54 1447 29 559 38 974
6 1482 5 1400 55 1607.5 30 770 44 1324
7 918 10 1738 57 2260 31 1364 47 1493
8 N.A.* 14 N.A. 58 1341 32 1056 49 1389
9 532 15 N. A. 59 1066 33 1256 51 956
13 979 17 1062
16 2593 19 474
34 750 20 285
35 1423 21 747
36 767 22 896
43 1594 23 335
45 384 24 1741
48 1370 25 1359
50 1152 26 1479
52 1125 41 2672
Mean: 1116
+
1119 1499 1117.2 1243
S.D.: 549 660 414.2 413 224
Analysis




















ASA SA SUA ASA SA SUA ASA SA SUA ASA SA SUA ASA SA SUA
Mean urinary recovery of acetyl salicylic, salicylic
and salicyluric acids over the first 4 and 16 hours
after admission in patients with mild to severe




THE RATIO OF URINARY RECOVERY OF SALICYLIC ACID












No. Ratio No Ratio No. Ratio No. Ratio No. Ratio
1 0.74 2 8.56 53 2.44 27 0.52 37 3.33
4 0.44 3 3.67 54 2.03 29 1.43 38 2.82
6 0.61 5 00 no 55 3.27 30 0.95 44 3.41
7 0.78 10 4.01 57 0.65 31 1.81 47 2.08
8 N.A.* 14 15.0 58 1.65 32 1 .26 49 4.61
9 0.58 15 5.9 59 3.45 33 0.64 51 3.67
13 1 .53 17 4.87
16 0.14 19 14.1
34 0.54 20 14.2
35 0.10 21 6.56
36 0.42 22 3.13
43 0.14 23 15.3
45 0.44 24 0.93
48 0.27 25 2.71
50 0.09 26 2.84
52 0.15 41 00o
Mean: 0.46
_L
6.54 2.41 1.10 3.32
S.D.: 0.38 5.22 1.08 0.49 0.85
Analysis




Urinary excretion of glucuronide conjugates
Glucuronide conjugates of salicylic acid in the urine varied
from 0 in a patient treated with alkali alone (No. 49) to 77% in a
control (No. 52). The total urinary recovery of salicylic acid
and percentage excreted as glucuronide conjugates are given in
Table 4. 22. The mean urinary recoveries of total (free and conjugated)
salicylic acid were 4523, 4330, 2768 and 966 mg with the alkali alone,
forced alkaline diuresis, forced diuresis and control groups respec¬
tively. The mean percentages which were conjugated were in reverse,
60, 42, 15 and 13 per cent in the control, forced diuresis, forced
alkaline diuresis and alkali alone groups respectively. There
were significant differences in the urinary recoveries of total
salicylic acid between the alkalinisation regimes and controls (p <
0.001), but not between the alkalinisation regimes and forced
diuresis or between the forced alkaline diuresis and alkali alone
regimes. The percentage excreted as conjugates was significantly
higher in the control and forced diuresis groups than in the forced
alkaline diuresis or alkali alone groups (p < 0.01) and (p < 0.005).
The urinary excretion of total and glucuronide conjugates of
salicyluric acid is shown in Table 4.23. The urinary recovery of
total salicyluric acid was lower than that of the salicylic acid in
all groups except for the control group in which it was more than
double the urinary recovery of salicylic acid. There were no
statistically significant differences in the urinary recoveries of
total salicyluric acid between the groups. There were significant
differences in the percentage excreted as glucuronide conjugates
between the forced alkaline diuresis and forced diuresis or alkali
alone groups, but not the control group (p < 0.05).
Correlation /

































































































































































































































AnalysisTotalF-Ratio=0.35p>0 of variance1F-R tio=2.95p<0 0
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Correlation between renal clearance of salicylic acid and urine pH
or flow rate
There were significant positive correlations between the renal
clearances of salicylic acid and urine pH in each group (p < 0.001)
with correlation coefficients ranging from 0.48 with forced alkaline
diuresis plus frusemide to 0.68 with alkali alone. These correlations
were more significant (except for forced alkaline diuresis with
frusemide) when the salicylic acid clearance was corrected for flow
rate (equivalent to the ratio of urine to plasma concentration).
The correlation and regression coefficients of the ratios of
urine to plasma concentrations of salicylic acid against urine pH
and flow rate are shown in Table 4.24. The positive correlation
between renal clearance of salicylic acid corrected for flow rate
and urine pH was also significant for forced alkaline diuresis
with frusemide.
The renal clearance of salicylic acid corrected for flow rate
for the 39 urine samples from the 6 patients treated with alkali
alone and 39 representative samples from 13 of the control patients
(first, middle and last urine sample from each) were plotted against
the corresponding urine pH to demonstrate the highly significant
relationship between the clearance and pH without the effects of
diuresis (Fig.4.10). There were significant negative correlations
between the ratios of urine to plasma salicylic acid concentrations
and urine flow rate in the forced alkaline diuresis and controls
(r = -0.43, p < 0.001 and r = -0.24, p < 0.05 respectively), but
not in the alkali alone and forced alkaline diuresis with frusemide.
There was a significant positive correlation between the ratio of




Figure 4.10. Correlation between the renal clearance of salicylic
acid and urine pH in 6 patients with aspirin poisoning
receiving alkali alone (•)and 13 control patients (o).
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in the forced diuresis group. There were positive correlations
between the urine flow rate and pH in all groups except in the
alkali alone ranging from p < 0.05 with the control to p < 0.001 with
forced fiuresis which was consistent with the significant positive
correlation between the ratio of urine to plasma salicylic acid
concentration and urine flow rate.
Multiple regression analysis
Multiple correlations between the ratio of urine to plasma
salicylic acid concentrations and urine pH and flow rate were
significant in all groups (p < 0.01) (Table 4.24.). The multiple
correlation coefficients between the ratio of urine to plasma
salicylic acid concentrations and urine pH and flow rate were 0.85,
0.77, 0.69, 0.68 and 0.51 with alkali alone, forced diuresis, control,
forced alkaline diuresis and forced alkaline diuresis with frusemide
respectively. The regression coefficients for pH were 6.26, 2.06,
0.531, 0.491 and 0.318 with alkali alone, forced alkaline diuresis,
control, forced diuresis and forced alkaline diuresis with fruse¬
mide, respectively. The regression coefficients for flow rate were
all negative.
The multiple regression equation for the alkali alone regime
was :
r = 6.26 pH -0.415F -0.33
(r is the ratio of urine to plasma salicylic acid concentrations,
pH is the urine pH and F is the urine flow rate). Thus for each
increase of one unit in urine pH the ratio will increase 6.26 fold,
whereas for the flow rate there is slight decrease. The equation
for the forced alkaline diuresis regime (second most effective) is :















































































and for the control, forced diuresis and forced alkaline diuresis
with frusemide equations are as follows :
r = 0.531 pH -0.102F -0.108
r = 0.491 pH -0.018F -0.102
r = 0.318 pH -0.02F -0.22
Therefore increasing the pH without diuresis enhanced the ratio
of urine to plasma salicylic acid concentrations. The least effect
of urine pH was shown in the forced alkaline diuresis with frusemide
treatment.
The correlation between the renal clearance of unbound salicylic
acid and urine pH (using individual urine samples) was also signifi¬
cant (r = 0.55, p < 0.001).
(g) Piscussion
Treatment regimes
Since the urine pH was significantly higher with the alkalinis-
ation regimes than in the other groups, and urine flow rate was
greater in the forced diuresis and forced alkaline diuresis groups
and enhanced by frusemide, all treatment regimes effectively
increased the urine pH or flow rate. The alkaline urine pH "in the
forced diuresis regime might reflect a greater degree of hyperven¬
tilation in the patients who had higher plasma salicylate con¬
centrations than the controls. Although the amount of sodium
bicarbonate was the same in the alkali alone and forced alkaline
diuresis regimes, the urine pH was lower in the latter, possibly
due to acid dextrose infusion, and the diluting effect of diuresis.
Lawson et al. (1969) reported a mean urinary pH below 7.0 with
similar /
similar forced cocktail diuresis, and this could be due to oxidation
of laevulose in alkaline solution. The difference between the forced
cocktail diuresis and forced alkaline diuresis regime used here, is
that glucose replaced laevulose and sodium bicarbonate was added
just before use rather than using the mixture already made with
sodium bicarbonate in the Pharmacy Department.
Plasma half-life of salicylic acid
The plasma half-lives of salicylic acid were all much shorter
during the infusion than after. This must have been largely due to
haemodilution (Chapter 1, Section V) and an increased volume of
distribution, since the urinary recovery of salicylate over that
period was not nearly sufficient to account for the fall observed.
The apparent plasma half-lives during the infusion were significantly
lower with the alkalinisation regimes than with the forced diuresis.
Thus alkalinisation also shortens the plasma half-life of salicylic
acid by enhancing the renal excretion. The plasma half-life of
salicylic acid during infusion is, therefore, not a valid index of
removal of salicylic acid from the body and its use as such is mis¬
leading. Although there were no statistically significant difference
in the apparent plasma half-lives between the alkalinisation groups,
the rate of fall of salicylic acid concentration during the infusion
was significantly greater with forced diuresis than with alkali alone
The plasma concentrations of salicylic acid after infusion
(4-16 hours) decreased with different slopes for each treatment.
The /
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The plasma half-life of salicylic acid over this period was compat¬
ible with the salicylate elimination. The plasma concentrations
of salicylic acid after infusion declined with similar initial
slope in 3 of the patients treated by alkali alone. In one of them
(No. 49) the plasma salicylic acid half-life was even shorter after
the infusion (2.62 hr). This patient had the highest urine pH and
a total of more than 5 g of salicylic acid was recovered in the
urine. There is no report of such a short plasma half-life of
salicylic acid with overdosage in the literature. In fact, the
serial plasma salicylate concentrations and half-lives reported
were measured by non-specific analytical methods ( Done, 1960;
Beveridge et al., 1964; Cumming et al., 1964; Morgan and Polak,
1969; Lawson et al., 1969; Ferguson and Boultros, 1970; James and
Martinak, 1975; Temple et al., 1976). However, the reported
plasma salicylate half-lives with different methods of intravenous
treatment ranged from 5 hours in a patient who was treated by
forced alkaline diuresis to over 24 hours in two patients who
received forced cocktail diuresis (Lawson et al., 1969).
The shortest mean plasma half-life of salicylic acid in the
alkali alone and the longest in the forced diuresis group were
consistent with the renal clearances and urinary recovery. The
alkali alone regime, therefore, was the best for the removal of
salicylic acid from the body.
As expected, glycine conjugation of salicylic acid was saturated
very early (usually before admission) and the plasma salicyluric
acid concentrations remained very low in all patients. The fall
in the plasma salicyluric concentrations during the infusions
might also be due to haemodilution.
Total /
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Total body clearance and volume of distribution of salicylic acid
The total body clearance was higher during than after the infusion
in all treated groups which is consistent with the higher renal
clearance and urinary recovery of salicylic acid. The apparent
volumes of distribution of salicylic acid did not change signifi¬
cantly after the infusion. The concentration-dependent volume of
distribution of total salicylic acid reported by Levy and Yaffe (1974)
was confirmed by using the individual samples in 5 patients. In
addition, it was confirmed that this reflects protein binding and in
fact, the volume of distribution of unbound salicylic acid declined
with increasing concentration.
Renal clearance, urine pH and flow rate
The increased renal clearance of salicylic acid with forced
diuresis was probably due to changes in both urine pH and flow
rate since they were higher in the treated groups than in the
control group, particularly during the infusion period.
The high renal clearances of acetyl sal icy!ic acid, unbound
salicylic acid and salicyluric acid (> 100 ml/min) indicate their
active tubular secretion which is consistent with previous reports
(Schacter and Manis, 1958; Bedford, Cumming and Martin, 1965).
The urine pH did not affect the urinary excretion and renal clear¬
ance of salicyluric acid presumably because it is not reabsorbed.
The higher renal clearance of salicylic acid in the alkalini-
sation groups compared with forced diuresis and controls is due to
the higher urine pH and decreased renal tubular reabsorption. The
correlation between the renal clearance of salicylic acid corrected
for flow rate and urine pH showed the highest correlation
coefficient /
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coefficient with the alkali alone regime (Table 4.24).The multiple
regression analysis between the ratio of urine to plasma salicylic
acid concentration and urine pH and flow rate also gave the highest
multiple correlation coefficient for the alkali alone group and
the least for forced alkaline diuresis with frusemide. These
findings were compatible with the observed renal clearance and
excretion of salicylic acid. The lack of increased efficacy of
forced alkaline diuresis with frusemide is consistent with the
findings of Berg (1977b).
The higher renal clearance of unbound salicylic acid and its
good correlation with urine pH is very similar to the results of
Smith et al. (1946).
Urinary recovery
The urinary recovery of acetyl salicylic acid accounted for
less than 0.5% of the total urinary recovery of salicylates which
is due to its rapid hydrolysis to salicylic acid. The proportional
urinary recovery of salicylic acid increased significantly and
salicyluric acid decreased with a higher pH, and the ratio of
salicylic acid to salicyluric acid was pH-dependent. There is no
such finding in the literature since acetyl salicylic and salicyluric
acids have not been measured separately following overdosage.
Although the urinary recovery of total salicylic acid
(including the glucuronide conjugates) was higher with the alkalin-
isation regimes, the percentage conjugated with glucuronide was
less /
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less than in the forced diuresis or control groups. This might be
due to excretion of more unchanged salicylic acid because of the
effect of pH on its renal clearance. Since the highest renal clear¬
ance and urinary recovery of salicylic acid was achieved with alkali
alone, it was more effective than the other regimes, including
forced alkaline diuresis.
(h) Summary and conclusions
The effects of changes in urine pH and flow rate on the
distribution and elimination of acetyl salicylic acid and its metabo¬
lites were studied in 34 adult patients with moderate to severe
aspirin poisoning (plasma salicylate 400 - 800 yg/ml).
The patients were treated with one of four intravenous regimes
of fluid and alkali over 3 hours according to the admission
plasma salicylate concentrations measured by a ward side-room assay
(modified Trinder's method). Sixteen patients received forced
alkaline diuresis (6 L isotonic dextrose/saline solution plus 18.9 g
sodium bicarbonate plus 9 g potassium chloride) 6 forced diuresis
(6 L isotonic dextrose/saline plus 9 g potassium chloride), 6 alkali
alone (18.9 g sodium bicarbonate and 4.5 g potassium chloride in 1| L)
and 6 forced alkaline diuresis with 80 mg frusemide given intravenously.
No specific treatment was given to 16 control patients with mild aspirin
overdosage.
Acetylsalic ylic acid was rapidly hydrol^sed to salicylic acid
and was only detected when absorption was delayed (25 patients).
All /
All treatments produced similar initial rapid falls in plasma
salicylic acid concentrations during the infusion period (0-4 hours)
but urinary salicylate excretion was only increased with the alkanin
isation regimes. Haemodi1ution and an increased volume of salicyli
acid distribution probably contributed to this initial fall, par¬
ticularly in the non-alkalinisation regime.
From 4-16 hours the mean apparent plasma half-lives were 30, 31
12, 14 and 9 hours in the control group, forced diuresis, forced
alkaline diuresis, forced alkaline diuresis with frusemide and
alkali alone regimes respectively.
Total body clearance, renal clearance and urinary recovery of
salicylic acid were significantly higher with the alkalinisation
regimes than with the forced diuresis alone.
The renal clearance of salicylic acid was a function of both
urine pH and flow rate in all groups. There was a direct relation¬
ship with the latter but the influence of pH increased dramatically
above 7.0 where it completely dominated the elimination kinetics of
salicylic acid.
The mean renal clearances of salicylic acid during the first
16 hours after admission were 1.4, 4.4, 18, 13 and 24 ml/min with
the control, forced diuresis, forced alkaline diuresis, forced
alkaline diuresis plus frusemide and alkali alone groups,
respectively.
The urinary recoveries of salicylic acid from 0-16 hours after
admission were 3871, 3599, 3434, 1529 and 376 mg with alkali alone,
forced /
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forced alkaline diuresis, forced alkaline diuresis plus frusemide,
forced diuresis and control groups, respectively. The ratio of
salicylic to salicyluric acid urinary recovery was highly pH-
dependent.
The plasma concentrations of salicyluric acid were uniformly
low (< 10 (jg/ml) throughout the study in all groups reflecting
saturation of glycine conjugation of salicylic acid. The very high
renal clearance of salicyluric acid was independent of urine pH and
flow rate.
Administration of alkali alone was more effective than the
other regimes including the forced alkaline diuresis, for the
removal of salicylic acid in acetyl salicylic acid poisoning.
SECTION V
EFFECTS OF PROSTAGLANDIN-MEDIATED CHANGES
IN FLUID AND ELECTROLYTE BALANCE AND




THE EFFECTS OF TREATMENT WITH FLUID AND ALKALI ON FLUID
RETENTION IN ASPIRIN POISONING
(a) Introduction
It is well known that acetylsalicylic acid and some of its meta¬
bolites inhibit the biosynthesis of prostaglandins (Vane, 1971; Smith
and Willis, 1971; Flower, 1974; Shen, 1979, Smith et al., 1979; Flower
et al., 1980). Aspirin exerts two separate effects on prostaglandin
formation in vivo, a rapid action of the intact molecule on easily
accessible tissue and a later action due to its hydrolysis to sali¬
cylic acid (Smith et al., 1979).
In acetylsalicylic acid poisoning, sodium and water retention is
likely to occur (Berg, 1977b), but because of insensible loss of fluid
due to vomiting, sweating and hyperventilation, dehydration may be a
problem in patients who were admitted a long time after ingestion.
However, a positive fluid balance, as calculated from fluid intake
and output was reported as a fluid "deficit" (Lawson et al., 1969)
and fluid retention has been reported in patients with aspirin over¬
dosage treated by forced diuresis (Savage et al., 1969; Temple et al.,
1976). In the study by Lawson et al. (1969), fluid "deficit" varied
from 0.6 to 3.6 litres in patients treated with oral fluids only
compared with 1.8 to 11.1 litres in patients treated by forced
diuresis. In the case report by Savage et al.(1969), there was
retention of 3.7 litres of fluid following treatment with 190 g
mannitol. Temple et al. (1976) reported positive fluid balances of
417 ml /
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417 ml and 1150 ml in a 4 month old male and a 21 month old female
respectively, but weight changes of the patients were not given.
Since insensible loss in aspirin poisoning may be considerable,
fluid balance without serial measurement of the patient's weight is
of limited use. Serial measurements of haematocrit or plasma pro¬
teins could be used as an index of haemodi1ution following forced
diuresis, but have only been reported by Lawson et al. (1969).
This study was undertaken to establish the changes in fluid
balance, patient's weight and haemoconcentration in aspirin poisoning
with and without treatment by diuresis.
(b) Patients and methods
Thirty-four patients aged 16-55 years of age (17 males and 17
females) with mild to severe aspirin poisoning were studied. Eight
patients (4 males and 4 females) received no specific treatment
(control patients, Chapter 1, Section IV), 8 (4 males and 4 females)
were treated with forced alkaline diuresis, 6 (3 males and 3 females)
with forced diuresis, 6 (3 males and 3 females) with alkali alone
and 6 (3 males and 3 females) with forced alkaline diuresis plus
frusemide (Chapter 2, Section IV). The patients were weighed before
and after gastric lavage, at the end of fluid infusion (at 4 hours
after admission for the controls) and then 8 hourly until discharge.
Fluid intake (i.v. and oral) and output (urine, vomit and other)
measurements were recorded.
Blood samples were taken for determination of the haematocrit at
the same time as for drug measurement (see Section IV) and 3 further
samples were taken (in the Lithium Heparin tubes) for biochemical
investigations on admission, at the end of infusion (at 4 hours after
admission /
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admission for the controls) and at 16 hours after admission. The
plasma albumin concentration was measured by the Technicon Sequential
Multiple Analysis plus Computer (SMAC ) System in the University Dep¬
artment of Clinical Chemistry, Royal Infirmary of Edinburgh.
Comparisons between the groups were performed using one way analy¬
sis of variance. If the differences were significant (p < 0.05) the
independent two-tailed Student t-test was used for the comparison of
each group. For the comparison of values before and after infusion
(4 and 16 hours after admission) the paired two-tailed Student t-test
was used.
(c) Results
Fluid balance and weight change
The weights of the patients did not change significantly after
gastric lavage. The overall mean change was +50.4 ± 360 (S.D.) g.
The fluid balance and weight changes for each patient at 4 hours
after admission are summarised in Tables 5.1. and 5.2. The fluid
balances were all positive except for one control patient (No. 35)
and 2 (Nos. 44 and 49) with alkali alone treatment. The mean of
fluid balance increases were 4621, 3565, 1577, 434 and 219 ml with
forced diuresis, forced alkaline diuresis, forced alkaline diuresis
plus frusemide, alkali alone and control groups respectively. The
weight changes at 4 hours were consistent with the fluid balance and
the mean differences for each group were +3833, +2513. +326, -417 and
-143 g respectively. There were highly significant differences in
the fluid balance and weight gain between the forced alkaline diuresis
group and the alkali alone or control groups (p < 0.001). There were





















1 0 3 +4000 53 +3350 27 +5400 37 +750
34 +550 14 +4000 54 +1230 29 +2325 38 +130
35 -950 20 +3000 55 + 500 30 +4600 44 -475
36 +400 22 +2800 57 +1150 31 +4800 47 +1100
45 +800 24 +4220 58 +1655 32 +5400 49 -350
48 0 25 +3700 59 + 1575 33 +5200 51 +1450
50 +450 26 +4100
52 +500 41 +3700
Mean: +219 +3565 1577 4621 434
S.D.: 544 556 960 1171 789
Analysis
of F-Ratio = 39.25 P < 0.01
variance:
* Fluid intake - fluid output
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TABLE 5.2.













No. 9 No 9 No. g No. g No. g
1 N.A.* 3 +2000 53 -500 27 +4100 37 +700
34 -500 14 +2000 54 -900 29 +2000 38 -1400
35 -500 20 +2500 55 +900 30 +4500 44 -500
36 -500 22 +2600 57 +1200 31 +4400 47 +500
45 +1200 24 +3500 58 +800 32 +3000 49 -300
48 -250 25 +3500 59 +455 33 +5000 51 -500
50 + 150 26 +3500
52 -600 41 +500
Mean: -143 +2513 +326 +3833 -417
S.D.: 644 1036 839 1118 671
Analysis




forced diuresis (p < 0.05) and forced alkaline diuresis with frusemide
groups (p < 0.005), but not between the forced alkaline diuresis with
frusemide and alkali alone or the control groups.
The positive fluid balances decreased with time in the forced
diuresis and forced alkaline diuresis groups, and increased in the
other 3 groups. The patients' weights also decreased in the forced
alkaline diuresis with frusemide group. Thus the differences were
less marked at 28 hours after admission. The fluid intake up to
28 hours varied from 1850 ml in a control patient (No. 50) to 10,775
ml in a patient (No. 27) treated with forced diuresis. The fluid
balance and weight changes at 28 hours after admission are shown in
Tables 5.3. and 5.4. The mean positive fluid balances were 3229,
3092, 2106, 1111 and 1151 ml with the forced alkaline diuresis, forced
diuresis, forced alkaline diuresis plus frusemide, alkali alone and
control groups respectively, while the corresponding mean weight
changes were 1393, 1550, 212, 190 and 267 g. There were significant
differences between the fluid balance with forced diuresis or
forced alkaline diuresis and alkali alone or control (p < 0.001) and
forced alkaline diuresis with frusemide groups (p < 0.01). There were
no statistically significant differences between the forced diuresis
and forced alkaline diuresis, nor between the other 3 groups. Similar,
but less significant differences in weight gain were found between
the groups. The differences in fluid balance and weight gain were
less at 28 hours than at the 4 hours in all groups.
Changes in haematocrit and plasma albumin
The mean serial haematocrit for each group of patients plotted

















No. ml No ml No. ml No. ml No ml
1 +705 3 +3025 53 +2435 27 +3625 37 +125
34 N.A.** 14 N.A. 54 +2824 29 + 1575 38 +450
35 N.A. 20 +3225 55 N.A. 30 N.A. 44 +1325
36 +900 22 +2700 57 +918 31 +4310 47 +2845
45 +1438 24 +4705 58 +2930 32 +3450 49 +810
48 +1075 25 +2630 59 + 1425 33 +2500 51 N.A.
50 +590 26 +3230
52 +2200 41 +3090
Mean: +1151 +3229 +2106 +3092 +1111
S.D. : 594 693 891 1066 1067
Analysis
of
variance : F-Ratio 8.14 p < 0. 01
* Fluid intake - fluid output. not available.
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TABLE 5.4.













No. 9 No g No. g No. g No. g
1 +200 3 + 1000 53 -1000 27 +1500 37 -200
34 N.A.* 14 N.A. 54 +1100 29 +550 38 -1700
35 N. A. 20 +1500 55 N.A. 30 N.A. 44 +750
36 -800 22 +1500 57 +500 31 +1300 47 +2200
45 +2000 24 +3800 58 +460 32 +1400 49 -100
48 -500 25 +500 59 0 33 +3000 51 N.A.
50 +1000 26 +700
52 -300 41 +750
Mean +267 +1393 +212 +1550 +190
S.D. 1058 1130 782 893 1428
Analysis
















Figure 5.1. Changes in mean haematocrit in patients with
severe aspirin poisoning receiving different




percent change for each patient is given in Table 5.5. The haem-
atocrit increased after infusion, but the mean values were still
lower at 16 hours than before the infusion (except for the forced
alkaline diuresis with frusemide group). The maximum fall in the
haematocrit was found in the forced alkaline diuresis group (12.9%)
which was significantly higher than in the control (p < 0.005) or
forced alkaline diuresis plus frusemide groups (p < 0.001). There
were no statistically significant differences between the forced
alkaline diuresis and forced diuresis or alkali alone groups.
The mean plasma albumin concentrations in each group before
and after infusion and the following day are shown in Figure 5.2. and
the individual percentage changes during the infusion are given in
Table 5.6. The maximum fall in plasma albumin concentrations during
the infusion was found with the forced alkaline diuresis group (20%)
which corresponds with the fall in haematocrit. The fall in plasma
albumin concentration was significant during the infusion in all
groups (p < 0.01 to p < 0.001) except for forced alkaline diuresis
with frusemide which again agrees with the haematocrit changes.
The decline in plasma albumin was significantly greater with forced
diuresis than with alkali alone (p < 0.005). The mean values
increased after infusion with the forced diuresis and forced
alkaline diuresis, but decreased in the other 3 groups (Fig. 5.2.)
(d) Piscussion
Although fluid retention was considered in some reports (Savage






















1 - 4.3 3 - 20 53 0 27 - 6.3 37 8.9
34 + 2.5 14 - 16 54 - 10 29 - 11 38 0
35 0 20 - 9.1 55 - 8.3 30 - 9.1 44 2.4
36 + 2.5 22 - 9.1 57 - 3.3 31 - 2.3 47 4.2
45 - 6.5 24 - 10 58 + 2.3 32 - 7.5 49 15
48 0 25 - 6.3 59 + 9.5 33 0 51 18
50 0 26 - 11
































Figure 5.2. Changes in mean plasma albumin concentrations in
patients with mild to severe aspirin poisoning
receiving different treatments of fluid and alkali
(normal range 36 - 47 g/1).
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TABLE 5.6.













No. % No. % No. % No % No %
1 - 15 3 -29 53 - 4 27 - 13 37 -6.7
34 - 11 14 -12 54 -7.5 29 - 16 38 - 8
35 - 8 20 -24 55 -20 30 - 22 44 -4.4
36 - 11 22 -13 57 +4.9 31 - 17 47 - 10
45 - 18 24 -19 58 -15 32 - 21 49 - 13
48 -4.5 25 -17 59 +4.9 33 -9.1 51 - 11
50 -4.5 26 -15
52 - 14 41 -30
Mean: -10.8 -20 -6.1 -16.4 -8.9
S.D.: 4.9 7.0 10.2 4.9 3.1
Analysis
of F - Ratio =. 5.32 p < O.Ol
variance :
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were only mentioned in one (Morgan et al., 1968). Since insensible
loss occurs in aspirin poisoning due to sweating and hyperventilation,
a positive fluid balance could not be interpreted as fluid retention
unless the insensible loss was taken into account by measuring the
changes in the patient's weight as well as fluid balance. Although
the fluid balance at 4 hours was positive for all groups, the mean
changes in weight were negative for the control and alkali alone
groups at that time. The greater weight gains and fluid balance at
the end of infusion in the forced diuresis and forced alkaline diuresis
groups than in the other groups, are due to the higher infusion load
(6 litres) and fluid retention. Frusemide induced a rapid diuresis
in all 6 patients and thus the fluid balance and weight gain were
significantly lower with this treatment than with forced diuresis or
forced alkaline diuresis. This is consistent with the findings of
Berg (1977b). As time passed, diuresis continued in the patients given
forced diuresis and forced alkaline diuresis and more fluid was
retained in the patients in the other groups. Therefore, the differ¬
ences became less significant. The weight gains, however, were still
significantly higher 28 hours after admission in the forced diuresis
and forced alkaline diuresis than in the other groups.
Haemodilution during the infusion of 6 litres of fluid (forced
diuresis and forced alkaline diuresis) and haemoconcentration with
forced alkaline diuresis plus frusemide after infusion were confirmed
by serial measurement of haematocrit and plasma albumin concentrations.
Although the changes in haematocrit were similar in the forced diur¬
esis and alkali alone groups, the fall in plasma albumin was signifi¬
cantly higher with forced diuresis than with alkali alone. In fact,
the fall in the haematocrit curve with alkali alone was similar to that
in /
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in the control group (Fig. 5.1.). The increased mean haematocrit
with forced alkaline diuresis plus frusemide was consistent with no
significant change in the plasma albumin. Similarly, there was no
significant haemodilution with the alkali alone treatment.
The changes in fluid balance and weight were generally consis¬
tent with the changes in haematocrit and plasma albumin, particularly
during the infusion.
(e) Summary and conclusions
Fluid balance and changes in weight and haemoconcentration were
studied in 34 patients with aspirin poisoning. The patients were
treated with either oral fluids only or one of the 4 intravenous
regimes of fluid and alkali.
Haemodilution resulting from fluid retention was confirmed by
changes in haematocrit and plasma albumin concentrations. The maximum
fall in haematocrit and plasma albumin at the end of infusion occurred
in the patients given forced alkaline diuresis and the minimum fall
was observed in the patients given forced alkaline diuresis plus
frusemide.
Haemodilution and fluid retention produced by the forced
diuresis or forced alkaline diuresis regimes were confirmed by serial
measurement of haematocrit, plasma albumin, patient weight and fluid
balance. These changes were reduced by intravenous frusemide.
However, the use of this diuretic did not enhance salicylate elimin¬
ation (Chapter 2, Section IV). There was no significant haemodilution




CHANGES IN PLASMA AND URINARY ELECTROLYTES AND CREATININE
(a) Introduction
The acute effects of therapeutic doses of acetyl salicylic acid
on renal function have been studied in the dog (Berg and Bergan, 1976;
Moncada et al., 1980) and in man (Berg, 1977a). The changes in plasma
and urinary sodium and potassium concentrations in salicylate poisoning
have been studied with different regimes of forced diuresis (Lawson
et al., 1969), acetazolamid and sodium bicarbonate (Morgan and
Polak, 1969), mannitol diuresis (Morgan, Bennett and Polak, 1968),and
mannitol and forced alkaline diuresis (Prowse et al., 1970).
Lawson et al. (1969) found a fall in plasma sodium concentration
only during the initial 2 hours in the patients treated by water diur¬
esis, and a decline in plasma potassium concentration with forced
alkaline diuresis, but the pattern of urinary excretion of sodium
and potassium was similar despite the differences in the treatment
regimes.
In the report of Morgan et al. (1968) plasma sodium concentra¬
tions ranged from 93 to 143 mmol/1 and they recommended the addition
of 20 mmol of potassium to each litre of intravenous fluid in
salicylate poisoning. Prowse et al. (1970) observed falls in serum
sodium, potassium, chloride and calcium concentrations in both groups,
but a greater fall in plasma sodium was found in patients treated
with mannitol. A greater fall was observed in plasma potassium con¬
centrations in patients who received forced alkaline diuresis.
This /
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This study was undertaken to monitor the effects of treatment
on plasma and urinary electrolyte concentrations, osmolality and
creatinine clearance in aspirin poisoning.
(b) Patients and methods
Six patients each of the control, forced diuresis, alkali alone,
forced alkaline diuresis and forced alkaline diuresis with frusemide
groups (Section IV) were studied. The amounts of electrolytes
administered in the different treatment regimes are shown in Table
5.7.
Blood samples (10 ml) were taken in lithium heparin tubes on
admission, at the end of infusion (at 4 hours after admission for
the control group) and 16 hours following admission. The plasma was
separated immediately and stored at -20°C. The urine samples were
collected as described in Chapter 1, Section IV and 20 ml aliquots
of each without preservative were placed in plain tubes and stored
at -20°C.
The plasma electrolyte and creatinine concentrations were meas¬
ured by Technicon Sequential Multiple Analysis plus Computer (SMAC )
system, urinary electrolytes by flame photometer (Instrumentation
Laboratory Inc Model IL 543), magnesium by atomic absorption
(Instrumentation Laboratory Inc. Model IL353), plasma and urine osmol¬
ality by Advanced Digimatic Osmometer Model 3D II, and urine creatin¬
ine by Beckman Creatinine Analyser 2, in the University Department of
Clinical Chemistry, Royal Infirmary, Edinburgh.
The paired two tailed Student t-test was used for the comparison
within the groups and the independent two tailed Student t-test for
the comparison between the groups.
(c) /
TABLE 5.7.












Sodium 231 255 486 486
Potassium 120 60 120 120
Chloride 351 60 351 351
Bicarbonate 0 255 255 255
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(c) Results
Plasma electrolytes and osmolality
The means and standard deviations of plasma electrolyte concen¬
trations and osmolality on admission, at the end of infusion (4 hours
for the control) and at 16 hours after admission, for each group of
patients are given in Tables 5.8. - 5.13.
Plasma sodium
The plasma sodium concentrations did not change significantly
during or after the infusion in any group (Table 5.8.). Although
the concentrations declined during the infusion in the forced diuresis
and forced alkaline diuresis with frusemide groups (135 and 134 mmol/1
respectively), they were in the normal range (132-144 mmol/1). The
plasma sodium concentration increased in the alkali alone regime
during infusion and the difference between the changes in this and
the forced diuresis group was significant (p < 0.02). The mean
values at 16 hours following admission were 142, 141, 140, 139 and
138 mmol/1 in the forced alkali diuresis, alkali alone, forced diuresis,
forced alkaline diuresis plus frusemide and control groups respectively.
Plasma potassium
The plasma potassium concentrations also did not change signifi¬
cantly during or after the infusion (Table 5.9.). The maximum fall
occurred with the forced alkaline diuresis regime from 4.2 to 3.5
mmol/1 (normal range 3.3 - 4.7 mmol/1), but the mean concentration
was higher on the following day (3.7 mmol/1). The mean values at 16
hours following admission were 4.0, 3.8, 3.7, 3.7 and 3.5 mmol/1 with
forced diuresis, control, alkali alone, forced alkaline diuresis and
forced /
TABLE5.8.


























































*Normalrange3.3-4 7mo /1.**Onadmission.* *4hrafterdmission.***16afteradmission.
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TABLE5.13.

































*Normalrange280-290m ol/kg.**Bef recompar dwiththendfinfusion.***Oadmission. ****4hrafteradmission.***16afterdmission.
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forced alkaline diuresis plus frusemide groups respectively. There
were no statistically significant differences between the plasma
potassium concentrations in the different treatment groups.
Plasma calcium
The plasma calcium concentrations on admission were in the normal
range (2.12 - 2.62 mmol/1) in all patients, but decreased significantly
4 hours later in all groups including the control (Table 5.10.). The
mean values at the end of infusion were below the minimum normal in
the forced diuresis (2.07), forced alkaline diuresis (2.03) and
forced alkaline diuresis with frusemide (2.00 mmol/1) groups.
However, mean plasma calcium concentrations returned to the normal
range at 16 hours following admission (Fig. 5.3.).
Plasma phosphate
The plasma phosphate concentrations on admission were normal
(0.8 - 1.4 mmol/1) in all patients except for one (No. 57) treated
with forced alkaline diuresis plus frusemide in whom the concentration
declined from 0.72 to 0.34 mmol/1 during the infusion. This patient
was a 24 year old woman with acute on chronic aspirin poisoning in
whom vagotomy had been carried out 8 months before admission because
of gastric ulcer.
The mean plasma phosphate concentrations decreased significantly
during the infusion in the forced diuresis, forced alkaline diuresis
and forced alkaline diuresis plus frusemide groups (p < 0.05, p < 0.01
and p < 0.025 respectively (Table 5.11.). The mean values at the end





Changes in plasma concentrations of calcium and
phosphate in patients with mild to severe aspirin
poisoning receiving different treatments of fluid
and alka1i.
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The mean concentration decreased from 1.20 to 1.13 mmol/1 in the
alkali alone group and increased from 1.20 to 1.31 mmol/1 in the
control group. The differences between the changes in the latter
two groups and the former three were highly significant (p < 0.01 to
p < 0.001). The mean plasma phosphate concentrations at 16 hours
after admission were 0.84, 0.80, 0.72, 0.69 and 0.68 mmol/1 in the
alkali alone, control, forced alkaline diuresis, forced alkaline
diuresis plus frusemide and forced diuresis groups respectively.
PIasma magnesiurn
The plasma magnesium concentrations on admission were all normal
(0.75 to 1.00 mmol/1), but decreased significantly during the infusion
in all treated groups (Table 5.12. and Fig. 5.4.). The mean values
at the end of infusion were 0.83, 0.79, 0.75, 0.74 and 0.66 mmol/1
in the control, alkali alone, forced diuresis, forced alkaline diuresis
and forced alkaline diuresis plus frusemide groups respectively. The
changes during infusion were significantly greater in the treated than
in the control groups (p < 0.01). The concentrations returned to
normal at 16 hours after admission.
Plasma osmolality
The plasma osmolality on admission was above the normal range
(280 - 290 mmol/kg) in all patients, but it decreased during the infu¬
sion. In the forced diuresis group the decline was significant
(p < 0.02) and below the minimum normal (280 mmol/kg) (Fig. 5.4.).
The mean values at the end of infusion were 296, 295, 289, 286 and
















Figure 5.4. Changes in plasma osmolality and magnesium concen¬
trations in patients with mild to severe aspirin
poisoning receiving different treatments of fluid and
alkali.
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with frusemide, forced alkaline diuresis and forced diuresis groups
respectively (Table 5.13.). At the end of infusion the plasma osmol¬
ality was significantly higher in the alkali alone than in the forced
diuresis group (p < 0.05). There were no statistically significant
differences between the groups at 16 hours after admission, although
the mean plasma osmolality was below the normal range in the forced
diuresis group (278 mmol/kg).
Urinary sodium potassium and osmolality
The means and standard deviations of urinary sodium and potassium
concentrations and osmolality and the sodium/potassiom ratio for
each group are shown in Table 5.14.
The urinary sodium concentration was less than 47 mmol/24 hr
(normal range 100 - 200 mmol/24 hr) in all control patients except one
(No. 43). The mean urinary sodium concentration was significantly
higher in the treated groups than in the controls (p < 0.005). The
mean urinary sodium excretion was 474, 272, 257, 212 and 50 mmol/
24 hr in the forced alkaline diuresis plus frusemide, alkali alone,
forced alkaline diuresis, forced diuresis and control groups, respec¬
tively. There were no statistically significant differences between
the forced diuresis, forced alkaline diuresis and alkali alone groups,
but sodium excretion was significantly lower than in the forced
alkaline diuresis with frusemide regime (p < 0.001, p < 0.02 and
p < 0.005 respectively).
Urine potassium
The urinary potassium was in the normal range (25 - 100 mmol/
24 hr) in all control patients, and only in 4 patients of the treated
groups. /





























*Normalrange100-200mmol/24hr.**No malrange25-1 0mol/4hr. ***Theratioswerecalculat dfoindiv duald tnther foreme nvaluesn torr po d.
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groups. The 24 hour potassium excretion in the treated groups was
significantly higher than in the controls (p < 0.005). The mean
values were 179, 148, 145, 124 and 51 mmol/24 hr in the forced alkaline
diuresis plus frusemide, forced alkaline diuresis, forced diuresis,
alkali alone and control groups respectively. There were no statis¬
tically significant differences between the treated groups.
Urine sodium/potassium ratio
The mean ratios of urinary sodium to potassium over the 24 hours
were 3.03, 2.40,2.04, 1.24 and 1.15 in the forced alkaline diuresis
plus frusemide, alkali alone, forced alkaline diuresis, control and
forced diuresis groups respectively. There were no statistically
significant differences between the forced diuresis, forced alkaline
diuresis and control groups, but the ratio in the forced diuresis
group was significantly lower than in the alkali alone and forced
alkaline diuresis with frusemide groups (p < 0.01). The ratio in the
control group was also significantly lower than in the forced alkaline
diuresis plus frusemide group (p < 0.01).
Urine osmolality
The mean values of urinary osmolality were 467, 420, 354, 330 and
298 mmol/kg in the control, alkali alone, forced alkaline diuresis
plus frusemide, forced alkaline diuresis and forced diuresis groups
respectively. There were no statistically significant differences
between the groups.
Creatinine clearance
The creatinine clearance over the whole period of study for each
patient /
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patient is shown in Table 5.15. The values varied from 18 ml/min
in a control patient (No. 36) to 170 ml/min in a patient who received
forced diuresis. The mean creatinine clearances were 105, 99, 98, 87
and 79 ml/min with forced alkaline diuresis plus frusemide, forced
diuresis, alkali alone, forced alkaline diuresis and control groups
respectively. There were no statistically significant differences
between the groups. Half the patients (15) had creatinine clearance
less than 100 ml/min with no marked differences between the groups.
There were no statistically significant correlations between
creatinine clearance and the renal clearance of salicylic and
salicyluric acids, the plasma salicylic acid half-life, urine pH and
flow rate, urinary sodium or potassium excretion or the ratio of
urinary sodium to potassium.
(d) Piscussion
Although different amounts of sodium, potassium and chloride
were administered intravenously in the different regimes, the plasma
sodium and potassium concentrations did not differ significantly
either at the end of infusion or 12 hours later. These findings are
in good agreement with those of Morgan et al. (1968), Lawson et al.
(1969) and Berg (1977) except that hypokalaemia occurred with the
forced alkaline diuresis regime of Lawson et al. (1969) in which
administration of potassium was delayed.
The significant fall in plasma calcium concentrations during
infusion is consistent with the findings of Prowse et al. (1970),
but since it does not correspond to the fall in haematocrit, it
cannot be attributed to haemodilution only as they claimed. Further¬
more, a similar fall was observed in the control patients (Fig. 5.3.).
However, /
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However, there was no obvious clinical evidence of hypocalcaemia and
the concentrations returned to normal without calcium supplements.
It is of interest that the fall in plasma phosphate concen¬
trations was significant with forced alkaline diuresis and forced
diuresis, but not with alkali alone. This fall is far too great to
be accounted for by haemodi1ution. It is associated with salicylate
intoxication per se, since it occurred in the controls, and infusion
of dextrose itself may cause a marked fall in plasma phosphate
(Guillou, Morgan and Hill, 1976).
Changes in plasma magnesium concentration, except in the report
by Morgan and Polak (1969) when it was mentioned as normal, have
not been reported in aspirin poisoning. The fall was not statisti¬
cally significant in the control patients and it could be due largely
to haemodilution.
The high plasma osmolality on admission in all groups and the
significant fall with forced diuresis and forced alkaline diuresis
are consistent with previous reports (Morgan et al., 1968; Berg,
1977b).
The low urinary sodium output in the control patients confirmed
the study of Berg (1977a). Only with alkali alone was the 24 hour
urinary sodium excretion (272 mmol) greater than the amount infused
(255 mmol), and even the highest sodium output with forced alkaline
diuresis plus frusemide (474 mmol) was less than the amount infused
(486 mmol). In addition, oral fluids also contained sodium which
must be taken into account. Thus there is no doubt that sodium is
retained, presumably as the result of the inhibitory effects of
aspirin on renal prostaglandin synthesis (Plotz and Kimberly, 1981).
The urinary excretion of potassium was abnormally high in all
the /
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the different groups. The low ratio of urinary sodium to potassium
with the control and forced diuresis groups was as described by Berg
(1977a), but the higher ratios with forced alkaline diuresis are
presumably due to higher sodium content of the infusion fluids.
The higher ratio with the alkali alone treatment is probably due to
the smaller amount of potassium administered.
The creatinine clearance was surprisingly low in half of the
patients, which is consistent with the observations of Muther and
Bennett (1980), and the nephrotoxicity of aspirin (Prescott, 1965,
1976 and 1979c; Kimberly and Plotz, 1981). The lack of correlation
between the creatinine clearance and renal clearance of salicylic acid
was also observed by Morgan and Polak (1971). The very low creatinine
clearance associated with urine flow rates of less than 0.5 ml/min in
normal subjects found by Chesley (1938) did not apply to the overdose
patients with low creatinine clearance.
(e) Summary and conclusions
Changes in plasma and urinary electrolyte concentrations, osmol¬
ality and creatinine clearance were studied in 30 patients with mild
to severe aspirin poisoning. The patients were treated with either
oral fluids or one of the 4 intravenous regimes of fluid and alkali.
The plasma sodium and potassium concentrations did not change
significantly during or after infusion and there were no statistically
significant differences between the groups, although the amounts of
electrolytes infused were not the same.
The plasma calcium concentrations on admission were normal
in all patients, but decreased significantly 4 hours later in all groups.
There were no hypocalcaemic symptoms and the concentrations returned to
normal 16 hours after admission without administration of calcium.
The /
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The plasma phosphate concentrations on admission were also
normal, but decreased significantly during infusion with the forced
diuresis and forced alkaline diuresis regimes, but not in the alkali
alone and control groups. The concentrations returned to normal 16
hours after admission in all except in the forced diuresis group in
which the mean plasma phosphate concentration was 0.68 mmol/1.
The plasma magnesium concentrations on admission were all normal,
but decreased significantly during infusion in all treated groups,
but not in the controls. The concentrations returned to normal at
16 hours in all groups.
The mean plasma osmolality on admission was abnormally high in
all groups, but declined significantly with forced diuresis treatment
to below the minimum normal at the end of infusion (275 mmol/kg) and
12 hours later (278 mmol/kg).
The urinary sodium excretion was very low in the control patients
(50 mmol/24 hr), but not in the treated groups because of sodium
infusion. The highest sodium output was obtained with forced alka¬
line diuresis plus frusemide (474 mmol/24 hr), but this was still
less than the amount of sodium infused (486 mmol/kg). Therefore
sodium was retained probably as a result of renal prostaglandin
synthetase inhibition by aspirin.
The urinary potassium excretion was normal in the control patients
and increased in the treated groups presumably because of potassium
supplements in the infusion fluids. Urinary osmolality was similar in
all groups.
The creatinine clearance was very low in some patients, and this
no doubt reflects the known nephrotoxic effects of salicylates.
There were no statistically significant differences between the groups.
The /
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The alkali alone regime had the least effect on the plasma and
urinary electrolytes, and forced diuresis showed the maximum distur¬
bances in comparison with the other treatments.
SECTION VI
CLINICAL, BIOCHEMICAL AND HAEMATOLOGICAL STUDIES




CLINICAL AND BIOCHEMICAL ABNORMALITIES IN ACETYLSALICYLIC ACID
POISONING AND THE EFFECTS OF TREATMENT WITH FLUID AND ALKALI
(a) Introduction
Although the clinical features of salicylate poisoning have been
well documented (Done, 1960; Cumming, 1961; Beveridge et al., 1964;
Bender, 1975; Anderson et al., 1976; Proudfoot and Prescott, 1977;
Temple, 1978; Matthew and Lawson, 1979), their frequency has not been
reported in detail. Only in one report (Beveridge et al., 1964) were
the clinical features of 18 patients with aspirin poisoning docu¬
mented for each patient separately.
Biochemical abnormalities such as acid-base disturbances
(Hyder et al., 1945; Winters et al., 1959; Proudfoot and Brown, 1969;
Gabow et al., 1978) and electrolyte abnormalities (Lawson et al.,
1969; Morgan and Polak, 1971; Berg, 1977b) have been investigated.
However, metabolic abnormalities related to salicylate poisoning
such as changes in lactate and pyruvate metabolism have not been
reported.
The present study was undertaken to document the clinical
features and to investigate possible changes in plasma total bicar¬
bonate, urate, urea, proteins, lactate and pyruvate concentrations
together with liver function tests in patients with aspirin poisoning.
(b) Patients and methods
The clinical features in 55 patients with aspirin poisoning who
were /
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were treated with different regimes of fluid and alkali were recorded.
Eighteen patients (9 males and 9 females) were treated with standard
forced alkaline diuresis, 6 (3 males and 3 females) with forced
diuresis, 6 (3 males and 3 females) with forced alkaline diuresis
plus frusemide, 7 (3 males and 4 females) with alkali alone and 18
controls (8 males and 10 females) with oral fluids only (Section IV).
Clinical findings were recorded during the first 4 hours and at 12
hours after admission. The patients were questioned for the presence
of tinnitus, deafness and other symptoms such as epigastric pain.
Physical examination was performed on admission, at the end of infusion
(4 hours after admission for the control patients) and at 12 hours
following admission. The pulse rate, temperature, respiration rate
and blood pressure were measured hourly for 12 hours.
The plasma total CC^, urate, urea, and total protein concen¬
trations and liver function tests were estimated by the Technicon Sequ¬
ential Multiple Analysis plus Computer (SMAC ) System in groups of 6
patients as described in Chapter 2, Section V. Plasma lactate and
pyruvate concentrations were measured in 6 patients each of the con¬
trol and forced alkaline diuresis groups. The venous blood samples
(2 ml) for lactate measurement were placed into tubes containing
80 pi fluoride reagent and centrifuged for 5 minutes at 3000 rpm
within 2 hours. The lactate concentration in the supernatant was
measured by Rotochem II Aminco, using a Boehringer kit (Product
No. 149993). For pyruvate measurements, blood (2 ml) was placed in
tubes containing 4 ml of 5% perchloric acid. After mixing the tube
was centrifuged immediately and the pyruvate concentration of the
supernatant measured using a Sigma pyruvic acid kit (No. 726-10).
The biochemical tests were all performed in the University Department





The clinical findings during the first 4 hours after admission
are expressed as the percentage of patients with positive symptoms
and signs of poisoning in Table 6.1. The mean peak plasma salicylic
acid concentrations in each group are also shown.
Tinnitus was the commonest symptom in all groups and occurred in
78% of the control patients, 94% of the patients who received the
forced alkaline diuresis and in all patients in the other 3 groups.
There was a clear relationship between the peak plasma salicylic
acid concentrations and tinnitus. Only one patient in the forced
alkaline diuresis group who had a low plasma salicylic acid concen¬
tration (271 yg/ml) did not complain of tinnitus. Four control
patients with peak plasma salicylate concentrations of 277 to 391
pg/ml also denied tinnitus. However, 91% of the 55 patients who
had plasma salicylic acid concentrations of 260 - 657 ng/ml complained
of this symptom. Subjective loss of hearing was the second commonest
symptom of aspirin poisoning and occurred in 83% of the patients
treated with forced alkaline diuresis, forced alkaline diuresis plus
frusemide and forced diuresis, in 50% of the control patients and in
43% of those treated with alkali alone.
Sweating was present in 56% of all patients, and the incidence
varied from 33% in the forced diuresis group to 83% in the forced
alkaline diuresis plus frusemide group. Hyperventilation (respiration
rate more than 20 per minute) was recorded in 86, 67, 61, 50 and 22
percent in the alkali alone, forced alkaline diuresis plus frusemide,
forced alkaline diuresis, forced diuresis and control groups respec¬
tively. Nausea, vomiting and epigastric pain or tenderness were noted
in /
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in 43, 38 and 34% of patients respectively. Flushing was also
present in 33% of all patients (Table 6.1.).
The clinical findings 12 hours after admission in the same
patients are given in Table 6.2. Tinnitus was still present in 45%
of all patients, but varied with different treatments. The lowest
frequency ( 28%) was found in the alkali alone and forced alkaline
diuresis groups and the highest (67%) in the control patients.
Tinnitus was also present in 50% of the patients treated by forced
diuresis, forced alkaline diuresis with frusemide. Deafness was
still present 12 hours after admission in 17, 11 and 6% of the patients
in the forced diuresis, control and forced alkaline diuresis groups
respectively, but in none of those in the alkali alone and forced
alkaline diuresis with frusemide groups. Sweating, hyperventilation
and flushing had disappeared in all patients 12 hours after admission.
Pyrexia was noted in 6 severely poisoned patients and tachycardia
(< 130 per minute) in 14 patients who received 6 litres of fluid over
3 hours.
All patients recovered uneventfully and were discharged 16 to
92 hours after admission.
Biochemical abnormalities
Plasma total CO2
Plasma total CO^ concentrations on admission were below normal
(24 - 30 mmol/1) in 22 out of the 30 patients (Table 6.3.).
The plasma total CO^ concentrations increased significantly
during infusion with the alkalinisation groups (p < 0.01 to p < 0.005)
and decreased significantly in the forced diuresis and control groups
(p < 0.01 and p < 0.05 respectively) (Fig. 6.1.). The mean values at
the /
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Figure 6.1. Changes in plasma total CO^ concentrations in
patients with mild to severe aspirin poisoning
receiving different treatments of fluid and alkali.
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the end of infusion (4 hours after admission for the controls)
were 28, 26, 26, 21 and 19 mmol/1 with alkali alone, forced alkaline
diuresis, forced alkaline diuresis plus frusemide, control and forced
diuresis groups respectively. There were no statistically significant
differences between the alkalinisation groups, but the plasma total CC^
concentrations were significantly higher in these than in the forced
diuresis and control groups (p < 0.01 and p < 0.05 respectively).
The plasma total CO^ concentrations at 16 hours after admission
had returned almost to normal in the non-alkalinisation groups, but
were still below normal in all the patients treated with forced
diuresis and 4 control patients. The mean values were 27, 26, 25, 24 and
21 mmol/1 with forced alkaline diuresis plus frusemide, forced alkaline
diuresis, alkali alone, control and forced diuresis groups respectively.
There were no statistically significant differences between the alkal¬
inisation groups, but the mean plasma total CO^ concentrations were
higher in these than in the forced diuresis (p < 0.001) but not the
control patients.
Plasma urate
The plasma urate concentration on admission was below the normal
range (male 0.12 - 0.42, female 0.12 - 0.36 mmol/1) in 3 patients, one
control and 2 given forced alkaline diuresis with frusemide. The
concentrations declined significantly during the first 4 hours after
admission in all groups including the control. The fall was most
marked in the diuresis groups (Table 6.4.). The mean plasma urate
concentrations declined further subsequently, particularly in the
alkaline alone and control groups and by 16 hours the concentrations
in all groups were similar. The initial rapid fall with the diuretic
regimes presumably reflected haemodilution.
Plasma /
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Plasma lactate and pyruvate
The plasma lactate concentrations were in the normal range
(0.63 - 2.44 mmol/1) in all control patients and those treated by
forced alkaline diuresis with no statistically significant difference
between them (Table 6.5.). The mean values were 1.18 and 1.12 mmol/1
respectively.
The plasma pyruvate concentrations were above the normal range
(35 - 80 ymol/1) in 3 control patients and 2 with the forced alkaline
diuresis regime (Table 6.5.). The mean values were 91 and 79 umol/l
respectively and did not differ significantly. There was no statis¬
tically significant correlation between pyruvate and the corresponding
plasma salicylic acid concentrations.
Other biochemical measurements
The plasma concentrations of urea, bilirubin, alkaline phosphatase,
alanine and aspartate aminotransferases, and urea stable lactate
dehydrogenase were normal in all patients and did not change signifi¬
cantly during or after infusion, except for urea which declined
significantly from a mean of 4.05 to 3.32 mmol/1 during infusion
(p < 0.05) in the forced diuresis group.
The changes in total plasma protein concentration were similar
to those observed with plasma albumin as described in Chapter 1,
Section V..
(d) Piscussion
The main clinical manifestations of salicylate poisoning in
adults are tinnitus, deafness, sweating, hyperventilation, flushing
and /
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and epigastric pain (Beveridge et al., 1964; Proudfoot and Prescott,
1977; Matthew and Lawson, 1979). Loss of consciousness is very rare
in adults and when it does occur, intoxication is severe and likely
to be fatal (Proudfoot and Prescott, 1977).
The correlation between tinnitus and plasma salicylic acid con¬
centrations is in agreement with the findings of Beveridge et al. (1964),
but deafness occurred in 63% of 55 patients in the present study com¬
pared with 100% of the 18 patients they studied. The frequencies of
sweating, hyperventilation and epigastric pain were similar to those
observed by Beveridge et al. (1964), but they did not mention nausea,
vomiting and gastric haemorrhage. Mongan et al. (1973) reported
tinnitus in 59 rheumatic patients who had serum salicylate concen¬
trations over 196 pg/ml (average 304 pg/ml), but Seltzer (1973) has
described tinnitus, deafness and vertigo after ingestion of only 2
plain aspirin tablets.
The more rapid relief of the symptoms of poisoning in patients
who were treated by alkali alone is consistent with the more rapid
elimination of salicylic acid in this group. The reduced efficacy of
the forced diuresis in enhancing salicylate elimination is also
reflected in the persistence of symptoms of salicylism. The combin¬
ation of frusemide and forced alkaline diuresis did not produce
greater relief of symptoms and this is as expected from elimination
kinetics.
The low plasma total CC^ concentration on admission is presum¬
ably a response to hyperventilation rather than metabolic acidosis
(Segar and Holliday, 1958; Temple, 1978). Again, as expected, concen¬




The decrease in plasma urate concentrations is presumably due to
the dose-dependent uricosuric effect of salicylate (Flower et al.,
1980). Changes in plasma urate concentrations following aspirin
overdosage have not been described previously.
The plasma lactate concentrations were within the normal range
in all patients and the pyruvate concentrations were abnormally high
in a minority of patients. There was no correlation between plasma
pyruvate and salicylic acid concentrations. There has been no report
of plasma lactate and pyruvate concentrations in aspirin overdosage,
although the theory of the inhibitory effects of salicylate on the
Krebs cycle dehydrogenases would be expected to increase the plasma
lactic and pyruvic acid concentrations (Segar and Holliday, 1958;
Temple, 1978).
The normal values for plasma bilirubin, alkaline phosphatase
and aminotransferases throughout the study in all patients provided
no evidence of acute salicylate-induced hepatotoxicity, but the time
was not long enough in all cases to exclude hepatotoxicity. However,
hepatotoxicity has been associated with chronic salicylate administra¬
tion (Sharbaro and Bennett, 1977; Bernstein et al., 1977; Schaller,
1978; Kolling and Hinddin, 1978; Gullner, 1979b).
(e) Summary and conclusions
The clinical features in 55 adult patients with aspirin poison¬
ing treated with oral fluids only or one of four intravenous regimes
of fluid and alkali were recorded.
Plasma concentrations of total CO^, urate, urea, were monitored
together with liver function tests in 5 groups of 6 patients. Plasma
lactate /
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lactate and pyruvate concentrations were measured in the control and
forced alkaline diuresis groups.
Tinnitus was the commonest symptom and was present in 91% of all
patients. It correlated well with plasma salicylic acid concentrations.
Subjective deafness occurred in 63% of the patients, while sweating,
hyperventilation, nausea, vomiting, epigastric pain/tenderness and
flushing were found in 56, 51, 43, 38, 34 and 33% of the patients
respectively.
These manifestations of salicylism had disappeared in most
patients 12 hours after admission. The most rapid improvement was
obtained with the alkali alone regime and the least improvement
occurred with forced diuresis.
The mean plasma total CC^ concentrations on admission were below
normal in all groups, but returned to normal within 4 hours in all
the alkalinisation groups. There was a further decline in the forced
diuresis and control groups.
The plasma urate concentrations decreased in almost all patients.
The greatest fall occurred during the first 4 hours in the diuresis
groups and this was due to haemodi1ution rather than the uricosuric
effect of aspirin
The plasma lactate concentrations were normal in all patients
and pyruvate concentrations were abnormally high in less than half.
There were no changes in the concentration of plasma urea, bili¬




HAEMATOLOGICAL CHANGES AFTER THERAPEUTIC DOSAGE
AND OVERDOSAGE OF ACETYLSALICYLIC ACID
(a) Review of the literature
The effects of acetyl salicyIic acid on platelet function have
been investigated for many years. Evans et al. (1968) studied the
inhibitory effects of aspirin and sodium salicylate on platelet
aggregation induced by collagen, antigen-antibody complex, gamma
globulin coated particles and thrombin. They concluded that dimin¬
ished aggregation was due to a defect in the release of adenosine
diphosphate. Weiss, Aledort and Kochwa (1968) reported the effects
of salicylates on the haemostatic properties of platelet in man.
They stressed that the ingestion of aspirin, but not sodium salicylate,
prolonged the bleeding time significantly and irreversibly impaired
platelet aggregation with a decreased release of platelet adenosine
diphosphate. O'Brien (1968) also demonstrated that adenosine
diphosphate is not released by platelets exposed to aspirin (but
not to sodium salicylate) and concluded that some enzyme pathways in
platelets were presumably damaged.
Smith and Willis (1971) revolutionised the knowledge of the
mechanism of action of acetyl salicylic acid on platelets by the
demonstration of its effects on prostaglandins. Willis and Kuhn
(1973) incubated platelet arachidonic acid with cyclo-oxygenase
and demonstrated an unstable factor which induced platelet aggreg¬
ation. This substance was identified as prostaglanding GH^, ah
intermediary /
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intermediary of the cyclo-oxygenase reaction (Hamberg and Samuelsson,
1973; Hamberg, Svensson, Wakoliayashi and Samuelsson, 1974; Hamberg,
Svensson and Samuelsson, 1975). Platelet prostaglandins are further
transformed to an unstable compound, thromboxane A^, by an enzyme
designated thromboxane synthetase which is of great potency as an
inducer of platelet aggregation (Needleman, Moncada, Bunting, Vane,
Hamberg and Samuelsson, 1976). The anti-aggregatory effect of
aspirin was shown to be due to acetylation of the active site of
cyclo-oxygenase (Morse, 1977; Raz, Isaak-son, Minkes and
Needleman, 1977).
Studies on microsomal extracts from blood vessels revealed
that prostaglandins are transformed into an unstable vasodilator
substance with potent anti-aggregatory activity (Moncada, Gryglewski,
Bunting and Vane, 1976). This compound, prostacyclin, is derived
from arachidonic acid metabolism in vascular tissue (Gryglewski, Bunting,
Moncada, Flower and Vane, 1976) and its generation is also inhibited
by acetylation of cyclo-oxygenase (Vane, 1971).
Changes in platelet function and gastrointestinal bleeding
following repeated administration of aspirin in rats and dogs were
studied by Mills, Lane, Otton, Cook and Philp (1979). The maximum
platelet aggregation responses to adenosine diphosphate were found
on the third day, which coincided with gastrointestinal bleeding.
Baumgartner (1979) concluded that low citrate concentrations in the rabbit
inhibit, and strongly enhance a possible inhibitory effect of acetyl-
salicylic acid on thrombus growth.
The bleeding time was significantly prolonged from a mean of
3.5 to 6.5 minutes following the ingestion of 600 mg aspirin
(Stuart et al. 1979), but a combination of 180 mg aspirin and
50 mg /
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50 mg dipyridamole 3 times daily had no such effect (Rajah, Penny,
Crow, Pepper and Watson, 1979).
The effects of aspirin and dipyridamole on platelet function
in divers were reported by Phi 1p, Anderson, Fields,
Mclntyre, Francy and Briner (1979). A reduction in circulating
platelet count was observed in all divers except in the groups who
received aspirin only, but platelet survival was shortened in all.
The effects of aspirin and aspirin lysinate on platelet function in
smokers and non-smokers were also investigated (Morgan, Duchosal,
Rogg and Miescher, 1980). Bleeding time and platelet adhesiveness
were similar for both groups and inhibition of platelet aggregation
was slightly less in the smokers than in the non-smokers.
Differential inhibition of prostacyclin production and platelet
aggregation by aspirin was studied by Masotti et al. (1979). They
concluded that a dose of 3.5 mg/kg of aspirin is most likely to
produce a consistent inhibition of platelet aggregation with
relatively less inhibition of prostacyclin production. This was
not confirmed by others (Pareti et al., 1980; O'Brien, 1980;
Hoogendijk and Ten Cate, 1980; Huijgen et al., 1980). However,
Ellis, Wright, Jones, Richardson and Ellis (1980) reported that
one-quarter of an aspirin tablet which inhibits a major portion of
platelet cyclo-oxygenase may not inhibit vascular cyclo-oxygenase
and may be more efficacious as an anti-thrombotic agent in man.
Pacciorette and Elock (1980)studied the effects of aspirin on
platelet aggregation as a function of dosage and time, and concluded
that the inhibition by a single oral dose of aspirin [>. 81 mg) may
be expected to persist for the life of the platelets affected.
Among four antiplatelet drugs studied for the prevention of
stroke, /
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stroke, aspirin was the only drug effective in reducing the incidence
of stroke and death in patients with transient cerebral ischaemia
(Hirsh, 1981).
The effects of acetyl salicylic acid in overdosage on platelet
function have not been reported. The present study was carried out
to investigate the effect of aspirin overdosage on platelet function
and haemostasis.
(b) Methods
Ten healthy volunteers (7 males and 3 females) aged 24-51 years
weighing 55-82 kg were studied with informed consent. They had not
taken any drugs for at least 2 weeks before the study.
On the first day, 30 ml of venous blood was taken; 2 ml was
placed in a tube containing soya bean thrombin (Wellcome Reagents
Ltd.) for fibrin degradation products assay, 10 ml in a universal tube
containing 31.3 mg (0.016M) sodium citrate for the measurement of
fibrinogen and plasminogen, and 18 ml in another universal tube
containing 2 ml of 3.8% sodium citrate for platelet aggregation
studies. Hess's test was performed (Dacie and Lewis, 1975) and the
bleeding time measured (Ivy, Nelson and Bucher, 1940). Fibrin degrad¬
ation products were estimated using latex particles coated with
antibody to human fibrinogen fragments D and E (Wellcome Laboratories,
Thrombo-Wellcotest, 1979). Fibrinogen was measured by the method of
Ellis and Stransky (1961), and plasminogen by the method Alkjaersig,
Fletcher and Sherry (1959).
Platelet aggregation was determined with a six channel aggrego-
meter (Malin Electronics, Model 6C AC6) using three twin channel
recorders (Mitsui, Limited, Model DBE2). The blood sample was
centrifuged /
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centrifuged immediately at 250 x g for 10 minutes, and the platelet
rich plasma removed. The remaining sample was further centrifuged
at 2000 x g for 15 minutes to obtain platelet-poor plasma. Aliquots
of the platelet-rich plasma (0.6 ml) were challenged with adenosine
diphosphate and adrenalin (2 and 2.5 uM ) in the final suspension,
and aggregation was followed by measuring the increase in trans¬
mission of light as clumping proceeded. The platelet-poor plasma
was used to zero the recorder for the respective platelet-rich plasma.
Aggregation was followed for 6 minutes and the results expressed as
percent transmission obtained at each minute interval. All samples
were challenged between 55 and 65 minutes after venepuncture.
On the second day, each subject took 20 mg/kg aspirin dissolved
in 200 ml of water following an overnight fast. Food, fluids and
tobacco were withheld for 2.5 hours. At 2 and 24 hours after
ingestion, the above tests were repeated.
The above tests together with platelet counts and measurement
of the prothrombin time ratio were performed (Quick, 1942) in 23
patients (10 males and 13 females) aged 16-59 years, weighing 43-86 kg
with mild to severe aspirin poisoning. The patients received diff¬
erent treatment; 7 controls, 7 forced alkaline diuresis, 3 forced
diuresis, 3 alkali alone and 3 forced alkaline diuresis with fruse-
mide (Chapter 2, Section IV).
Paired and independent two-tailed Student t-tests were used
for comparisons, taking p < 0.05 as the minimum level of statistical
significance.
(c) Results
Hess's test and bleeding time /
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Hess's test and bleeding time
The Hess's test was negative (less than 10 petechiae) in all
healthy volunteers and overdose patients.
The effects of aspirin on bleeding time in the normal subjects
and in the overdose patients are illustrated in Table 6.6. The
bleeding time increased significantly in the normal subjects from
a mean of 1.77 minutes before taking the aspirin to 2.72 minutes at
2 hours (p < 0.0025), and 2.27 minutes at 24 hours (p < 0.05) after
ingestion. The patients with aspirin poisoning had a wider range of
bleeding time than the healthy subjects. There were no statistic¬
ally significant differences between the groups of patients. The
overall mean was 3.65 minutes, which was significantly higher than
the controls (p < 0.001) (Fig. 6.2.). There was a significant
difference between the bleeding time in the overdose patients and
the healthy subjects 24 hours (but not 2 hours) after ingestion
(p < 0.05). The bleeding times obtained in both the healthy volun¬
teers and overdose patients were all within the accepted normal
range (1-7 minutes) for the method used.
Plasminogen^ fibrinogen and fibrinogen degradation products
The plasma fibrinogen and plasminogen concentrations are given
in Table 6.7. Aspirin produced no significant changes in the plasma
fibrinogen and plasminogen concentrations in the healthy volunteers.
The mean plasminogen concentration was normal in the patients with
aspirin poisoning, but plasma fibrinogen concentrations were abnor¬




















































Figure 6.2. Plasma concentrations of fibrinogen and plasminogen
and bleeding time in 23 patients with mild to severe
aspirin poisoning (•) and 10 healthy subjects (o)
who had not taken any drug for 2 weeks before the
study.
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The concentrations of plasma fibrinogen degradation products
was normal ( < 10 pg/ml ) in all healthy subjects after taking
aspirin. Five of the overdose patients (22%) had increased concen¬
trations >(10 pg/ml).
Platelet aggregation
The results of the platelet aggregation studies are shown in
Figure 6.3. In both the healthy subjects and patients with aspirin
poisoning, the second phase of platelet aggregation was abolished
following challenge with adrenaline. The controls illustrate the
classical aggregation pattern with the second wave of aggregation
following adenosine diphosphate release from the platelets. The
first phase of aggregation was impaired in the overdose patients.
Challenge with adenosine diphosphate (Fig. 6.3.) shows dis¬
aggregation of platelets following the first phase response in all
groups receiving aspirin. There was no marked difference between
the healthy subjects and patients. The platelets of the control
subjects responded to stimulation with adenosine diphosphate arid
there was no subsequent disaggregation before aspirin administration.
Platelet count and prothrombin time ratios in patients
with aspirin poisoning
The platelet counts in patients with aspirin poisoning ranged
from 81 to 340 x 109/1 (normal range from 150 to 400 x 109/1). Only
9
one patient (No. 5) had a platelet count below normal (81 x 10 /l).
This patient had a previous history of polycythemia and the plasma
concentrations of fibrinogen degradation products were increased
(> 40 pg/ml). However, the mean platelet count (including Patient
No. 5) was 208 x 109/1.
The /
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Figure 6.3. Platelet aggregation patterns in 21 patients with
mild to severe aspirin poisoning and 10 healthy
subjects, before, 2 and 24 hours after a single oral
dose of 20 mg/kg aspirin.
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The prothrombin time ratio in patients with aspirin overdosage
ranged from 1.2 to 1.8 with a mean of 1.4.
(d) Piscussion
A significant increase in the bleeding time after therapeutic
doses of aspirin has been reported by many investigators (Stuart
et al., 1979; Miekle, 1981), but there have been no reports of the
effects of toxic doses of aspirin.
Variation in the bleeding time response to low doses of aspirin
was noted in the present study, and similar variation was described
by Weiss et al (1968). These workers found a significant increase
in bleeding time in 6 young males 2 hours after ingestion of 0.3 g
aspirin, using the Ivy technique. The slight shortening of the
bleeding time at 24 hours compared with 2 hours after ingestion of
the aspirin is consistent with the irreversible effect on cyclo-oxy-
genase activity (Ali et al., 1980), and the entrance of new plate¬
lets into the circulation (10% daily). However, the significantly
longer bleeding time in the overdose patients relative to that 24
hours after a therapeutic dose indicates a somewhat greater effect
following a toxic dose of aspirin (most of the samples from the
overdose patients were obtained after 24 hours).
Interpretation of the increased concentrations of fibrinogen
degradation products in 5 patients is uncertain, but disseminated
intravascular coagulation has been described in salicylate intoxic¬
ation (Sbarbaro and Bennett, (1977).
The results of the platelet aggregation studies in the healthy
volunteers are in good agreement with previous reports (O'Brien,
1968; Evans et al., 1968; Morse, 1977; Rajah et al., 1979; Mills et
al., /
270
al., 1979; Miekle et al., 1981). Following aspirin administration
adenosine diphosphate challenge causes disaggregation of platelets
after the initial wave of aggregation. This test is relatively crude,
but there were no obvious differences in the behaviour of platelets
following therapeutic doses and overdosage of aspirin. Adrenaline
challenge showed a similar pattern with absence of the second phase
of aggregation. The increased prothrombin time ratio in the poisoned
patients probably reflects the well-known inhibitory effect of sali¬
cylate on the hepatic synthesis of clotting factors (Coldsweig,
Kapusta and Schwartz, 1976). In view of these findings, it can be
concluded that aspirin in therapeutic doses and overdosage have
similar adverse effects on haemostasis.
(e) Summary and conclusions
Haemostasis was compared in 23 patients with aspirin poisoning
and in 10 healthy volunteers taking a single oral dose of 20 mg/kg.
The Hess's test was normal in all overdose patients and healthy
volunteers.
The bleeding time was significantly increased in the normal
subjects from a mean of 1.77 minutes before aspirin to 2.72 minutes
at 2 hours (p < 0.0025) and 2.27 minutes at 24 hours (p < 0.05)
after ingestion. The mean bleeding time in the overdose patients
was prolonged even further to 3.65 minutes (p < 0.001). All values
were within the normal range (1-7 minutes).
Plasma fibrinogen and plasminogen concentrations were normal
in both groups. Fibrinogen degradation products were abnormally
increased (> 10 ug/ml) in 5 poisoned patients.
The /
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The second phase of platelet aggregation following challenge
by adenosine diphosphate and adrenalin was abolished in both the
normal subjects and the overdose patients. There were no marked
-differences between the groups.
The platelet count was normal in all overdose patients except
one who had a history of polycythemia.
The mean prothrombin time ratio was increased in the patients
with aspirin overdosage and varied from 1.2 to 1.8 (mean 1.4).
SECTION VII





(a) Acetyl sal icy!ic acid absorption
Acetyl sal icy!ic acid was absorbed rapidly when given in solution
(20 mg/kg) to healthy subjects with the mean peak plasma concentration
occurring at 30 minutes. This is in agreement with previous reports
(Levy, 1961; Leonard, 1963; Rowland et al., 1972). Absorption
appeared to be faster when it was given one hour after sodium bicar¬
bonate and the mean peak plasma concentration occurred at 15 minutes.
Similar enhancement of aspirin absorption by sodium bicarbonate has
been noted by Leonard (1963) and Cook and Hunt (1970).
The absorption of acetyl salicylic acid following overdosage has
not been investigated previously, although some investigators have
commented on apparent delay in absorption as judged by the recovery of
aspirin tablets remaining in the stomach at gastric aspiration and
lavage (Matthew et al., 1966; Matthew, 1970; Springer, 1980). Further¬
more, delayed peak plasma salicylate concentrations in aspirin pois¬
oning have been reported (Beveridge et al., 1964; Ferguson and Boutros,
1970). Since unchanged acetyl salicylic acid was not measured in these
reports, it is impossible to distinguish between delayed absorption
and slow hydrolysis of the drug. In the present study very slow and
delayed absorption was observed in some patients with aspirin over¬
dosage. Plasma acetyl salicylic acid concentrations continued to increase
for as long as 18 hours in one control patient and the unchanged drug
was detected in the plasma up to 24 hours after ingestion. This
delayed /
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delayed absorption could be due to either slow dissolution of the
tablets or slow gastric emptying following overdosage.
(b) Metabolism and distribution
Acetyl salicylic acid was rapidly hydrolysed to salicylic acid and
only 1-2% of the dose was excreted unchanged in the urine in the healthy
volunteers. This is in general agreement with previous reports
(Rowland et al., 1967; Levy, 1978; Levy, 1981). Following overdosage,
even less of the total recovered was excreted unchanged (0.5%), but
there are no previous reports of the urinary recovery of unchanged
acetylsalicylic acid for comparison.
Salicylic acid is the major metabolite of acetylsalicylic acid.
It is eliminated by renal excretion and by conjugation and oxidative
metabolism (Milne, 1962; Terweij-Groen et al., 1980; Levy, 1981).
Conjugation with glycine to form salicyluric acid, is the main route
of elimination with low therapeutic doses, but this process is satur¬
ated when the amount of salicylate in the body exceeds approximately
360 mg (Levy, 1965b). Salicyl phenolic glucuronide (but not salicyl
acyl glucuronide) is also saturated at higher salicylic acid concen¬
trations (Levy et al., 1972). The oxidative metabolites (e.g. gentisic
acid) and the recently described new metabolite (gentisuric acid) are
minor metabolites (Fig. 1) which account for about 1% of the total
urinary recovery of salicylate. The ratio of the urinary recovery of
salicylic to salicyluric acids is not only related to the dose
absorbed, but also to the urine pH.
Albumin is not the only plasma protein to which salicylic acid is
bound as was previously believed (Reynolds and Cluff, 1960; Butterman et
al. /
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al., 1962). The binding of salicylic acid to albumin accounted for
only half of the total bound to plasma proteins at certain concentra¬
tions and this has not been reported previously. However, the
increase in the fraction unbound to total plasma proteins with
increasing plasma salicylic acid concentrations has been reported
before (Smith et al., 1946; Wosilait, 1976; Ekstrand et al., 1979;
Rowland, 1980). However, there have been no detailed studies of
salicylate binding at concentrations encountered following aspirin
poisoning. The marked increase in free salicylic acid at high plasma
concentrations is of major significance in relation to toxicity after
overdosage. Only unbound salicylic acid can pass the blood brain
barrier, and therefore its concentration in plasma may closely reflect
concentrations in the central nervous system and cerebrospinal fluid.
In addition, a fall in blood pH will increase brain and decrease plasma
concentrations (Reed and Palmisano, 1975).
The concentration-dependent volume of salicylic acid distribution
found in the present study confirmed the findings of Levy and Yaffe
(1974), and this effect is probably due to the marked dependence of
protein binding on salicylate concentration. In fact, the volume of
distribution of unbound salicylic acid increased or remained constant
as the total plasma concentrations decreased following overdosage.
Diflunisal is extensively bound to plasma proteins (Verbeeck et al.,
1980) and this probably accounts for its longer plasma half-life
following a therapeutic dose.
Although haemodilution during infusion in the overdose patients
treated by forced diuresis regimes was confirmed by serial measurements
of haematocrit and plasma albumin concentrations, the apparent volume
of salicylic acid distribution did not seem to change significantly.
Thi s /
This is probably a pharmacokinetic artefact resulting from the use
of inappropriate methods for the calculation of volume of distribution
since plasma and extracellular volumes and salicylate clearance were
changing rapidly during the infusion.
(c) Urine pH and flow rate
In the healthy volunteers given aspirin and diflunisal, satis¬
factory and virtually identical changes in urine pH and flow rate
were achieved following the administration of sodium bicarbonate.
Hanzlik (1926) failed to enhance salicylate elimination with sodium
bicarbonate, but this was presumably because insufficient was given to
alkalinize the urine.
In the present study with the overdose patients, there was also
a satisfactory increase in urine pH and flow rate, although the immed¬
iate increase in flow rate was limited by fluid retention unless
frusemide was also given. The highest urine pH was obtained with
alkali alone and the highest flow rate with forced alkaline diuresis
plus frusemide. Since laevulose and even glucose might be degraded
to acidic compounds in alkaline solution (Conn and Stumpf, 1972), it
is important not to add the bicarbonate until immediately before use.
Even so, autoclaved dextrose solutions are very acidic and some of the
added sodium bicarbonate is therefore wasted in neutralisation. The
use of sodium bicarbonate alone is therefore, simpler and more effec¬
tive in raising the urine pH.
The significant positive correlation between the urine pH and
flow rate, in the forced alkaline diuresis regimes is an obvious
artefact (Morgan and Polak, 1971).
(d) /
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(d) The effects of changes in urine pH and flow rate on the plasma
half-life and total body clearance of salicylic acid
The significantly lower plasma salicylic acid half-life and
increased total body clearance with alkaline diuresis in the healthy
volunteers is in agreement with previous reports (Smith et al., 1946;
Levy and Leonard, 1971; Levy, 1978). These changes are due entirely
to the increased renal clearance of salicylic acid in alkaline urine.
The mean reduction in plasma salicylate half-life was 34%. However,
this was not the case for diflunisal. Although its renal clearance
increased significantly with alkaline diuresis, there was no change in
the plasma half-life and total body clearance. However, the renal
clearance of diflunisal is very low and only 5-7% of the dose was
excreted unchanged in the urine.
The shortening of the apparent plasma salicylic acid half-life
in the poisoned patients during infusion of 6 litres of fluid
(particularly with forced diuresis) must have been due largely to
haemodilution. The changes in haematocrit and plasma albumin, total
protein, calcium, phosphate, urate, magnesium and salicyluric acid
concentrations all point to significant expansion of the plasma and/
or extracellular fluid volumes. In addition, the amounts of sali¬
cylic acid recovered during the infusion are too small to account for
the observed fall in plasma concentrations. For example, in the forced
diuresis group, it can be calculated (from the apparent volume of dis¬
tribution and the urinary recovery) that the mean plasma concentrations
would only have fallen by about 7% without haemodilution. In fact, the
observed fall was 33%. However, the decrease in plasma salicylic acid
half-life during the infusion period in the alkalinisation groups
(particularly /
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(particularly alkali alone) was also due to enhanced renal excretion
as a result of the increase in urine pH. There was no evidence of
haemodilution in the alkali alone group and the observed fall in
plasma salicylate concentrations during the first 4 hours (35%)
corresponded exactly with the amounts recovered in the urine over
the same period.
After the infusion was completed, the plasma salicylic acid half-
life became longer in all patients except 3 who received alkali alone.
Interestingly, in one of these patients the plasma salicylic acid
half-life (2.62 hours) was virtually identical to the shortest indivi¬
dual plasma half-life following a therapeutic dose of aspirin in the
healthy volunteers with alkaline diuresis (2.61 hours). This is even
shorter than the mean plasma salicylate half-life (2.9 hours) reported
with a low therapeutic dose (0.25 g aspirin) in which elimination
followed first-order kinetics (Levy, 1965b). In fact, in the present
study it was not possible to confirm with certainty the elimination
of salicylate by first-order kinetics at toxic concentrations as
reported by Levy (1965b, 1978). He mentioned that with very high doses
of salicylate, elimination appears to be first-order, since the zero-
order contribution is too small to be noticeable except during the
terminal elimination phase. This is true, particularly when the
urine pH is very high (above 8.0), in which case the zero-order contri¬
bution may not be obvious at all. With low urine pH as in the control
patients, the renal excretion of salicyluric acid exceeded that of
salicylic acid.
In the control patients, the total body clearance of salicylic
acid tended to increase with time in some patients as the plasma
concentration of salicylic acid declined and this could have been due
to /
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to a change from zero-order to first-order elimination kinetics.
This might also account for the much higher total body clearance of
salicylic acid in the healthy volunteers than in the control overdose
patients.
Of the different treatment regimes used in the patients with
aspirin overdosage, administration of alkali alone produced the
greatest reduction in plasma salicylic acid concentration, and in
this respect it was at least as good and probably better than any of
the other treatments. In addition, the decline in plasma salicylic
acid concentration was only matched by a corresponding increase in
the urinary excretion in the alkali alone group. Forced diuresis was
the least effective treatment and the mean plasma salicylate half-
life after completion of the infusion was the same as in the control
group.
(e) The effects of changes in urine pH and flow rate on salicylate
renal clearance and excretion
A significant positive correlation was found between the renal
clearance of salicylic acid and urine pH both in the healthy volun¬
teers and the overdose patients. Similar findings have been reported
by numerous investigators (Smith et al., 1946; Lawson et al., 1969;
Morgan and Polak, 1969). Morgan and Polak (1971) used mannitol to
produce diuresis with sodium lactate, acetazolamide and sodium bicar¬
bonate to raise the urine pH. They also found a better correlation
between the urine pH and renal clearance of salicylate, when the
urine flow rate was held constant. However, the correlation between
flow rate and renal clearance of salicylate became less significant
when /
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when the urine pH was held constant. The significant correlation
between the renal clearance of salicylate and the urine flow rate
can be attributed in part to the positive correlation between urine
pH and flow rate. McPherson et al. (1955) and Morgan and Polak (1971)
believed that a relatively small effect of urine flow rate on the
renal clearance of salicylate might be masked by the much greater
effect of urine pH as was seen in the present study.
Weiner, Washington and Mudge (1959) studied the renal clearance
of salicylate in the dog and showed that salicylate enters the tubular
lumen from the plasma by glomerular filtration and tubular secretion.
In the filtrate it exists in two forms : salicylate ions and unionized
salicylic acid, the proportion of each depending on the pH. The
tubular epithelium is highly permeable to the latter, but much less
permeable to salicylate ions. Therefore, the extent of reabsorption
depends on the concentration gradient of unionized salicylic acid
between the tubular fluid and peritubular capillaries and this is
related to the urine pH. Salicylic acid is a moderately strong orga¬
nic acid with a pKa of 3.0. An increase in urine pH increases the
fraction present in the ionized form, decreases tubular reabsorption
and thus enhances the urinary excretion of salicylate.
The ratios of the concentrations of ionized, unionized and total
salicylic acid in the tubular fluid and peritubular capillaries can
be calculated using the Henderson-Hasselbalch equation. If it is
assumed that the blood pH is 7.45 and that there is diffusion equi¬
librium of the unionized salicylic acid, the urine/blood ratios of
the salicylic acid concentrations for urine pH values of 5.0, 6.0,
7.0, 8.0 and 9.0 are 0.0036, 0.036, 0.36, 3.6 and 36 respectively.
The calculation for a urine pH of 5.0 and a blood pH of 7.45 with
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a pKa value of 3.0 for salicylic acid is as follows :
Cu I + 10<ur1ne PH"PKa) 1 + 102
R = = = 0.0036
Cp 1 + l0(b,°od PH-pKa) , t 104-«
R is the ratio of urine concentration (Cu) to plasma concentration (Cp)
of salicylic acid. Similarly, at a urine pH of 8.0 the ratio is 3.6,
a thousand-fold increase.
Thus for each unit increase in urine pH, the renal clearance of
salicylic acid should increase ten-fold. In practice, a smaller
value is found, perhaps because of protein binding or failure to
achieve complete distribution equilibrium, especially at high urine
flow rates. In the present study, the factor as determined by mul¬
tiple regression analyses, was 6.3 with alkali alone, 2.1 with the for¬
ced alkaline diuresis and even less with the other treatment regimes
(Table 4.24.). Morgan and Polak (1971) found an approximately four¬
fold increase in salicylate clearance for each rise of one unit in
urine pH, irrespective of whether alkaline diuresis was induced with
mannitol and sodium lactate or acetazolamide plus sodium bicarbonate.
Although multiple regression analysis indicated that urine flow
rate had a negative effect on the ratio of urine to plasma concen¬
trations of salicylic acid, this cannot be the case biologically,
since forced diuresis gave a significantly higher renal clearance of
salicylic acid than in the controls.
The higher renal clearance of unbound salicylic acid (> creatinine
clearance) indicates active tubular secretion as well as glomerular
filtration and tubular reabsorption (Milne et al., 1958; Schachter
and Manis, 1958; Bedford et al., 1965). Since the renal clearance
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of unbound salicylic acid was measured only in 5 patients, insufficient
data were available for multiple regression analyses of the effect of
changes in urine pH and flow rate.
The addition of frusemide to the forced alkaline diuresis regime,
had no obvious effect on the urine pH and although it induced a rapid
diuresis, it failed to further enhance salicylate elimination.
Similar findings were reported by Berg (1977b). Thus, there is no
indication for the use of frusemide (or presumably, other diuretics)
unless fluid retention is a cause for concern.
Alkaline diuresis produced a significant increase in the renal
clearance of salicyluric acid in the healthy volunteers. However, the
explanation is unlikely to be pH-dependent tubular reabsorption of
salicyluric acid. There was no such correlation between urine pH
and salicylurate clearance in the patients with aspirin poisoning,
and under these conditions, conjugation of salicylic acid with glycine
was fully saturated throughout the period of study, confirming the
observations of Levy (1965a, 1965b) and Levy et al. (1969).
The ratio of the urinary recovery of salicylic acid to salicyl¬
uric acid increased significantly with alkalinisation of urine both
in the healthy volunteers and overdose patients. The ratio was much
greater in the overdose patients reflecting saturation of glycine
conjugation of salicylic acid in the presence of much larger amounts
of salicylic acid (Levy, 1965b, 1978, 1981). Indeed, the urinary
recovery of salicyluric acid was essentially the same in all overdose
patients, irrespective of the treatment regimes.
Administration of alkali alone in the poisoned patients produced
the highest renal clearance and the greatest urinary recovery of
salicylic acid. Of the different regimes used, it was the most effec¬
tive in enhancing renal salicylate elimination following overdosage.
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(f) The effects of different treatment regimes on clinical and
biochemical abnormalities
The effects of the different regimes of fluid and alkali on the
clinical manifestations of aspirin poisoning corresponded well with
their different effects on the elimination of salicylic acid. Although
the manifestations of salicylate toxicity were similar in all the
treatment groups during the first 4 hours after admission, the pro¬
portion of patients with salicylism 12 hours after admission was lowest
in the alkali alone group. Thus, more rapid recovery was obtained
with this method of treatment. Other investigators have been pre¬
occupied with salicylic acid kinetics, and no information is available
concerning the relative efficacy of different treatments on the
clinical features of acetyl salicylic acid poisoning.
The pH-partition theory can be applied to the distribution of
salicylate between blood and brain. Elevation of blood pH will tend
to reduce the concentrations in the brain and the administration of
sodium bicarbonate (alkali alone) has been used for the treatment of
salicylate poisoning in children (Temple, 1978; Done, 1978).
The positive fluid balance and weight gain (both at the end of
infusion and 12 hours later) was much less with alkali alone than
with forced diuresis and forced alkaline diuresis (but not forced
alkaline diuresis with frusemide). This is in good agreement with
previous reports (Lawson et al., 1969; Savage et al., 1969; Temple
et al., 1976; Berg, 1977b) although weight gain (perhaps a more reli¬
able index of fluid retention than fluid balance) was not mentioned.
All the changes in haematological and biochemical measurements were
consistent with significant fluid retention and haemodilution during
infusion in the forced diuresis, but not alkali alone groups.
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Fluid retention caused by attempts to induce a diuresis rarely
seems to cause serious problems in patients with salicylate poisoning.
However, forced diuresis is not without risk and can cause serious
problems in the elderly and in patients with cardiac and renal disease
(Prescott, 1974). Furthermore, serious and sometimes fatal pulmonary
and cerebral oedema has often been reported in patients with aspirin
poisoning who were subjected to treatment by diuresis (Proudfoot and
Brown, 1969; Ferguson and Boutros, 1970; Whitehall, 1973; Tweedale,
1974; Davis and Burch, 1974; Broderick et al., 1976; Heffner et al.,
1979). It is clearly dangerous and unnecessary to use a forced
diuresis regime when better results can be obtained simply and more safely
by administration of alkali alone.
Different amounts of sodium, potassium and chloride were admini¬
stered in the different treatment regimes, but the plasma sodium and
potassion concentrations did not change significantly and there were
no significant differences between the groups.
Hypocalcaemia occurred in all groups of patients, but there were
no obvious clinical symptoms or signs and the plasma calcium concen¬
trations eventually returned to normal spontaneously. The most
marked falls occurred with forced alkaline diuresis, forced alkaline
diuresis plus frusemide and forced diuresis while the least effect was
observed with the control and alkali alone groups.
The fall in plasma phosphate concentrations was greatest with the
diuresis regime , possibly because of the additional effects of dex¬
trose itself (Guillou et al., 1976), and least with alkali alone.
Aspirin overdosage itself produces a fall in plasma phosphate concen¬
trations, since similar but less marked changes occurred in the control




As expected the mean plasma osmolality on admission was above
the normal range in all groups and the subsequent fall was more
marked with the diuresis regimes. Other investigators have reported
similar findings (Morgan et al., 1968; Berg, 1977b).
The plasma total CO^ concentration on admission was abnormally
low in all groups of patients, but there was rapid improvement with
the alkalinisation regimes particularly alkali alone. However,
forced diuresis had the opposite effect. The low plasma CO^ concen¬
trations presumably reflect respiratory alkalosis, although in some
patients there may also have been a contribution from metabolic
acidosis.
(g) Urinary sodium excretion and renal function
The low urinary excretion of sodium in the patients with aspirin
poisoning is consistent with its well known inhibitory effects on
renal medullary prostaglandin synthesis (Kimberly et al., 1979;
Plotz and Kimberly, 1981). The acute effects of therapeutic doses of
aspirin on renal function are thought to be reversible, but other renal
homeostatic mechanisms such as induction of antidiuretic hormone may
also be involved (Plotz and Kimberly, 1981). Inhibition of prosta¬
glandin E synthesis has been proposed as the mechanism of acute
impairment of renal function observed in patients given aspirin
(Kimberly et al., 1979; Moncada et al., 1980). However, therapeutic
doses of aspirin also produce acute proximal tubular injury (Prescott,
1980). Salicylic acid is as active as aspirin in inhibiting prosta¬
glandin synthesis while in vitro it is much less active (Smith et al.,
1979). This suggests that salicylic acid undergoes metabolic activ¬
ation and in this context it should be noted that gentisic acid is a
much /
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much more potent inhibitor than salicylic acid (Shen, 1979). Sali¬
cyluric acid is apparently inactive, while 4-amino-salicylic acid
has the same activity as aspirin (Flower, 1974). These differences
must be interpreted with caution however, because of marked species
and organ differences in susceptibility to inhibition of prostaglandin
synthesis by different compounds..
Prostaglandin E dilates renal medullary arterioles and increases
blood flow to the inner cortex at the expense of the outer cortex,
while prostaglandin F2^and thromboxane A^ reduce renal blood flow.
Prostaglandins inhibit the effects of antidiuretic hormone on the collec¬
ting ducts and also inhibit the reabsorption of sodium from the renal
tubules and collecting ducts (Plotz and Kimberly, 1981). The inhibi¬
tion of synthesis of renal prostaglandins by aspirin probably accounts
for the fluid retention"and reduced sodium excretion observed follow¬
ing overdosage and these effects are probably due to reduced renal
blood flow and glomerular filtration rate (Berg, 1977a, 1977b; Smith
et al., 1979; Kimberly et al., 1979). However, these actions alone
are unlikely to explain the low creatinine clearance which was observed
in half of the patients with aspirin poisoning. Acute tubular necrosis
and renal failure are recognised complications of salicylate poison¬
ing (Krasnoff and Bernstein, 1947) and even in therapeutic doses,
aspirin produces acute tubular damage in man as indicated by a
striking increase in the urinary excretion of renal tubular cells
(Scott et al., 1963; Prescott, 1965) The fluid and sodium retention
and markedly reduced creatinine clearance in some patients with
aspirin poisoning is probably due to a combination of medullary





There were surprisingly few clinically significant abnormalities
of haemostasis following aspirin overdosage. Although the mean
bleeding time was significantly higher in the patients than in the
healthy volunteers given a dose of 20 mg/kg, the values were still
within the normal range (Ivy et al., 1940). Fibrinogen degradation
products were raised in 5 patients, suggesting mild disseminated
intravascular coagulation, a complication which has been observed
previously (Sbarbaro and Bennett, 1977).
The inhibition of platelet aggregation was no different from
that observed following therapeutic doses of aspirin (Mills et al.,
1979; Miekle et al., 1980). Finally, the mild prolongation of the
prothrombin time was of no clinical significance. This effect has
often been described following chronic high dose salicylate therapy
(Goldsweig et al., 1976). There is clearly no indication for the
routine use of vitamin K in aspirin poisoning as was recommended in





(a) Studies with aspirin and diflunisal in healthy volunteers
1. The absorption, metabolism and renal excretion of acetyl salicylic
acid was studied in 6 healthy male volunteers following a single oral
dose of 20 mg/kg aspirin in solution. The study was then repeated
under conditions of alkaline diuresis induced by oral administration
of sodium bicarbonate (3 g 4 times daily).
2. Aspirin was rapidly absorbed with peak plasma acetyl salicylic
acid concentrations of 17 yg/ml and 15 ug/ml at 15 and 30 minutes with
and without sodium bicarbonate, respectively. Acetyl salicylic acid
was rapidly hydrolysed to salicylic acid and only 1-2% of the dose
was excreted unchanged in the urine.
3. The mean plasma salicylic acid half-life was 3.56 ± 0.89 and
5.66 ± 1.48 hr with and without alkaline diuresis respectively
(p < 0.05). There was a corresponding increase in the total body
clearance of salicylic acid and this was due entirely to the pH-
dependent increase in renal clearance of salicylic acid. There was
a highly significant correlation between the renal clearance of
salicylic acid (corrected for flow rate) and urine pH.
4. The plasma concentrations of salicyluric acid were very low
(< 10 ug/ml) and the renal clearance very high (567 ± 84 and 443 ±
117 ml/min with and without alkaline diuresis, respectively).
5. The pattern of urinary excretion of acetyl salicylic acid and
its metabolites depends on the urine pH. In the control study, 1.2%
of the dose was excreted as acetyl salicylic acid, 8.3% as salicylic
acid /
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acid and 62% as salicyluric acid, whereas the corresponding values
with alkaline diuresis were 2%, 38% and 42.3% respectively. The mean
ratio of the urinary recovery of salicylic to salicyluric acid was
0.13 in the control study and 0.90 with alkaline diuresis.
6. A1kalinisation of the urine significantly enhanced the urinary
excretion of salicylic acid and reduced the plasma salicylic acid
half-1ife.
7. Similar studies were carried out in 6 healthy volunteers with
diflunisal (difluoro-phenyl salicylic acid). This compound is
extensively bound to plasma proteins and largely metabolised by
glucuronide conjugation.
8. Administration of sodium bicarbonate significantly increased the
renal clearance and excretion of diflunisal, but had no effect on
the plasma half-life and area under the plasma concentration-time
curves. There was no significant correlation between the renal
clearance of diflunisal and urine pH or flow rate, but the renal
clearance increased with time and declining plasma concentrations of
the drug.
(b) Studies in patients with aspirin overdosage
1. Serial plasma and urine concentrations of acetyl salicylic,
salicylic and salicyluric acids were measured (using high performance
liquid chromatography) in 50 patients with mild to severe aspirin
poisoning. The patients received either oral fluids only (controls)
or one of four intravenous regimes of fluid and alkali (over 3 hr) to
establish the relative importance of urine pH and flow rate on sali¬
cylate elimination. Sixteen patients were treated with forced
alkaline diuresis (6 L of isotonic dextrose and saline solution
containing /
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containing 18.9 g of sodium bicarbonate and 9 g of potassium chloride),
6 with forced diuresis (as above, but without the sodium bicarbonate),
6 with forced alkaline diuresis plus frusemide (the same regime as
forced alkaline diuresis plus 80 mg of frusemide intravenously) and 6
with alkali alone (1.5 litres of 1.26% sodium bicarbonate containing
4.5 gm of potassium chloride).
Serial measurements were made of fluid balance, weight changes,
haematocrit and plasma and urinary osmolality together with concen¬
trations of electrolytes and creatinine. In addition, serial meas¬
urements were made of the plasma concentrations of urea, albumin
total protein, calcium, magnesium, phosphate and urate, together with
liver function tests. The effects of aspirin on haemostasis were
compared in the overdose patients and healthy volunteers given a
single oral dose of 20 mg/kg.
The clinical manifestations of salicylate poisoning were assessed
on admission and 4 and 12 hours later.
The binding of salicylic acid to plasma proteins and albumin was
studied in vitro and in the patients with aspirin overdosage using an
ultrafiltration technique.
2. The absorption of acetyl salicylic acid was delayed despite
gastric aspiration and lavage in some patients as judged by the
persistence of acetyl salicylic acid in the plasma and in some cases,
increasing plasma concentrations of salicylic acid. Presumably,
there was slow dissolution of tablets and/or delayed gastric emptying.
3. In the 16 control patients the mean salicylic acid plasma half-
life was 30 ± 9 hours. Glycine conjugation of salicylic acid was
saturated as shown by low and relatively constant plasma concentra¬
tions of salicyluric acid (1-10 ug/ml). The mean total body clearance
of salicylic acid was only 5.4 ± 1.9 ml/min compared with 23.2 ± 5.1
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ml/min in the healthy volunteers. The mean renal clearance of sali¬
cylic acid (1.4 ± 1.4 ml/min) was also less than that of the healthy
volunteers (2.2 ± 1.4 ml/min). The mean renal clearance of salicyl¬
uric acid was similar (493 ± 317 ml/min).
The mean urinary recovery of salicylic acid over the first 16
hours was very low (376 ± 320 mg) while 1116 ± 549 mg of salicyluric
acid was excreted over that period. The mean ratio of urinary
recovery of salicylic to salicyluric acid was 0.48.
4. In the patients given different regimes of fluid and alkali,
there was a rapid fall in plasma salicylic acid concentrations during
the infusions. The mean plasma half-life values during the first 4
hours were 8.5, 6.6, 6.4 and 5.1 hours in the forced diuresis, forced
¥
alkaline diuresis plus frusemide, forced alkaline diuresis and alkali
alone groups, respectively. This fall in plasma salicylic acid con¬
centrations could not be accounted for (except in the patients given
alkali alone) by enhanced urinary salicylate excretion. The amounts
of unchanged salicylic acid recovered in the urine during the first
4 hours were 162, 437, 2171, 1551 and 2435 mg in the control, forced
diuresis, forced alkaline diuresis plus frusemide, forced alkaline
diuresis and alkali alone groups, respectively.
5. The rapid fall in plasma salicylic acid concentrations during
the infusion was due in part to haemodi1ution as shown by fluid
retention, weight gain and reduction in the haematocrit, and plasma
concentrations of albumin, calcium, magnesium, phosphate, urate and
salicyluric acid. The mean plasma osmolality on admission was
abnormally high in all groups. The mean values were within the normal
range 4 hours after admission except in the forced diuresis group in
whom the mean plasma osmolality at 4 and 12 hours was 275 and 278
mmol/kg respectively. Fluid retention was minor in the control
patients /
292
patients and in those given alkali alone and forced alkaline diuresis
with frusemide, and most marked in those given forced diuresis and
forced alkaline diuresis. There may also have been changes in the
distribution of salicylic acid, although it was not possible to show
that the apparent volume of distribution was increased by treatment.
Changes in the apparent plasma half -life of salicylic acid
during forced alkaline diuresis are often used as an index of the efficacy
of removal of the drug following overdosage. This is clearly inappro¬
priate. In the patients given forced diuresis the fall was due
almost entirely to haemodilution while in those given alkali alone
the fall corresponded exactly to that predicted from the increased
urinary excretion of salicylic acid.
6. During the 12 hours after the infusion was completed, there were
«
marked differences in the plasma salicylic acid half-lives of the
different treatment groups. The mean plasma half-life in the patients
given forced diuresis was 30.6 hours - virtually the same as in the
control patients (30.1 hours). The mean urine flow rate in the former
group was 5.8 ml/min compared with 1.4 ml/min in the controls.
Diuresis alone was clearly ineffective in enhancing the elimination of
salicylic acid.
The mean plasma salicylic acid half-lives over the period of
4-16 hours in the patients given forced alkaline diuresis, forced
alkaline diuresis plus frusemide and alkali alone were 11.6, 14.1 and
9.1 hours, respectively. Alkali alone appeared to be the most
effective treatment.
7. The mean urinary recovery of unchanged salicylic acid during the
first 16 hours was 1529, 3432, 3460 and 3871 mg with forced diuresis,
forced /
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forced alkaline diuresis plus frusemide, forced alkaline diuresis
and alkali alone, respectively. Thus the urinary excretion of sali¬
cylic acid was inversely related to the plasma half-life in the
different treatment groups. The urinary recovery of salicylic acid
was greatest in the alkali alone group.
8. There were marked changes in the pattern of urinary excretion of
acetyl salicylic acid metabolites in the different groups. The excre¬
tion of salicyluric acid was similar in all groups, reflecting satur¬
ation of glycine conjugation of salicylic acid. On the other hand,
the proportion of the total excreted as salicylic acid depended on
the urine pH. The ratios of the urinary recovery of salicylic to
salicyluric acid over the first 16 hours after admission were 1.93,
3.23, 4.54 and 4.40 with forced diuresis, forced alkaline
diuresis plus frusemide; forced alkaline diuresis and alkali alone
respectively.
9. The mean renal clearances of salicylic acid over the first 16
hours were 4.4, 13, 18 and 24 ml/min with the forced diuresis, forced
alkaline diuresis plus frusemide, forced alkaline diuresis and alkali
alone groups, respectively.
10. The renal clearance of salicylic acid was highly dependent on
urine pH and there were highly significant correlations between the
renal clearance, urine pH and plasma half-life. The highest mean
urine pH was obtained with alkali alone (8.1) and the lowest (6.5) with
the forced diuresis regime.
11. The renal clearance of acetyl salicylic acid, but not salicyluric
acid was correlated with urine pH. The mean renal clearance of sali¬
cyluric acid was 454 ml/min and there were no significant differences
between the control and treatment groups.
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12. Multiple regression analyses gave regression coefficients for
urine pH against the ratio of urine to plasma salicylic acid con¬
centration which were 0.53, 0.49, 0.32, 2.06 and 6.26 for the control,
forced diuresis, forced alkaline diuresis plus frusemide, forced
alkaline diuresis and alkali alone groups, respectively. Thus, for
each increase of one unit in urine pH, the ratio of urine to plasma
salicylic acid concentrations increased 6.26 fold in the alkali
alone group, 2.06 fold in the forced alkaline diuresis and much less
in the other three groups. Paradoxically, the regression coefficiants
for flow rate were all negative and changes in flow rate had no
marked effect on salicylate elimination.
13. The binding of salicylic acid to plasma proteins decreased as
the plasma salicylate concentrations increased both in vitro and in
vivo. Thus the percentage unbound rose from approximately 20% at a
total plasma salicylate concentration of 100 yg/ml to 75% at 600 ug/ml.
This finding is of major toxicological significance since the tissue
(including central nervous system) salicylate concentration closely
reflects the unbound salicylic acid concentration in plasma. The
binding of salicylic acid to albumin accounted for about half of the
total binding to plasma proteins.
14. Tinnitus was present in 91% of all patients on admission and
correlated well with plasma salicylic acid concentrations. Subjec¬
tive deafness occurred in 63% patients, while sweating, hyperventil¬
ation, nausea, vomiting, epigastric pain/tenderness and flushing
occurred in 33% - 56% of the patients.




15. Although different amounts of sodium, potassium and chloride
were given in the different treatment regimes, there were no signifi¬
cant differences in the plasma sodium and potassium concentrations
between the groups and no significant changes during the infusion in
any of the groups.
16. The urinary sodium excretion was very low in the control patients
(50 mmol/24 hr), but not in the treated groups, presumably because of
the sodium administered during the infusion. Similarly, the urinary
potassium excretion was normal in the control patients, but increased
in the treated groups.
17. The creatinine clearance was less than 100 ml/min in 15 of the
30 patients in whom it was measured. The lowest value was 18 ml/min
in a 21 year old female and in 9 (30%) the creatinine clearance was
75 ml/min or less. The established nephrotoxicity of salicylate
together with the reduction in medullary blood produced by inhibition of
prostaglandin E synthesis probably account for the marked fluid retention
which occurs when attempts are made to force a diuresis in patients
with aspirin poisoning.
18. The adverse effects of acetyl salicylic acid on haemostasis were
similar in the healthy volunteers given a dose of 20 mg/kg and in
the overdose patients. However, the bleeding time was increased to a
greater extent following overdosage and in 5 patients there was
evidence of disseminated intravascular coagulation.
19. Of the different regimes of fluid and alkali studied for the
treatment of aspirin poisoning, administration of 1.5 litres of 1.26%
sodium bicarbonate alone was the simplest, most effective and probably
safest. It produced the greatest fall in plasma salicylate concen¬
trations, the biggest increase in the renal clearance and urinary
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excretion of salicylic acid and the most rapid relief of the symptoms
and signs of poisoning. Unlike forced diuresis and forced alkaline
diuresis, it did not cause fluid retention and weight gain and there
were no significant biochemical disturbances. The addition of
frusemide to the standard regime of forced alkaline diuresis did not
increase salicylate elimination and forced diuresis was virtually
ineffective.
Administration of sodium bicarbonate without excessive fluid
appears to be the treatment of choice for aspirin poisoning and
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APPENDIX I
INDIVIDUAL PLASMA CONCENTRATIONS AND
URINARY EXCRETION DATA



































































































































































































































































































































































4 - 6 110 5.6 5.13 1168 11.1
6 - 8 130 5.5 5.57 811 N.D.*
8 - 10 95 5.6 5.22 1012 N.D.
10-15 265 6.3 47.0 976 N.D.
15-24 585 6.4 25.5 531 N.D.
M.B. 0 - 2 60 6.9 237 1162 189
with 2.-4 790 7.3 75.4 156 N.D.
NaHC03 4 - 6 940 6.9 42.3 105 N.D.
6 - 8 400 7.5 171 204 N.D.
8-10 305 7.4 148 250 N.D.
10 - 12 580 7.2 148 68 N.D.
12-24 1495 7.5 133 44 N.D.-
M.L. 0 - 2 36 5.9 18.6 1969 143
Control 2 - 4 115 6.0 15.4 1125 12.3
4 - 6 107 7.1 192 1078 N.D.
6 - 8 85 6.5 125 1221 N.D.
8 - 10 290 5.9 18.7 391 N.D.
10-12 205 7.4 89.6 567 N.D.
12-24 600 6.6 28.0 454 N.D.
M.L. 0 - 2 130 7.9 475 742 169
with 2 - 4 1640 7.5 79.7 75.0 N.D.*
NaHC03 4 - 6 410 7.7 174 267 N.D.
6 - 8 1236 7.6 40.3 71 .2 N.D.
8 - 10.5 1130 7.8 25.1 66.5 N.D.
10.5 - 12 1000 7.7 13.5 38.2 . N.D.
12-24 2115 7.6 5.26 24.4 N.D.
* not detectable
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J.C. 0-2 150 5.8 21.6 474 55.5
Control 2-4 96 5.9 32.2 1011 43.5
4-6 72 7.1 301 2338 N.D.*
6-8 135 7.4 301 757 N.D.
8-10 158 6.2 40.5 502 N.D.
10-12 310 5.9 19.4 559 N.D.
12-24 480 6.1 26.2 531 N.D.
J.C. 0-2 270 7.4 192 327 90.2
with 2-4 800 7.3 106 134 N.D.
NaHC03 4-6 505 7.9 217 224 N.D.
6-8.5 580 8.0 198 314 N.D.
8.5-11 117 7.7 156 696 N.D.
11-12 242 7.4 19.1 149 N.D.
1 12-24 2780 7.3 N.D. 27.6 N.D.
H.R. 0-2 57 6.6 348 1569 352
Control 2-4 70 6.4 186 1523 11.6
4-6 26 8.0 744 814 3.40
6-8 25 6.7 145 793 N.D.
8-10 106 7.0 181 756 N.D.
10-12- 96 6.3 49 823 N.D.
12-24 445 6.1 15.5 442 N.D.
H.R. 0-2 95 7.8 947 889 313
with 2-4 252 7.6 251 395 5.75
NaHC03 4-6 195 7.8 415 566 N.D.
6-8 245 7.7 179 303 N.D.
8-10 1185 7.4 126 50.3 N.D.
10-12 685 7.4 21 .3 79.6 N.D.
12-24 1620 7.2 5.56 51 .3 N.D.
* not detectable
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R.A. 0-2 80 5.4 54.2 2186 85.7
Control 2-4 55 5.6 25.3 2333 7.4
4-6 75 5.2 10.7 2161 N.D. *
6-8 78 5.3 7.30 1775 N.D.
8-10.25 135 5.6 4.02 1136 N.D.
10.25-12 116 6.7 33.4 811 N.D.
12-24 440 6.0 17.6 610 N.D.
R.A. 0-2 130 8.0 335 719 169
with 2-4 650 7.4 85.5 179 N.D.
NaHC03 4-6 1860 7.5 46.0 59.2 N.D.
6-8 1780 7.3 37.6 55.0 N.D.
8-10 1610 7.4 23.0 54.2 N.D.
10-12 1260 7.6 20.3 58.0 N.D.
/
12-24 835 7.0 11.5 106 N.D.
I. K. 0-2 92 7.8 604 1111 395
Control 2-4 110 7.0 199 1093 5.65
4-6 100 7.1 315 1061 N.D.
6-8 184 7.1 182 613 N.D.
8.10 212 6.8 91 .0 382 N.D.
10-12 560 7.1 28.3 123 N.D.
12-24 645 6.3 10.8 198 N.D.
I. K. 0-2 285 7.9 387 327 153.4
wi th 2-4 680 7.4 150 184 N.D.
NaHC03 4-6 1450 7.6 86.4 99.5 N.D.
6-8 1480 7.4 30.6 56.3 N.D.
8-10 470 7.5 53.5 137 N.D.
10-12 800 7.3 7.90 41 .0 N.D.




















































































































Hours Control with NaHC03
Subject after Dif 1 uni sal Dif1unisal
ingestion concen¬ concen¬
Volume pH tration Volume PH tration
(ml) (ug/ml) (ml) (pg/ml)
M.B. 0- 2 50 5.6 6.8 56 8.6 26.3
2- 4 25 5.9 14.2 160 6.1 7.0
4- 6 70 5.8 5.9 120 6.6 11.7
6- 8 150 5.6 4.2 150 7.3 23.1
8-10 170 5.4 3.0 300 6.6 5.4
10-12 260 5.8 3.0 690 7.1 3.3
12-24 450 5.7 7.4 2610 7.4 7.6
24-36 420 5.6 6.5 2200 7.7 6.4
36-48 490 6.6 3.6 1720 7.7 8.1
48-60 540 5.8 3.0 1750 7.6 4.1
60-72 750 5.6 1.5 790 6.2 2.3
I.K. 0- 2 285 5.9 2.0 290 8.2 5.1
2- 4 65 5.9 7.7 750 7.8 3.2
4- 6 65 7.0 16.0 640 7.8 5.1
6- 8 126 7.4 11.5 600 7.6 4.2
8-10 112 6.5 3.0 640 7.2 2.7
10-12 70 6.1 2.0 615 7.9 6.0
12-24 640 5.7 3.7 730 7.2 12.7
24-36 '860 6.8 3.8 3635 7.9 2.9
36-48 1340 6.5 1 .6 730 7.7 7.3
48-60 1160 7.0 2.0 1040 7.8 6.3
60-72 1100 7.3 0.9 810 6.5 1 .4
H.R. 0- 2 76 6.2 2.6 45 8.0 31
2- 4 46 5.9 12.0 30 6.8 22.7
4- 6 48 5.8 7.4 65 6.5 9.6
6- 8 170 5.8 3.2 120 7.0 12
8-10 160 6.5 3.6 70 8.1 18.4
10-12 96 6.1 5.2 130 8.7 22.7
12-24 500 5.9 5.2 860 8.1 6.9
24-36 985 6.7 2.4 1600 8.2 3.8
36-48 1100 7.3 3.4 1890 7.1 0.53
48-60 870 6.4 1 .5 1470 7.7 0.4
60-72 630 6.1 1 .0 910 6.6 0.2
B.M. 0- 2 70 6.0 5.2 120 8.6 13.1
2- 4 174 6.5 8.3 178 7.9 17.7
4- 6 236 7.1 11.2 1150 7.5 2.7
6- 8 206 6.8 8.7 950 7.5 2.7
8-10 89 6.0 19.3 290 7.4 10.0
10-12 65 5.7 17.5 475 7.7 9.2










Volume pH tration Volume pH tration
(ml) (ug/ml) (ml) (yg/ml)
B.M. 12-24 417 5.8 16.8 1490 7.5 9.8
(Cont'd) 24-36 245 5.5 23.9 3805 7.4 2.2
36-48 385 5.8 7.8 960 7.6 2.4
48-60 237 5.6 7.4 2040 7.4 1 .6
60-72 495 6.5 3.5 660 6.9 2.2
M.K. 0- 2 65 7.5 7.2 110 8.6 5.2
2- 4 95 6.9 14.4 60 8.8 91 .8
4- 6 76 6.5 19.8 95 8.2 85.5
6- 8 38 6.8 16.5 180 7.7 24.1
8-10 25 6.5 18.2 520 7.7 8.0
10-12 25 6.1 18.0 1170 7.6 2.8
12-24 520 6.0 13.8 1540 7.3 8.7
24-36 1100 7.1 8.1 2130 7.7 8.0
36-48 800 6.8 5.8 2420 7.5 1 .0
48-60 380 6.0 7.4 1010 7.3 1 .4
60-72 920 7.3 2.7 925 7.1 0.8
R.A. 0- 2 121 7.3 5.4 75 8.2 18.9
2- 4 70 7.2 30.8 425 7.1 3.9
4- 6 70 6.2 13.7 1025 7.2 1.9
6- 8 76 5.7 8.65 1160 7.2 1.8
8-10 73 5.6 13.9 540 7.1 4.6
10-12 53 5.5 8.9 1185 7.4 3.3
12-24 415 5.8 16.3 1245 6.8 7.3
24-36 750 6.7 6.1 4140 7.6 4.0
36-48 505 7.2 9.7 1935 6.8 2.8
48-60 530 6.5 3.5 1120 7.1 2.5
60-72 990 6.2 2.0 640 6.1 2.3
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE
CONTROL
Patient Hours









1 3 243 3.3 28
4 290 4.9 25
5 320 3.8 22
6 350 3.6 20
7 390 3.6 N.D.*
11 355 3.6 N.D.
15 302 3.6 N.D.
17 295 3.6 N.D.
23 238 3.6 N.D.
35 163 3.3 N.D.
4 6 290 1.9 N.D.
7.50 250 2.62 N.D.
15.25 192 2.89 N.D.
22.50 170 2.90 N.D.
6 2.83 296 1 .9 6.3
3.25 318 1.9 4.6
3.92 329 2.0 1 .8
4.83 306 1.7 N.D.
5.83 282 1 .8 N.D.
8 252 1.8 N.D.
17.66 205 2.4 N.D.
7 4 308 2.5 N.D.
4.92 314 3.02 N.D.
5.92 292 4.0 N.D.
8.42 263 4.1 N.D.
17.25 197 3.9 N.D.
21 172 4.0 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND














8 8.16 363 3.17 N.D.*
10.75 317 2.75 N.D.
13.5 303 2.93 N.D.
22.75 231 2.51 N.D.
25.83 233 3.23 N.D.
9 8 364 3.44 N.D.
9 435 2.89 N.D.
13 299 1 .59 N.D.
24.75 233 3.82 N.D.
29.58 201 4.27 N.D.
13 2 264 3.0 24.3
3 277 2.8 8.9
4.16 272 2.64 4.2
7.16 272 2.88 3.3
16.66 227 3.24 N.D.
16 3.5 391 4.47 N.D.
5.25 327 4.38 N.D.
6.5 272 2.66 N.D.
10.75 260 3.36 N.D.
14.58 226 3.48 N.D.
34.25 122 3.72 N.D.
34 3.25 328 2.29 5.0
4.25 373 2.54 N.D.
5.25 339 2.46 N.D.
8.25 258 2.02 N.D.
12.25 233 3.0 N.D.
14.58 231 3.06 N.D.
16.93 207 3.17 N.D.
20.50 177 3.20 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND














35 3 276 2.44 N.D.*
3.5 280 3.14 N.D.
5 254 2.88 N.D.
10.5 212 3.65 N.D.
13.5 215 4.24 N.D.
16 178 4.3 N.D.
22 157 4.3 N.D.
36 16.42 336 1 .85 N.D.
17.58 316 1.80 N.D.
21.16 299 1.81 N.D.
23.83 258 1.87 N.D.
32.33 235 2.65 N.D.
35.58 186 2.17 N.D.
43 14 441 4.70 N.D.
14.66 453 5.06 N.D.
16 384 3.15 N.D.
17.25 387 3.73 N.D.
18.75 385 3.51 N.D.
22 366 4.63 N.D.
24 362 4.56 N.D.
26.5 324 4.59 N.D.
36.5 235 4.41 N.D.
48.5 119 3.17 N.D.
60 14.30 2.21 N.D.
45 12.75 319 1.47 3.5
13.25 333 1 .71 2.96
13.92 338 1 .94 3.14
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND


















































































































PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND











52 3.5 334 1.52 N.D*
5 345 1.60 N.D.
10.25 279 1.47 N.D.
13.5 270 1.90 N.D.
19 235 1.91 N.D.
25 221 2.02 N.D.
31.5 140 1.80 N.D.
41.5 112 1.87 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AMD




No. after Salicylic Salicyluric Acetyl salicylic
ingestion acid acid acid
2 8.0 467 2.51 N.D.*
9.0 380 1.90 N.D.
10.0 288 2.00 N.D.
11.0 225 2.11 N.D.
15.0 146 2.30 N.D.
17.25 101 2.81 N.D.
21.0 50.7 2.50 N.D.
35.5 N.D. N.D. N.D.
3 4.75 473 2.15 11.3
• 5.75 244 1 .34 N.D.
6.75 302 2.08 N.D.
11.25 257 1.88 N.D.
23.00 129 1 .66 N.D.
46.33 7.7 0.81 N.D.
5 3.58 451 3.6 8.2
4.67 467 5.1 N.D.
5.5 438 4.2 N.D.
7.5 331 3.3 N.D.
10 282 2.91 N.D.
11 262 3.22 N.D.
12.5 236 3.33 N.D.
14.5 205 3.91 N.D.
18.5 152 2.60 N.D.
26.5 74.3 2.42 N.D.
38 9.1 1 .50 N.D.
10 17.25 556 6.54 7.38
17.67 571 7.05 5.48
18.67 513 5.38 N.D.
19.75 449 4.62 N.D.
21 .17 368 4.27 N.D.
21 .83 364 4.94 N.D.
24 322 5.13 N.D.
26.17 291 5.96 N.D.
31.17 246 7.24 N.D.
31.5 251 7.69 N.D.
36.17 235 7.26 N.D.
14 8.75 529 1 .90 N.D.
10.50 380 1 .61 N.D.
11 .50 282 1 .03 N.D.
13.25 211 1 .61 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE
FORCED ALKALINE DIURESIS
PIasma concentrations (yg/ml)
Patipnt Hni ir Qi u l 1 ci 1 l i 1 w Li I j
No. after Salicylic Salicyluric Acetyl salicylic
ingestion acid acid acid
14 15.25 165 1.70 N.D.*
(Cont'd) 17.42 121 2.11 N.D.
32.33 41.5 1.61 N.D.
34.00 37.6 1.90 N.D.
15 8.00 386 4.1 N.D.
9.17 381 3.23 N.D.
9.93 362 3.33 N.D.
12.75 221 2.70 N.D.
15.00 151 2.65 N.D.
17.75 136 3.17 N.D.
39.00 2.8 0.8 N.D.
17 4.5 613 4.40 13.4
5.67 586 4.21 37.5
6.75 585 2.82 39.7
8.67 526 2.69 8.0
14.5 302 3.01 N.D.
19.0 211 3.09 N.D.
23.0 149 3.39 N.D.
27.25 115 3.71 N.D.
43.5 5.30 1 .49 N.D.
19 1 .75 335 1 .78 26.7
1 2.75 338 1.70 13.1
4.5 366 1 .63 9.1
5.75 277 1 .38 3.1
7.5 271 1 .75 8.4
9.5 221 1 .42 3.6
19.83 210 2.26 N.D.
20 1 .83 285 1.0 3.3
4.75 491 0.88 11.0
6.17 441 0.78 3.4
7.5 333 0.77 N.D.
9.0 247 0.75 N.D.
12.5 180 0.77 N.D.
17.17 130 0.91 N.D.
31 .75 70.6 1 .01 N.D.
21 4.0 399 3.28 N.D.
4.67 402 3.26 N.D.
7.0 296 2.83 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE
FORCED AL (ALINE DIURESIS
PIasma concentrations (ug/ml)
Patient Hours
No. after Salicylic Salicyluric Acetyl salicylic
ingestion acid acid acid
21 8.0 296 2.45 N.D.*
(Cont'd) 9.0 200 2.55 N.D.
14.5 92.5 3.23 N.D.
22 9.5 397 3.59 N.D.
10.5 358 3.01 N.D.
11.33 375 1.92 N.D.
12.42 289 2.35 N.D.
13.33 245 2.31 N.D.
14.33 162 1 .93 N.D.
*
15.33 125 2.50 N.D.
16.33 118 2.54 N.D.
18.0 101 2.51 N.D.
36.5 7.60 1 .41 N.D.
23 5.17 271 1.11 4.7
7.5 133 1.08 3.8
18.5 63.0 2.45 N.D.
24 8.83 506 3.48 N.D.
10.0 455 4.22 N.D.
12.0 436 4.01 N.D.
14.0 330 2.90 N.D.
16.0 287 2.72 N.D.
25.0 283 5.30 N.D.
26.33 263 4.47 N.D.
30.5 265 5.64 N.D.
49.75 143 3.62 N.D.
25 12.5 390 3.11 N.D.
13.5 375 2.52 N.D.
14.5 302 1 .82 N.D.
15.75 229 1 .54 N.D.
17.0 180 1 .61 N.D.
18.75 137 1.60 N.D.
20.0 117 1.40 N.D.
24.42 89.0 2.15 N.D.
35.75 25.3 1 .72 N.D.
48.0 N.D. N.D. N.D.
61 .0 N.D. N.D. N.D.
26 11 .83 495 3.89 N.D.
12.83 365 2.30 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE
FORCED ALKALINE DIURESIS
Plasma concentrations ( jg/ml)
Patient Hours
No. after Salicylic Salicyluric Acetylsalicylic
ingestion acid acid acid
26 13.83 312 2.04 N.D.*
(Cont'd) 15.0 244 2.14 N.D.
16.0 218 2.31 N.D.
18.08 160 2.11 N.D.
21 .17 122 2.48 N.D.
35.83 18 2.04
41 21 .5 657 6.09 N.D.
23.5 547 3.55 N.D.
24.75 490 3.00 N.D.
26.5 491 2.80 N.D.
26.75 480 2.76 N.D.
27.5 447 2.93 N.D.
31 .5 403 2.66 N.D.
35.5 360 2.93 N.D.
40.33 335 3.12 N.D.
49 295 2.74 N.D.
63.17 178 3.25 N.D.
67.5 173 3.65 N.D.
*
not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND




No. after Salicylic Salicyluric Acetyl salicylic
ingestion acid acid acid
27 6 470 2.68 N.D.*
7.33 406 2.56 N.D.
8.5 385 2.52 N.D.
9.33 382 2.56 N.D.
11 342 2.25 N.D.
13 313 2.13 N.D.
18.5 297 2.45 N.D.
23.25 286 2.49 N.D.
32.5 182 2.38 N.D.
-
42.66 128 2.65 N.D.
29 2.66 330 2.2 20.7
3.66 378 2.7 25
6 311 1.9 3.25
7 278 1.6 N.D.
9.25 227 1 .85 N.D.
10.92 209 1 .85 N.D.
12.5 198 2.22 N.D.
20.25 185 2.75 N.D.
24.25 163 4.04 N.D.
30 8.5 422 3.7 N.D.
12 279 2.5 N.D.
17.33 251 2.33 N.D.
1
31 4 540 2.65 6.78
4.75 509 2.55 3.95
5.92 460 2.08 6.9
7.25 450 1 .98 4.3
8.42 384 1 .88 2.6
10 380 2.14 N.D.
14.83 323 2.07 N.D.
17.58 306 2.11 N.D. .
20.5 281 2.51 N.D.
29.25 206 3.16 N.D.
39.75 161 3.39 N.D.
32 2.67 482 2.75 6.8
3.33 452 2.4 4.5
4.75 362 1 .95 N.D.
6.5 303 2.04 N.D.
8 258 2.56 N.D.
13.17 244 2.51 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AMD

























33 2 532 4.84 6.5
3 482 4.0 2.6
4 414 3.54 N.D.
5 396 4.65 N.D.
7 366 5.54 N.D.
8.17 373 4.45 N.D.
10.5 343 4.01 N.D.
25 249 7.25 N.D.
30 189 5.72 N.D.
* not detectable
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PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND














37 4 475 4.2 3.1
4.83 474 3.6 3.2
6 459 3.2 N.D.*
7 353 3.6 N.D.
8 325 3.8 N.D.
10.83 242 3.3 N.D.
11.83 244 3.4 N.D.
13.93 184 4.1 N.D.
23.75 106 4.4 N.D.
38 1 394 2.7 17.4
1.75 413 2.2 6.3
3.25 329 1 .9 N.D.
4.25 315 2.0 N.D.
5.25 212 2.4 N.D.
7.75 226 2.4 N.D.
13.25 175 2.6 N.D.
15.42 174 2.7 N.D.
18.58 167 2.9 N.D.
21 .75 126 3.0 N.D.
44 2.25 576 4.40 42.4
4 514 3.86 5.68
5 408 3.26 N.D.
6 335 3.73 N.D.
8.83 198 3.20 N.D.
11.5 142 4.28 N.D.
14 109 4.70 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND














44 18 83 5.25 N.D.*
(Cont'd) 21 36 5.40 N.D.
31.5 5.9 2.93 N.D.
36.66 N.D. N.D. N.D.
47 1.25 370 3.78 3.35
2.75 428 3.7 6.7
4 470 3.96 7.3
5 419 3.25 1.63
6 388 2.96 1 .41
8 312 3.41 N.D.
10 325 3.58 N.D.
12.25 270 4.14 N.D.
16.5 204 5.83 N.D.
26.66 102 3.91 N.D.
38 49 4.00 N.D.
49 2 471 2.15 15.8
3.5 355 2.04 1.23
5 245 1.48 N.D.
6 209 1 .48 N.D.
7 170 1.72 N.D.
8 166 2.34 N.D.
9 105 2.07 N.D.
11 69 1.77 N.D.
15 20.3 1 .29 N.D.
19 N.D. N.D. N.D.
25 N.D. N.D. N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND











51 11 346 1.25 N.D.*
12 305 1 .00 N.D.
14 243 0.92 N.D.
14.75 180 0.92 N.D.
15.75 147 0.99 N.D.
20.5 101 0.99 N.D.
25 44 0.94 N.D.
28 23 0.80 N.D.
* not detectable
PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE













53 4 347 1.25 N.D.*
5 314 1.23 N.D.
6 260 1.33 N.D.
7 249 1.60 N.D.
8.25 244 2.27 N.D.
10.67 192 1.86 N.D.
12.92 161 1.57 N.D.
18 79.2 2.00 N.D.
24.5 16.3 0.94 N.D.
32.16 N.D. N.D. N.D.
54 2.5 539 4.46 6.2
4.08 529 5.40 7.1
5.17 442 3.37 5.9
6.83 388 4.1 5.1
8.5 319 4.75 4.4
10.17 279 4.90 3.2
11 .08 265 5.11 2.4
13 252 5.56 1.33
16.5 196 4.63 N.D.
25 139 4.85 N.D.
39 22.7 3.27 N.D.
50.92 N.D. N.D. N.D.
55 2.25 527 5.97 7.7
3.5 551 5.55 6.0
4.5 450 5.12 N.D.
6.5 349 4.71 N.D.
* not detectable
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PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE












(Continued) 7.5 269 3.06 N.D.*
9 251 2.12 N.D.
11 232 2.75 N.D.
14 224 3.47 N.D.
19 197 3.55 N.D.
57 24.0 449 10.4 N.D.
25.75 492 9.6 N.D.
27.5 354 5.7 N.D.
29.5 262 5.0 N.D.
30.5 240 5.9 N.D.
31.5 205 6.7 N.D.
35.5 176 8.8 N.D.
39.0 99.3 7.4 N.D.
48 10.1 4.1 N.D.
60.67 N.D. N.D. N.D.
65.25 N.D. N.D. N.D.
58 3 512 3.67 5.56
4 457 3.01 1 .86
5 423 3.01 N.D.
6 373 2.99 N.D.
7.17 369 2.98 N.D.
8.17 341 3.09 N.D.
10.17 315 2.91 N.D.
14.17 262 2.96 N.D.
* not detectable
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PLASMA CONCENTRATIONS OF SALICYLIC, SALICYLURIC AND
ACETYLSALICYLIC ACIDS IN PATIENTS WITH ASPIRIN OVERDOSAGE



































59 8.25 392 3.34 3.35
9 383 2.99 3.89
10 359 2.66 5.82
11 328 2.66 3.68
12.25 308 2.93 3.01
13.5 340 3.22 N.D.
14.75 333 3.52 N.D.
17 327 3.46 N.D.
21 254 2.97 N.D.
28 185 3.54 N.D.
37.25 130 3.52 N.D.
* not detectable















1 3-6 720 6.7 326 269 70
6-10 560 6.8 696 436 69
10-13 450 6.4 476 562 N.D.*
13-17 425 6.2 309 491 N.D.
17-19 320 6.1 205 708 N.D.
19-23 415 6.1 201 1033 N.D.
23-31 .5 970 6.1 54.2 549 N.D.
31.5-34 195 5.6 57 928 N.D.
4 8.5-10.5 350 7.0 308 223 12.5
10.5-12.33 350 5.4 114 511 12.1
12.33-18.5 265 5.2 53 642 N.D.
18.5-21.83 290 5.2 25 403 N.D.
6 2.83-4.5 790 5.4 411 332 51.5
4.5-6 645 6.9 295 295 N.D.-
6-9 660 6.2 128 653 N.D.
9-14 425 5.9 91 1409 N.D.
7 1-5 270 7.2 1242 669 21 .2
5-20 460 7.5 258 308 N.D.
7.33-8.25 290 7.0 182 230 N.D.
8.25-10 420 6.3 97 319 N.D.
10-14 190 5.3 30.3 955 N.D.
14-17 360 5.4 13.3 592 N.D.
17-20 375 5.5 7.0 258 N.D.
8 N.A.** N.A. N.A. N.A. N.A. N.A.
9 8-11.25 629 6.4 233 214 N.D.
1 1 .25-22.5 365 5.6 257 944 N.D.
22.5-26.75 550 5.7 91 .3 561 N.D.

















13 2-2.83 240 6.5 296 382 184
2.83-3.16 340 6.5 177 176 40
3.16-4.66 250 7.0 393 258 18.5
4.66-5.66 300 7.1 738 325 5.5
5.66-6.08 300 7.1 341 151 N.D.*
6.08-7.42 310 7.1 296 114 N.D.
7.42-8.16 150 7.2 839 348 N.D.
8.16-9.33 80 7.2 1966 1172 N.D.
9.33-13.42 50 6.6 1284 3200 N.D.
13.42-15.92 55 6.5 957 2954 N.D.
15.92-16.66 40 6.1 409 2910 N.D.
16 4-7.33 410 5.9 32.15 389 N.D.
7.33-14.66 40 6.0 42.18 2355 N.D.
1 14.66-31.25 565 6.0 186 1982 N.D.
34 20-22 210 6.9 208 386 N.D.
22-1.75 60 7.0 1688 1957 N.D.
1 .75-5.5 150 6.7 644 1178 N.D.
5.5-9 260 6.3 111 588 N.D.
9-10.75 240 7.2 237 605 N.D.
10.75-12 50 6.4 96 1921 N.D.
12-14.25 60 6.6 288 1945 N.D.
35 1-7 660 6.5 100 733 N.D.
7-11.5 270 6.4 118 1746 N.D.
11 .5-15.75 155 6.3 104 2119 N.D.
15.75-17.92 130 5.8 25 1863 N.D.
















36 8-18 285 7.1 1211 1610 N.D.*
18-30 250 6.4 203 2443 N.D.
30-35.58 130 5.4 50 2283 N.D.
43 14.66-18.5 300 5.8 62.5 1098 N.D.
18.5-22 265 6.1 23.2 1072 N.D.
22-24.5 140 6.1 33.0 1867 N.D.
24.5-27 160 6.1 48.3 1437 N.D.
27-30 360 6.4 37.8 1314 N.D.
30-34.5 135 6.0 24.0 833 N.D.
34.5-36.5 290 5.9 48.1 2729 N.D.
36.5-38.5 430 6.1 28.8 733 N.D.
38.5-41.66 220 6.7 49.0 406 N.D.
41.66-43.83 460 6.9 255 1179 N.D.
43.83-47 370 7.1 143 840 N.D.
47-49.5 740 7.0 235 692 N.D. •
49.5-52.5 400 6.4 84.8 294 N.D.
52.5-58.5 920 6.0 34.1 727 N.D.
58.5-60 360 6.7 14.7 442 N.D.
45 0-14.5 590 6.6 643 622 N.D.
14.5-23.5 97 5.7 262 1032 N.D.
23.5-30.5 660 5.8 196 994 N.D.
30.5-36.5 910 5.8 96.3 640 N.D,
36.5-38.5 555 5.0 80.5 767 N.D.
48 4.5-9 420 6.2 331 462 N.D.
9-15.66 250 6.0 359 2199 N.D.













Salicylic Salicyluric Acetyl sali-


























































































































2 7.75-8.5 475 7.6 1270 246 14.8
8.5-9.5 1120 7.7 783 78 N.D.*
9.5-10.25 1220 7.7 438 40 N.D.
10.25-15.5 1680 7.8 756 123 N.D.
15.5-20.75 420 7.6 578 710 N.D.
20.75-31 540 7.5 82 200 N.D.
31-33 520 6.7 N.D. 53 N.D.
33-39 1300 6.7 N.D. 220 N.D.
3 4.5-7.25 1050 7.5 551 103 N.D.
7.25-7.75 450 7.5 434 39.8 N.D.
7.75-8.25 490 7.7 406 37.3 N.D.
8.25-9.0 530 7.9 446 69.8 N.D.
9 - 10 355 7.9 614 128 N.D.
10 -21 370 7.9 1571 1304 N.D.
21-25.25 70 8.5 2543 1876 N.D.
5 1.25-6.5 730 7.4 672 . 219 3.8
3.5-7.17 710 7.4 505. 116 N.D.
7.17-7.25 205 7.3 495 120 N.D.
7.25-8.08 1150 7.7 553 102 N.D.
8.08-9.5 850 7.7 741 180 N.D,
9.5-12,5 590 7.3 911 310 N.D.
12.5-15.0 420 7.1 1162. 820 N.D.
15.0-19.75 530 7.8 645 515 N.D.
19.75-23.21 250 7.5 117 1758 N.D.
23.25-36.5 585 6.8 229 1938 N.D.
10 15.5-19.0 315 7.4 4774 1445 Ill
19-20.83 oo 7.8 3935 548 12.5


















10 24.25-29 790 6.9 516 536 N.D.*
lont'd) 29-31 610 6.9 339 408 N.D.
31-35 320 6.9 91 .3 179 N.D.
35-36.5 710 6.7 97.8 180 N.D.
14 5.75-10 410 7.5 2724 416 91 .3
10-10.5 555 7.5 838 35.7 N.D.
10.5-11 550 6.8 820 45.2 N.D.
11-11 .75 650 7.7 759 42.8 N.D.
11.75-12.17 675 7.6 503 27.8 N.D.
12.17-12.58 675 7.8 424 21 .5 N.D.
15 7.0-10.5 150 6.9 3355 2339 N.D.
10.5-11 .5 810 7.5 1137 143 N.D.
11.5-12.83 890 6.9 852 134 N.D.
17 3.0-5.0 690 7.1 527 193 348
5.0-6.17 630 7.4 875 278 272
6.17-6.5 710 7.5 895 124 131
6.5-7.17 630 7.6 803- 87.8 87.7
7.17-8.5 570 8.2 1459 124 71 .8
8.5-16.5 710 8.0 2531 439 17.7
16.5-22.5 290 7.2 3143 1877 N.D.
22.5-23.75 120 6.8 888 2221 N.D.
19 3.25-3.93 500 7.3 528 59.7 53,3
3.93-4.5 710 7.4 624 60.5 52.7
4.5-4.75 570 7.5 494 26.5 8.4
4.75-5.0 560 7.5 652 35.5 17.2
5.0-5.5 680 7.5 586 34.5 6.0
5.5-5.75 560 7.6 466 28.4 N.D.
5.75-6.0 710 7.6 391 23.0 N.D.
* not detectable















19 6.0-6.75 500 7.6 533 49.0 N.D.*
ont1d) 6.75-7.75 440 7.7 1260 187 N.D.
7.75-8.83 350 7.6 997 143 N.D.
8.83-17.0 415 7.9 2649 997 N.D.
17.0-19.5 210 7.9 1307 593 N.D.
20 4.0-6.0 320 7.4 1186 73.1 31 .1
5.0-6.25 345 7.5 792 22.0 6.8
6.25-6.58 360 7.7 603 20.0 5.8
6.58-7.0 290 7.7 803 30.5 N.D.
7.0-7.42 210 7.9 767 23.1 N.D.
7.42-7.58 240 7.8 601 19.0 N.D.
7.58-7.83 660 7.8 495 13.7 N.D.
7.83-8.17 . 405 7.9 504 14.3 N.D.
8.17-8.5 245 7.9 708 23.4 N.D.
8.5-9.08 255 8.1 1081 40.0 N.D. .
9.08-10.25 320 8.2 1636 89.0 N.D.
10.25-16.25 325 7.5 1861 ' 378 N.D.
16.25-26.5 220 8.1 768" 598 N.D.
21 5.0-6.5 790 6.4 1238 585 91 .0
6.5-7.5 690 8.0 1615 201 29.1
7.5-8.5 620 8.0 947 92.1 N.D.
8.5-9.0 740 8.0 800 78.0 N.D.
9.0-10.0 245 8.1 617 129 N.D'.
22 8.0-12.25 660 7.3 1316 421 17.4
12.25-12.5 630 7.9 430 52.0 N.D.
12.5-12.83 540 7.8 340 31 .3 N.D.
12.83-13.25 565 7.8 378 38.0 N.D.


















22 13.83-14.0£ 500 7.9 342 50.1 N.D.*
ont'd) 14.08-14.58 510 7.9 402 69.6 N.D.
14.58-15.17 410 8.0 483 104 N.D.
15.17-20.5 440 7.5 743 593 N.D.
20.5-32.17 445 7.0 214 1132 N.D.
32.17-33.17 250 7.1 25.5 115 N.D.
23 0-5.33 600 7.6 1652 139 288
5.33-5.75 570 7.9 929 51 .0 119
5.75-6.17 630 8.2 794 64.2 11.6
6.17-6.75 740 8.4 699 65.0 N.D.
6.75-7.5 595 8.2 798 68.0 N.D.
7.5-9.5 670 8.3 945 140 N.D.
24 1.25-9.25 330 6.1 1.858 2752 197
1 9.25-14.0 1020 7.2 1693 478 N.D.
14.0-15.75 1250 7.5 675 140 N.D.
15.75-19.25 1010 6.8 547 • 393 N.D.
19.25-27.5 570 5.2 248- 1490 N.D.
27.5-30.58 560 6.0 233 681 N.D.
30.58-47.0 475 5.6 587 6977 N.D.
25 11.0-14.25 475 7.1 2380 1200 N.D.
14.25-15.33 690 7.5 797 99.7 N.D.
15.33-15.92 475 7.8 858 103 N.D.
5.92-17.0 590 8.1 1020 108 N.D.
17.0-18.58 505 8.1 1431 193 N.D.
18.58-22.83 268 7.9 1703 918 N.D.
22.83-32.0 510 6.5 202 1188 N.D.
32.0-33.83 80 8.1 601 746 N.D.


















25 35.83-38.0 190 8.1 181 534 N.D.*
nt' d) 38.0-41.0 370 7.4 60.0 278 N.D.
41.0-42.83 355 7.4 13.2 68.0 N.D.
42.83-44.0 230 7.5 12.0 82.8 N.D.
44.0-46.5 230 7.4 10.0 88.0 N.D.
46.5-50.5 200 7.4 N.D. 42.7
50.5-58.0 270 7.4 N.D. 13.8 N.D.
58.0-61.17 810 7.5 N.D. 4.8 N.D.
26 10.5-12.25 855 7.2 1020 490 N.D.
12.25-12.75 705 7.6 570 119 N.D.
12.75-13.25 800 7.8 567 92.5 N.D.
13.25-14.0 840 7.9 469 75.2 N.D.
14.0-14.5 860 7.9 463 96.0 N.D.
14.5-16.5 705 7.9 570 305 N.D.
16.5-18.5 285 7.2 559 340 N.D. •
18.5-20.5 210 7.0 237 838 N.D.
20.5-22.0
'
320 6.9 89.0 347 N.D.
22.0-23.25 470 7.4 60.0 227 N.D.
23.25-34.0 320 6.6 12.8 528 N.D.
41 18.5-26.17 580 6.2 1267 3363 N.D.
26.17-26.0 480 7.2 1253 147 N.D.
26.0-27.5 530 7.0 860 171 N.D.
27.5-30.5 540 7.8 776 291 N.D.
30.5-31 .0 280 6.7 725 424 N.D.
31.0-33.0 330 6.3 415 529 N.D.
33.0-35.5 350 6.2 347 509 N.D.
35.5-41.5 400 5.7 221 681 N.D.
41.5-47.5 350 5.8 278 1123 N.D.














































27 6-8.5 240 6.1 571 923 17.5
8.5-9.83 230 6.0 386 749 13
9.83-10.75 270 6.0 359 620 11
10.75-11.67 350 6.0 292 391 N.D.*
11.67-12.67 210 5.8 260 438 N.D.
12.67-13.75 215 5.8 192 403 N.D.
13.75-14.67 380 5.9 128 320 N.D.
14.67-15.5 390 5.9 81 252 N.D.
15.5-18 720 5.9 49 390 N.D.
18-19 310 6.0 57.3 402 N.D.
19-19.75 530 6.1 64 199 N.D.
19.75-21 570 6.3 101 322 N.D.
21-22 285 6.3 115 355 N.D.
22-23 355 6.6 162 289 N.D.
23-24 495 6.9 340 362 N.D.
24-25.33 450 6.8 244 214 N.D.
25.33-26.75 175 6.6 187 ■ 382 N.D.
26.75-27.5 150 5.8 100. 819 N.D.
27.5-30.42 560 5.6 30 451 N.D.
30.42-32.61 345 5.4 18.8 576 N.D.
32.67-40 280 5.4 43.7 1662 N.D.
40-41 ' 310 5.6 45.7 493 N.D.
41-42.67 140 5.4 13.7 982 N.D.
29 0-3.5 395 7.3 322 133 246
3.5-6 920 7.3 316 74.5 N.D.
6-8.25 730 7.6 326 56.5 N.D.


















29 13-16 375 5.8 74.2 513 N.D.*
(cont'd) 16-17.5 415 5.7 20 238 N.D.
17.5-19 500 5.7 13.5 150 N.D.
19-24.5 450 5.2 17.9 374 N.D.
30 5-9 ' 470 6.3 110 367 N.D.
9-9.75 330 6.7 465 785 N.D.
9.75-10.75 660 6.9 160 116 N.D.
10.75-11.5 670 7.0 154 107 N.D.
11.5-12.17 550 7.0 133 73.6 N.D.
12.17-12.75 310 7.2 129 87.5 N.D.
12.75-17.33 450 6.2 233 656 N.D.
31 1-7.33 890 7.8 2517 531 62.8
7.33-9 680 7.7 1494 224 29.6
9-14 850 6.7 426 530 N.D. .
14-16 840 6.8 133 184 N.D.
16-17 930 7.0 139 144 N.D.
17-20 750 6.6 146" 141 N.D.
20-32.5 620 5.9 71 .7 1459 N.D.
32.5-39.75 250 5.7 51 .8 2953 N.D.
32 0-4 470 7.1 781 250 N.D.
4-5 540 7.3 510 131 N.D.
5-5.75 700 7.1 583 184 N.D.
5.75-6.5 710 6.8 467 120 N.D.
6.5-7 740 6.9 365 91 N.D.
7-8.17 648 7.2 292 94.6 N.D.


















32 12.75-14.33 415 6.3 159 249 N.D.*
(Cont1c 14.33-16.33 745 5.8 152 325 N.D.
16.33-20.25 540 5.8 133 387 N.D.
20.25-23.75 470 4.7 130 652 N.D.
23.75-26 320 5.5 107 956 N.D.
26-31 140 5.3 63.6 1678 N.D.
31-33.58 95 5.4 53.3 2135 N.D.
33.58-36.75 80 5.6 73.1 2019 N.D.
33 0-3.5 370 6.9 669 517 160
3.5-4.5 230 7.8 551 201 58.4
4.5-6.5 320 7.2 463 199 68.8
6.5-8 1360 6.9 350 252 21.8
8-10 175 5.5 113 873 N.D.
10-12 260 5.4 58 1546 N.D.
12-14.83 1030 5.9 25.8 204 N.D. .
14.83-19.5 1600 6.0 10 236 N.D.
19.5-21.33 545 5.9 9 ' 315 N.D.
21.33-24.5 225 5.3 12 ' 964 N.D.
24.5-26.5 50 5.5 62.5 3313 N.D.


















37 2.5-5 550 7.0 267 326 130
5-5.75 660 7.8 868 222 N.D.*
5.75-6.33 470 7.6 915 107 N.D.
6.33-8 500 7.8 1597 265 N.D.
8-9 390 8.0 2081 348 N.D.
9-11 665 7.8 891 222 N.D.
11-13.83 380 7.5 1090 382 N.D.
13.83-20 320 7.9 1023 1594 N.D.
20-23.75 150 7.0 279 2033 N.D.
38 1.25-2.75 490 7.2 547 141 N.D.
12.75-3.25 770 7.3 444 89.4 N.D.
3.25-4.75 580 7.8 1232 194 N.D.
4.75-11.25 430 7.6 2103 1231 N.D.
11.25-17.61 130 6.9 747 1548 N.D.
17.67-21 .71 230 6.5 133 876 N.D.
44 1 - 2.25 235 6.7 269 103 233
2.25-3.83 520 7.5 1030 ' 135 N.D.
3.83-4.75 710 8.0 1738 " 275 N.D.
4.75-6 615 8.4 2334 205 N.D.
6 - 7.75 345 8.6 3401 476 N.D.
7.75-10.93 176 8.4 4014 1483 N.D.
10.93-13 66 8.3 2673 2640 N.D.
13 -19.75 320 6.6 182- 1524 N.D.
19.75-22 117 5.7 217 1229 N.D.
22-22.5 140 5.9 237 1328 N.D.
22.5-29 180 6.1 22 2162 N.D.
47 ?-4 610 7.3 825 593 175
4-7.5 460 8.4 4551 719 56


















47 11.5-13.5 500 7.5 733 359 N.D.*
(Cont'd) 13.5-15.5 340 7.7 910 543 N.D.
15.5-17.66 360 8.0 1520 829 N.D.
17.66-21 400 7.6 435 597 N.D.
21-23.5 285 7.4 306 853 N.D.
23.5-27.5 240 7.4 288 1636 N.D.
27.5-30 200 7.4 144 1946 N.D.
30-32 260 7.3 78.0 607 N.D.
32-35.5 210 7.4 90.0 663 N.D.
35.5-38 640 7.8 98.0 621 N.D.
49 0.75-3.75 940 8.0 1213 208 232
3.75-5.5 890 8.5 1776 299 25.5
5.5-9.83 650 8.9 2782 682 N.D.
9.83-17.5 570 8.8 875 939 N.D.
17.5-25 410 8.6 10.1 197 N.D. •
25-26.5 300 8.1 N.D. 14.7 N.D.
26.5-35.5 370 7.9 N.D. 31 .6 N.D.
35.5-39 290 7.7 N.D. 14.7 N.D.
51 8-12.33 735 7.5 822 366 N.D.
12.33-18 640 8.7 2820 763 N.D.
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53 ? - 4.33 705 8.0 956 328 30.1
4.33-5.17 1110 8.1 444 69.3 N.D.*
5.17-5.5 1430 8.2 383 64.5 N.D.
5.5-5.83 650 8.3 381 44.8 N.D.
5.83-6.17 420 8.3 421 53.5 N.D.
6.17-8.75 520 8.4 400 281 N.D.
8.75-14.5 420 7.9 1435 1236 N.D.
14.5 - 21 390 7.6 602 1102 N.D.
21 - 32 240 6.2 81 1290 N.D.
54 ? - 3 460 7.0 1450 145 370
3 - 5.33 900 7.4 1457 295 360
5.33-5.75 1020 7.4 884 118 39.4
5.75-6.5 920 7.5 600 70.8 N.D.
6.5-7.25 730 7.7 705 63 N.D.
7.25-7.67 666 7.7 634 54.8 N.D. ■
7.67-8.67 1090 7.8 680 75 N.D.
8.67-13.83 690 7.3 430 668 N.D.
13.83-23.25 280 5.8 337 2395 N.D.
23.25-34.5 320 6.3 180 1150 N.D.
34.5-38.83 450 6.5 92 795 N.D.
38.83-45.75 530 6.3 12.0 235 N.D.
45.75-50.5 220 7.2 4.0 53.3 N.D.
55 ? - 2.75 760 5.8 166 160 359
2.75-3.93 820 7.1 479 197 104
3.93-4.43 800 7.5 732 73.5 13.1


















55 4.66-5.0 560 7.4 300 45.1 N.D. *
(Cont'd) 5.0 - 5.5 630 7.5 378 63.0 N.D.
5.5 - 6.0 560 7.6 459 72.1 N.D.
6.0 - 6.5 600 7.6 376 77.8 N.D.
6.5 - 7.5 630 7.6 675 139 N.D.
7.5 - 10.0 520 7.7 436 250 N.D.
10.0-14.0 320 7.4 902 1259 N.D.
14 - 17.33 500 7.3 732 642 N.D.
17.33 - 19 130 7.0 8.33 1193 N.D.
57 0 - 0.5 95 5.5 62.1 5092 N.D.
0.5 - 3.0 915 6.3 175 453 N.D.
3.0 - 3.5 830 7.0 189 66.6 N.D.
3.5 - 4.07 610 7.3 229 75.8 N.D.
4.07 - 4.5 650 7.4 254 91.8 N.D.-
4.5 - 4.83 1060 7.4 241 74.1 N.D.
4.83 -5.33 940 7.6 247 78.5 N.D.
5.33-6.5 930 7.4 229 167 N.D.
6.5-11.25 530 6.3 225 1317 N.D.
11.25-14.0 100 7.5 924 3426 N.D.
14.0-16.75 150 7.9 966 2488 N.D.
16.75-25.11 370 7.3 316 2181 N.D.
25.17 - 34 172 7.5 35.2 1620 N.D.
34 - 37.17 45 8.4 N.D. 222 N.D.
37.17 - 40 110 8.7 N.D. 47.2 N.D.
58 ? - 4.17 270 6.4 1074 1319 139
4.17-4.67 475 6.7 582 377 44.4
4.67-5.17 970 7.0 540 149 13.4
* not detectable
URINARY EXCRETION DATA















58 5.17-5.67 940 7.4 570 73 N.D.*
Cont'd) 5.67-5.93 650 7.4 635 65.4 N.D.
5.93-6.43 1190 7.5 698 51 N.D.
6.43-7.67 1130 7.4 600 98.2 N.D.
7.67-9.67 510 7.4 616 283 N.D.
9.67-14.17 390 7.1 502 617 N.D.
14.17-iai: ' 240 6.7 325 984 N.D.
18.17-23.67 230 6.2 115 1356 N.D.
23.67-27.93 160 6.2 53.2 1652 N.D.
27.93-30.67 165 6.8 181 1587 N.D.
30.67-33.67 500 7.1 71 .2 717 N.D.
33.67-38.67 250 7.1 122 1005 N.D.
38.67-42.17 175 6.5 63.2 2644 N.D.
42.17-45.67 285 6.7 15.4 627 N.D.
59 ? - 7.83 360 7.9 2442 678 213
7.83-10.33 1020 7.8 472 33.5 15.2
10.33-11 .17 2050 8.2 306 23.6 8.2
11.17-12.5 850 8.1 539 51 .3 N.D.
12.5-15.0 1320 8.5 595 84.5 N.D.
15.0 -18.5 410 8.6 2289 791 N.D.
18.5-24.0 685 7.5 761 576 N.D.
24 - 27.93 560 7.4 339 417 N. D.
27.93-34.83 630 6.7 100 608 N.D.
34.83-37.0 550 6.9 42.3 261 N.D.
37.0-39.25 290 6.6 47.8 282 N.D.
* not detectable
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Control 36 15.1 68 427
43 118 51 348
45 37.6 91 434
48 41.1 44 462
50 40.2 18 405
52 47.5 35 724
Forced 20 284 145 241
al kal i ne 22 410 125 292
diuresis 24 112 153 441
25 201 57 324
26 420 324 193
41 120 84 486
Forced 27 255 203 341
diuresis 29 152 136 179
30 283 343 279
31 154 158 319
32 252 158 346
33 177 157 323
Alkali 37 273 176 455
al one 38 333 143 457
44 258 122 441
47 196 81 426
49 296 71 308
51 277 150 434
Forced 53 489 212 379
alkaline 54 341 115 337
diuresis 55 633 296 306
+ 57 424 77 421
frusemide 58 362 197 422
59 596 177 236
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niqucs are leading to a rapid increase in the standard of analyses which the laboratory can
offer to the ward. •
_
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HPLC in Clinical Pharmacological Studies of Analgesic Drugs
L. F. Prescott, i. S. King, Lindsey Brown, M. Balali and P. I. Adriaenssens
Univcrsitv Department of Therapeutics and Clinical Pharmacology, The Royal Infirmary, Edinburgh,
EU3 9Y \V
Most of the methods used for the assay of analgesics such as aspirin and paracetamol in
biological fluids are non-specific and there are major difficulties with the determination of
their metabolites. Gas - liquid chromatographic methods overcome the problems of
specificity, but with therapeutic concentrations of these drugs derivatisation is necessary
because of their polar nature. The introduction of HPLC has been a great advance and it
is now possible to separate and measure many polar drugs and metabolites by using simple
procedures.
We have developed simple, rapid and specific HPLC assays for aspirin, salicylic acid,
paracetamol, antipyrine, diflunisal, phenylbutazone and mefenamic acid in plasma and
urine. With aspirin and paracetamol, metabolites can be measured simultaneously. No
solvent extraction is required and the whole procedure can usually be completed within a
few minutes.
The general method for the determination of these drugs in plasma consists of the addition
of a suitable internal standard, precipitation of plasma proteins with perchlorc acid or
acetone, centrifugation and direct injection of 5-10 /d aliquots of the clear supernatant into
the HPLC column. The methods for urine are even simpler. The aqueous internal standard
is added and an aliquot of the mixture injected into the column.
The columns were internally polished stainless steel, 100-150 X 4.5 mm i.d., packed with
5 /tin Cis-botidod spherical silica (Hypersil-ODS or Sphcrisorb-ODS) and fitted with septum
injectors. An Orlita pump (Model AE 10-4) was used witli a Cecil Model 212, Pye Model LC3
or Waters Model 440 ultraviolet detector, a strip-chart recorder and an integrator. The
solvent was aqueous prcpan-2-ol containing combinations of formic or acetic acid, potassium
nitrate, potassium dihydrogen phosphate and modifiers such as ethyl acetate. Details of the
assays of these analgesics in plasma are summarised in Table I. Minor modifications to the
solvent composition were occasionally required for optimum separation of the drugs and
metabolites from potentially interfering peaks in urine.
Using the ratios of the peak area or peak height of the drugs to those cf internal standards,
tin: calibration graphs were linear over a wide range of concentrations and passed through
the origin. The.limits of measurement are less than 1 gig ml-1 and the standard deviation
of the methods over the therapeutic range of plasma concentrations is 3-5%.
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Table I
Details of HPLC assays of aspirin and metabolites, paracetamol and
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Fig. 1. HPLC of plasma
from a patient with aspirin
overdosage. SU = Salicyl¬
uric acid, AS = acetylsali-
cylic acid, AT = acet-p-
toluididc, BZ = benzoic
acid, SA = salicylic acid.
Fig. 2. HPLC of blank
urine (left) and urine from
a patient with aspirin
overdosage (right). G =
Gentisic acid, SU = sali¬
cyluric acid, AS = acetyl-
salicvlic acid, at = acet-
p-toluiclide internal stan¬
dard, BZ = benzoic ac;d
internal standard and sa
= salicylic acid.
Fig. 3. HPLC of
plasma from a
patient who took
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Details cf the methods for the determination of paracetamol and its sulphate, glucuronide,
cysteine and'mcrcapturic acid conjugates have been published.1-2 Chromatograms obtained
during routine assays of aspirin, antipyrine and diflunisal in phisma are shown in Figs. 1-4.
These methods have been used for clinical pharmacological and pharmacokinetic studies
in healthy subjects and hospital patients. No serious problems have been encountered with
interference from endogenous compounds or other drugs. Extensive and detailed studies
have been carried out cn the metabolism of paracetamol following overdosage and the effects
of treatment with sulpliydryl compounds, such as Ar-acetylcysteine. In addition, the effects
of different diets, other drugs, liver disease and gastrointestinal disease on paracetamol
absorption and metabolism have been studied. This work simply could not have been done
in the time without simple, rapid methods for the determination of paracetamol and its
metabolites.
The methods could readily be scaled down for plasma samples of 100 pi and virtually all
currently available, acidic, anti-inflammatory analgesics can be chromatographecl under
these conditions.
1. Howie, P., Aclriaenssens, P. I., and Prescott, L. F., J. Pharm. Pharmac., 1977, 29, 235.
2. Adriaensscns, P. I., and Prcscott, L. F., Br. J. Clin. Pharmacol., 1978, 6, 87.
Clinical Analysis of Steroids by HPLC
P. F. Dixon, P. Lukha and N. R. Scott
Pathology Department, Bromley Hospital, Bromley, Kent
Most of the physiologically active steroids possess some specific ultraviolet absorbance, e.g., .
the A4-3-oxo configuration of corticosteroids at about 240 nm and the aromatic A-ring of
oestrogens at about 280 nm, and can thus be detected directly in HPLC systems. However,
the sensitivity is low and theory predicts that steroids measurable in plasma are at present
limited to the most abundant corticosteroid, Cortisol, its precursors if Cortisol biosynthesis is
blocked by disease or pharmacological agents, administered steroids and, during late






Fig. 4. HPLC of blank
plasma (left) and plasma
following a therapeutic
dose of diflunisal (DF)
(right). FA = Flufen-
amic acid internal stan¬
dard.
References
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FAILURE OF
ALKALINE DIURESIS
TO ENHANCE DIFLUNISAL ELIMINATION
MEHDI BALALI-MOOD* & L.F. PRESCOTT
University Department of Therapeutics and
Clinical Pharmacology. The Royal Infirmary. Edinburgh. EH3 9YW
1 The effects of alkaline diuresis on the elimination of a single oral dose of 750 mg diflunisal were
studied in six healthy male volunteers.
2 The plasma concentrations and half-life of diflunisal were not reduced by alkaline diuresis.
3 The 72 h urinary recovery of unchanged diflunisal was more than doubled with alkaline diuresis,
but even so, only 5-7% of the administered dose was excreted unchanged.
4 With alkaline diuresis there was a significant increase in the mean renal clearance of diflunisal
from 0.27 to 0.46 ml/min, but there was no significant correlation between the renal clearance of
diflunisal and urine flow or pH.
5 However, there was a significant increase in the overall mean renal clearance of diflunisal from
0.22 ml/min over the period 0-24 h to 0.73 ml min from 48-72 h.
6 Forced alkaline diuresis is unlikely to be of value in diflunisal poisoning.
Introduction
Diflunisal (2', 4', difluoro-4-hydroxy-3-biphenyl-
carboxylic acid) is a derivative of salicylic acid with
similar pharmacology and toxicology. However, it is
longer acting (Tempero, Cirillo & Steelman, 1977)
and is claimed to cause less gastrointestinal bleeding
(De Schepper & Tjanramaga, 1978) and to have less
marked effects on platelet function (Smith Sibinga,
1977).
Diflunisal is a lipid-soluble, organic acid (pKa 3.3)
and as such its renal clearance should be pH
dependent (Milne, 1965). The effects of urine flow
and pH on the renal clearance of diflunisal were
studied by conventional clearance techniques in
anaesthetized dogs (Baer, Breault & Russo, 1978).
The net renal clearance of diflunisal was very low
(about 1% of the glomerular filtration rate) and
changes in the urine flow or pH had very little effect.
About half of a single i.v. dose of diflunisal is
excreted in the urine in dogs (50% unchanged and
50% as glucuronide conjugates) whereas in man, 95%
of an oral dose appears in the urine, principally as
glucuronide conjugates (Tocco, Breault, Zacchei,
Steelman & Perrier, 1975). Forced alkaline diuresis has
been recommended for the treatment of diflunisal
overdosage, but the effects on its removal are
unknown.
* Department of Pathology and Laboratory Sciences, Emam
Reza Medical School, Mashhad University, Mashhad, Iran.
0306-5251/80/080163-03 $01.00
We have measured the plasma concentrations and
renal excretion and clearance of the drug in the
healthy male volunteers under different conditions of
urine flow and pH.
Methods
Six healthy ambulant male volunteers aged 20-37
years weighing 60-82 kg were studied with informed
consent. Each took 750 mg diflunisal (three Dolobid
tablets) with 200 ml water following an overnight fast
after which food, fluids and tobacco were withheld
for 2 h. Venous blood was taken at 0, 0.5, 1, 2, 3, 4, 8,
12, 24, 36, 48 and 72 h and urine was collected 2
hourly for 12 h and then 12 hourly for another 60 h.
Urine volume and pH were measured and urine and
plasma samples were stored frozen. Normal fluid
intake, diet and activity were allowed, but alcohol
and other drugs were not taken during the study.
The experiment was repeated in the same
volunteers not less than 2 weeks later with
administration of sodium bicarbonate capsules (3 g
four times daily) the day before and for 48 h after the
diflunisal. The fifth dose of sodium bicarbonate (the
first dose on the second day) was given 1 h before the
diflunisal. Fluid intake was increased to give a urine
output of about 4 litres daily.
Unchanged diflunisal was estimated in plasma and
urine by high performance liquid chromatography
P) Macmillan Journals Ltd 1980
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Time after ingestion (h)
Figure 1 Mean plasma concentrations ofdiflunisal with
(•) and without (O) alkaline diuresis in six healthy
subjects after an oral dose of 750 mg.
(Prescott, King, Brown, Balali & Adriaenssens,
1979). The plasma half-life, renal clearance and
urinary recovery of the unchanged drug were
calculated before and during alkaline diuresis. The
plasma half-life was calculated during the linear
elimination phase by the method of least squares and
the area under the plasma concentration-time curve
(AUC) by the trapezoidal rule. The renal clearance
was calculated by dividing the amount of diflunisal
excreted in the urine during each collection period by
the corresponding AUC. Comparisons were
performed using the paired, two tailed Student's f-test,
with P = 0.05 as the minimum level of statistical
significance.
0 24 48 72 0 24 48 72
Time after ingestion (h)
Figure 2 Increase in mean renal clearance of diflunisal
with time following a single dose of 750 mg with (^) and
without (□) alkaline diuresis in six healthy subjects.
Results
The plasma concentrations of diflunisal were similar
throughout in both studies (Figure 1). Peak
concentrations were reached within 3-4 h and the
mean values were 112+15 and 118 + 11 (s.d.) pg/ml
with and without sodium bicarbonate respectively
(Table 1). The mean plasma half-life values were
virtually identical in both studies (12.9+1.5 and
12.5 ± 1.5 h). If anything, plasma concentrations were
higher rather than lower during alkaline diuresis, the
mean AUC up to 72 h was also greater with sodium
bicarbonate, but the difference was not statistically
significant (Table 1).
The 72 h urinary recovery of diflunisal was more
than doubled by alkaline diuresis but even so, only
5-7% of the administered dose was excreted
Table 1 Effects of alkaline diuresis on the disposition of diflunisal
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Values given are mean ± s.d.
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unchanged. There was a significant increase with
alkaline diuresis in the renal clearance of diflunisal
from 0.27 to 0.46 ml min (Table 1) but there was no
statistically significant correlation overall between the
renal clearance of diflunisal and urine flow or pH
(r = 0.08 and r = 0.04 respectively).
Unexpectedly, there was a progressive and highly
significant increase in the renal clearance of diflunisal
with time (Figure 2) irrespective of urine flow or pH
(r = 0.75, P < 0.001 with diflunisal alone and
r = 0.49, P< 0.001 with alkaline diuresis). The
overall mean renal clearance of diflunisal increased
from 0.22 ml min over the period 0-24 h to 0.73
ml min from 48-72 h. There was a corresponding
significant negative correlation between plasma
concentrations and renal clearance of diflunisal with
and without sodium bicarbonate (r=~0.50,
/'<0.001 and r=— 0.66, P<0.001 respectively).
Discussion
Although the mean renal clearance and the 72 h
urinary recovery of diflunisal were significantly
increased by alkaline diureses, only 5-7% of the dose
was excreted unchanged and there were no reductions
in the plasma concentrations and half-lives. Plasma
concentrations were actually higher with alkaline
diuresis, possibly due to changes in absorption or
distribution. The mean plasma half-life of 12-13
hours is consistent with the previous reports of dose-
dependent elimination of diflunisal (Tocco et al.,
1975; Tempero, Cirillo & Steelman, 1978).
We were surprised to find no significant overall
correlation between the renal clearance of diflunisal
and urine flow or pH. On the other hand there was a
highly significant relationship between the time after
administration (and plasma concentrations) and the
renal clearance of diflunisal irrespective of urine flow
or pH. The explanation for these findings is
unknown. Possibilities include induction of renal
tubular transport of diflunisal with time, or that the
maximum tubular secretory capacity was exceeded at
higher plasma concentrations. Similar findings have
been reported for the renal clearance of salicyl acyl
glucuronide (but not salicylic acid) by Schachter &
Manis (1958). We have confirmed that there is no
correlation between the renal clearance of salicylic
acid and plasma concentration and time after
administration of therapeutic doses of aspirin in
healthy volunteers. Interestingly, an opposite
relationship has been described between the renal
clearance of disopyramide and plasma
concentrations. This was attributed to concentration-
dependent plasma protein binding of the drug
(Cunningham, Shen, Shudo & Azarnoff, 1977).
Forced alkaline diuresis has been recommended for
the treatment of diflunisal overdosage (ABPI Data
Sheet Compendium, 1979-1980). In one report it
appeared to have little beneficial effect, although no
measurements were made (Upadhyay & Gupta,
1978). The results of the present study provide no
basis for the use of forced alkaline diuresis for
diflunisal poisoning.
This work was supported by Thomas Morson
Pharmaceuticals (Division of Merck Sharp & Dohme Ltd).
We are grateful to Mr I S. King for technical assistance.
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